|Publication number||US8709385 B2|
|Application number||US 12/836,444|
|Publication date||29 Apr 2014|
|Filing date||14 Jul 2010|
|Priority date||14 Jan 2008|
|Also published as||CA2712120A1, EP2242476A2, US20110008266, WO2009090558A2, WO2009090558A3|
|Publication number||12836444, 836444, US 8709385 B2, US 8709385B2, US-B2-8709385, US8709385 B2, US8709385B2|
|Inventors||Dov Tamarkin, Alex Besonov, Tal Berman, David Schuz, Elana Gazal|
|Original Assignee||Foamix Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (882), Non-Patent Citations (283), Referenced by (33), Classifications (32), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to PCT Patent Application No. PCT/IB2009/005012, filed Jan. 14, 2009, entitled “POLOXAMER FOAMABLE PHARMACEUTICAL COMPOSITIONS WITH ACTIVE AGENTS AND/OR THERAPEUTIC CELLS AND USES,” which claims the benefit of priority under 35 U.S.C. §119(e) to (1) U.S. Provisional Patent Application No. 61/020,950, filed Jan. 14, 2008, entitled “METHODS FOR POLYMER COMPOSITIONS AND USES THEREOF,” and (2) U.S. Provisional Patent Application No. 61/077,779, filed Jul. 2, 2008, entitled “POLOXAMER FOAMABLE PHARMACEUTICAL COMPOSITIONS WITH ACTIVE AGENTS AND OR THERAPEUTIC CELLS AND USES,” the contents of all of which are incorporated by reference.
External topical administration is an important route for the administration of drugs in disease treatment. Many groups of drugs, including, for example, antibiotic, anti-fungal, anti-inflammatory, anesthetic, analgesic, anti-allergic, corticosteroid, retinoid and anti-proliferative medications are preferably administered in hydrophobic media, namely ointment. However, ointments often form an impermeable barrier, so that metabolic products and excreta from the wounds to which they are applied are not easily removed or drained away. Furthermore, it is difficult for the active drug dissolved in the carrier to pass through the white petrolatum barrier layer into the wound tissue, so the efficacy of the drug is reduced. In addition, ointments and creams often do not create an environment for promoting respiration of the wound tissue and it is not favorable to the normal respiration of the skin. An additional disadvantage of petroleum jelly-based products relates to the greasy feeling left following their topical application onto the skin, mucosal membranes and wounds.
A gel is a semi-rigid, jelly-like colloidal dispersion of a solid with a liquid. The main constituent of gels is liquid, e.g., water, yet they behave like solids due to the addition of a gelling agent. A hydrogel is a network of polymer chains that are water-insoluble, sometimes found as a colloidal gel in which water is the dispersion medium.
Foams are considered a more convenient vehicle for topical delivery of active agents. There are several types of topical foams, including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components, and oleaginous foams, which consist of high oil content. Certain foams, such as shaving foams and hair mousses are not suitable as vehicles for topical drugs, because, for example, they do not absorb into the skin following application (e.g., shaving foams) or because they contain foaming surfactants that can be irritating, (e.g., ionic surfactants, in the case of shaving foam and hair mousse). “Quick-break” thermolabile foams are not ideal because they typically contain substantial amounts of alcohol, which can cause skin drying and irritation and are not convenient as they collapse quickly so that it is difficult to apply them on the target area. Also alcohol containing foams are not suitable for the treatment of open wounds and burns, neither are they suitable for treatment of body cavities, such as the vagina. On the other hand breakable foams, which remain stable on exposure to body temperature but break upon mechanical stimulation allowing easy and convenient spreading are desirable for pharmaceutical use.
Poloxamers, also known by the trade name Pluronics, are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). Because the lengths of the polymer blocks can be customized, many different Poloxamers exist.
Compositions comprising Poloxamers are known in which Poloxamer is merely one ingredient in a complex combination of excipients with or without active pharmaceutical ingredients. Poloxamer has also been used as a constituent of foam produced by mechanical lathering without propellant.
However, most prior art foam compositions that contain Poloxamer lack stability and collapse upon contact with a delivery site in/on a subject. Some pharmaceutical compositions for rectal or vaginal administration have been developed, which comprise: (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabilizer which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance. These compositions must be delivered using multi-compartment syringes and rely on there being a chemical reaction between parts i) and ii). In the example xanthan and Poloxamer are in combination, wherein the concentration of poloxamer is less than 0.2% and xanthan gum is present in a five fold higher concentration than Poloxamer.
Foam compositions for rectal administration of a solid powder in which the surfactant is Poloxamer have been published. Such compositions include (a) over 25 wt % of a powdered active principle, and (b) 1-20 wt % of a surfactant, and the balance (c) being water. The powdered active principle has a particle size of less than 20 μm.
Also published are compositions of matter without fatty alcohol where the surfactant may be Poloxamer but in the Poloxamer examples the concentration of Poloxamer is 1.6% and a high level of ethyl alcohol (60%) is used to form a foamable delivery system.
A composition has been disclosed comprising (a) monohydric alcohol (b) surfactant comprising a dimethicone surfactant and (c) a builder to improve or provide stability of a foam derived from the composition, in which the builder can be a Poloxamer and wherein the alcohol is 35% to 99.5%. In the examples the Poloxamer foam builder was 0.08% and 0.3% and the alcohol was 65% ethanol 200% proof.
Sprayable germicidal foam compositions to cover wounded skin containing Poloxamer which remain stable for at least an hour and have a half life of 5-7 hours are known. Fatty acids and fatty alcohols are required and the Poloxamer must not exceed 3× the fatty acids or be less than half their combined amount. In the examples Poloxamer was 1.5% to less than 2%.
Foamable suspension gel formulations containing benzyl peroxide in combination with clindamycin have been published in which the gel base contains 0.1 to 2% of a thickening agent. In the Examples, the thickening agent is 1% xantham gum, and it is used with a dispensing or wetting agent (1% Poloxamer 188 and other components), with water being the main component. Although other agents are listed as dispersing or wetting agents only Poloxamer 188 is used in the examples. Good wetting agents are typically considered to be poor foaming agents and vice versa.
Liquid bioadhesive microemulsions or liopsomic dispersions containing proteinic substances are described in which the composition contains a fixing copolymer. At body temperature the viscosity of the compositions is increased and provides an increased residence time at the administration site.
A composition for a foam and a process for preparing have been disclosed in the art, the composition including by weight (a) more than 25% of an active ingredient in powder form; (b) from 1% to 20% of a surfactant; the balance being composed of water, wherein the powder of the active ingredient has a particle size below 20 μm. The surfactant can be a mixture of two surfactants one being a hydrophilic surfactant with a HLB greater than 10 and the other being a polyoxyalkylene-based surfactant (possibly, Poloxamer). In the examples, the amount of hydrophilic surfactant is much greater than the Poloxamer.
The use of Poloxamers with ability to change the sol-gel transition temperature by pH adjustment and by ionic strength adjustment has been disclosed. The preferred polymers are those which form gels at a concentration range of 10% to 50% of the polymer to water.
The use of thermosetting copolymers (Pluronic 127 or Lutrol127) with liposomic dispersions to administer a peptide or protein drug to a body surface is known. In the examples 13%-19.5% copolymers were used.
Other prior art complex compositions include formulations comprising a polymeric agent, which may be a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface. Such phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca2+). Non-limiting examples of phase change polymers include poly(N-isopropylamide), and Poloxamer 407®. High concentrations of Poloxamer are used for gelling.
There are disclosed new, improved, convenient to use, stable foam Poloxamer carrier formulations and pharmaceutical compositions, which are an advance over the prior art.
Foams are complex dispersion systems which do not form under all circumstances. Slight shifts in foam composition, such as by the addition of active ingredients, may destabilize the foam. Foams are very complex and sensitive systems and are not formed at will. Mere addition of basic ingredients like oil, surfactant and propellant is far from sufficient to produce foams of quality that are homogenous, stable, breakable upon mechanical force and can be used to provide a shelf stable pharmaceutical or cosmetic composition. Small deviations may lead to foam collapse. Much consideration needs to be given to facilitate the introduction of an active agent, such as examining compatibility and non reactivity with the various excipients and container and determining shelf life chemical and physical stability.
Neubourg (US 2006/0099151), for example, notes that the stability of foam is strongly dependent on the specific composition of the foam forming components, so that even small deviations in the composition may lead to a collapse of the foam. Gordon et al. (U.S. Pat. No. 3,456,052). also teaches that one cannot generate a good quality foam by simply adding a propellant to a mixture of components:
The term “foam” is a general term that encompasses a range of substances. Accordingly, the context in which “foam” is discussed must be examined carefully. The type and quality of the foam is of critical importance. There are many different types of foams and within each foam type there are many levels of qualities. For example, the froth on the head of beer, lather of shampoo, and lather of shaving cream have been loosely described as foam but all are different from one another. At one end of the cosmetic or pharmaceutical foam spectrum the foam can be long lasting and essentially not readily breakable like shaving foams. At the other end of the spectrum the foam can be quick breaking and collapses upon release.
Thermolabile foams are an example of type of quick breaking foam. They can contain significant amounts of thermolabile substances that aid their collapse upon being exposed to an increased temperature for example when applied to a body surface at 37 C. Upon being exposed to the higher temperature they collapse rapidly. Examples are foam formulations that comprise significant amounts of volatile solvents.
Breakable foam is a specialized type of foam. It is a low density foam that is stable on release at least in the short time span of several minutes, which facilitates application to a target area; but can break readily upon the application of shear force such as gentle rubbing to spread easily over a target surface. It is not thermolabile (and does not melt at skin temperature) and nor does it display late or long delayed expansion over minutes.
Some foams expand slowly whilst others do so quickly. Some foams foam immediately and some demonstrate delayed foaming. Some require mechanical lathering and some expulsion by propellant. Whilst they all fall under the so called term “foam” and may appear to have some common ingredients the results and properties of these products are different.
A suitable foamable formulation for a particular application may present challenges at several levels. For example, a foam formulation may require a stable pre foam formulation; a stable pre foam propellant formulation and ultimately delivery an effective measured amount of active agent to a target. Each of these objectives poses its own unique challenges.
The pharmaceutical and cosmetic foams discussed herein are generated in general terms by manufacturing a suitable foamable carrier composition and loading the carrier in a pressurized valved canister with an appropriate propellant. Upon expelling the canister contents a foam can be released. The type, nature and quality of the foam depends inter alia on the carrier composition, the active agent, the propellant and the method of manufacture and storage. Making a stable (physically and chemically) formulation that can be stored in a canister with a propellant that remains stable and can produce a breakable foam of quality on release is far from trivial.
An additional difficulty frequently encountered with propellant foams is their inability to dispense a satisfactorily uniform application of the medically active ingredient throughout the use of the aerosol container. This is particularly due to the fact that the active material is not stably dispersed in the foamable composition so that it will have a tendency to settle to the bottom. Further, the dispersed material will sometimes clog the spray dispensing valve to further interfere with the uniform dispensing of the medicament. Issues such as the effect of the propellant on the properties of the formulation such as viscosity and miscibility can be critical; whilst the pressure of the propellant; and the shakability of the pre foam formulation with propellant can also effect the ability to achieve satisfactory uniform application as well as the ability to avoid jets and tailing.
In an aspect there is provided a pharmaceutical or cosmetic composition comprising a foamable carrier comprising:
In certain embodiments the Poloxamer comprises at least one of Poloxamer 124, Poloxamer 188, Poloxamer 237, Poloxamer 338 or Poloxamer 407 or mixtures of two or more thereof, such as 407 and 124. In a preferred embodiment the Poloxamer comprises at least one of Poloxamer 188 and Poloxamer 407 or mixtures thereof. In another embodiment the Poloxamer capable of fixing the composition, such as, Poloxamer 407. In an aspect the Poloxamer is about 0.2% to about 2% by weight. In different embodiments the Poloxamer comprises a molecular weight in a range (i) between about 2,000 and about 2,400; or (ii) between about 6,800 and about 8,900; or between about 7,600 and about 9,500; or (ii) between about 9,800 and about 14,600; or (iii) between about 12,000 and about 18,000. In certain aspects the ratio of Poloxamer to non ionic surface active agent is about 1:2; about 1:1; about 2:1; about 4:1; about 8:1; about 10:1; about 15:1; about 20:1; about 30:1; about 40:1; about 50:1, or any range or combination thereof (e.g., from about 1:2 to about 50:1; from about 1:1 to about 1:50; from about 2:1 to about 50:1; from about 4:1 to about 50:1; from about 8:1 to about 50:1; from about 10:1 to about 50:1; from about 15:1 to about 50:1; from about 20:1 to about 50:1; from about 30:1 to about 50:1; from about 40:1 to about 50:1; from about 1:2 to about 1:1; from about 1:2 to about 2:1; from about 10:1 to about 50:1; from about 2:1 to about 8:10; etc.). In other aspects, the ratio of Poloxamer to polymer or polysaccharide is from about 1:1 to about 50:1 (e.g., from about 1:2 to about 50:1; from about 1:1 to about 1:50; from about 2:1 to about 50:1; from about 4:1 to about 50:1; from about 8:1 to about 50:1; from about 10:1 to about 50:1; from about 15:1 to about 50:1; from about 20:1 to about 50:1; from about 30:1 to about 50:1; from about 40:1 to about 50:1; from about 1:2 to about 1:1; from about 10:1 to about 50:1; from about 2:1 to about 8:10; etc.).
In one or more embodiments the viscosity of the composition at about body temperature is substantially greater than the viscosity of the composition at room temperature.
In certain aspects, the percentage by weight of polyoxyethylene component of the poloxamer is between about 70% and about 85% of the Poloxamer.
In some embodiments, the foam produced has a mild cooling effect or sensation. Without being bound by a theory it is thought that the propellant can either be trapped to some extent in the polymeric spaces or network of the formulation or in the gel and when the expelled foam is applied to the skin some residual evaporation takes place.
In one or more embodiments the Poloxamer formulation aids the intradermal penetration of the active agent so that it is in excess of about 300 micrograms/cm2/24 hr.
In one or more embodiments the Poloxamer improves the absorption of the active agent into the stratum corneum and thereafter into the dermis without a substantial increase in transdermal penetration.
In one or more embodiments the Poloxamer is included in the formulation in an amount sufficient to dissolve an active agent in an aqueous phase, wherein such an active agent is not fully soluble in said aqueous phase.
In one or more embodiments when the active agent is not otherwise fully soluble in water, in hydrophobic solvent, or in the oil phase of the emulsion, the Poloxamer is present in the composition in an amount sufficient to solubilize the active agent in the composition.
In one or more embodiments the active agent comprises at least one of diclofenac, salicylic acid or clindamycin or mixtures of two or more thereof.
In one or more embodiments the active agent in an effective amount is capable of causing the composition to form a gel, which in the presence of a sub effective amount would be liquid. For example salicylic acid can cause Poloxamer to gel
In one or more embodiments the gelling effect is a result of a reduction in pH and or an increase of ionic strength.
In an aspect there is provided a Poloxamer composition, further comprising at least one ingredient, comprising:
In an aspect there is provided a foamable Poloxamer composition further comprising a foam adjuvant comprising a fatty alcohol having 15 or more carbons in their carbon chain; or a fatty acid having 16 or more carbons in their carbon chain; or fatty alcohols, derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain; or a fatty alcohol having at least one double bond; a fatty acid having at least one double bond; or a branched fatty alcohol; or a branched fatty acid or a fatty acid substituted with a hydroxyl group or mixtures of two or more thereof.
In an aspect the Poloxamer formulation is an oil in water emulsion.
In an aspect there is provided a Poloxamer pharmaceutical or cosmetic cell composition comprising:
In an aspect there is provided a Poloxamer composition which is suitable as a cell therapy composition comprising:
In one or more embodiments any one or more of the Poloxamer cell formulations further comprises an active agent.
In one or more particular embodiments where an active agent is provided in the carrier formulation the active agent can be encapsulated, for example in a microsponge or any other of the encapsomes described below
In another aspect there is provided pharmaceutical or cosmetic foamable composition for application to a delivery site in a subject, the composition comprising:
In one or more embodiments the poloxamer and the polymeric agent or polysaccharide when present together act synergistically so that the amount of poloxamer required can be substantially reduced.
In one or more embodiments the polymeric agent or polysaccharide is water soluble or water dispersible.
In one or more embodiments the composition comprises about 95-99.8% water.
In one or more embodiments said at least one water-soluble or water dispersible polymeric agent or polysaccharide comprises one or more of a an acrylic acic polymer, a permulen, a carbomer, methocel, sodium CMC, PVP and xanthan gum.
In one or more embodiments said at least one silicone compound comprises one or more of cyclomethicone, dimethicone, cyclomethicone and dimethicone Copolyol (DC3225C).
In one or more embodiments the Poloxamer foam has a density of between about 0.01 to about 0.2 g/cm3 In one or more limited embodiments the Poloxamer foam has a density in excess of about 0.2 g/cm3 and the foam can takes the form of an aerated gel upon application to a delivery site, wherein the delivery site comprises skin or a body cavity.
In an aspect there is provided pharmaceutical or cosmetic foamable composition for application to a delivery site in a subject, the composition comprising:
In an embodiment the hydrophobic solvent comprises a silicone. In an embodiment the hydrophobic solvent further comprises an oil. In an embodiment the hydrophilic solvent comprises a glycol. In an embodiment the hydrophilic solvent comprises glycerin. In an embodiment the hydrophilic solvent comprises a glycol and glycerin. When the Poloxamer composition comprises a silicone, a glycol and glycerin the intradermal penetration of the active agent can be in excess of about 300 micrograms/cm2/24 hr.
In an embodiment the Poloxamer improves the absorption of the active agent into the stratum corneum and thereafter into the dermis without a substantial increase in transdermal penetration.
In an embodiment there is provided a method of treating, alleviating or preventing a disorder of a mammalian subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical Poloxamer composition comprising an active agent or therapeutic cells or fragments thereof, to an afflicted target site of said mammalian subject.
In an embodiment there is provided method of treating, alleviating or preventing a disorder of a mammalian subject in need thereof, comprising administering a therapeutically effective amount of a foam produced from a Poloxamer composition comprising an active agent or therapeutic cells or fragments thereof, to an afflicted target site of said mammalian subject.
In one or more embodiments the propellant is separate from the formulation.
In one or more embodiments the composition is packaged in a dual chamber device having two canisters connected to a mixing means arranged and adapted to mix the contents of the canisters upon simultaneous release of their content, wherein the aqueous Poloxamer surfactant system is stored in a first canister and the aqueous therapeutic cells are packaged in a second canister wherein the surfactant system and the therapeutic cells are capable of being mixed upon being expelled from the canisters; and wherein the propellant in the second canister is separate from the therapeutic cells.
In one or more embodiments the dual chamber device has a metered dose means for each canister.
In one or more embodiments there is provided a method of treating, alleviating or preventing a disorder of a mammalian subject in need thereof, comprising administering a therapeutically effective amount of a gel or foam produced from a Poloxamer composition of claim 1 to an afflicted target site of said mammalian subject.
In one or more embodiments there is provided a Poloxamer composition having the following properties:
wherein the resultant foam has at least 5 of the following properties:
In one or more embodiments the Poloxamer composition has one property and the foam has 6 or 7 or all the properties. In one or more embodiments the composition has both properties. In one or more further embodiments the resultant foam has 6 or 7 or all of the properties.
One key element is the Poloxamer polymeric agent used in the formulation. Another contributing factor can be the additional presence of a polymer or polysaccharide. These polymeric agent(s) can contribute to the stability and stabilization of the formulation. Concentrations of polymeric agents and other thickeners have in the past been used to achieve very high viscosities of at least 20,000 cps to a million or more cps. Surprisingly, it has been unexpectedly found that by using low viscosities of the order of about 16,000 cps or less to about 1 cps, or less than about 10,000, or less than about 8000, or less than about 6000, or less than about 4000, or less than about 2000, or less than about 1000, for the pre foam formulation whose viscosity can be further reduced upon inclusion of propellant it has been possible to achieve a stable formulation that produces breakable foam of quality. It is unexpected that a hydrophilic highly aqueous formulation can provide Without being bound by any theory it may be the case that the polymeric agent(s) can provide an infrastructure or network around the propellant that unexpectedly is able to trap some propellant and or propellant is trapped in a gel or semi gel composition such that when the composition is released from a pressurized canister a quality form is released with good dispensing. This possibility is suggested by the observation that certain formulations when expelled provides a foam, which when applied immediately to a skin surface causes a mild cooling sensation, which may be due to propellant escape from the polymer network Moreover, the composition is able to stabilize the active agent physically and chemically.
In one or more embodiments an emulsion Poloxamer composition is provided comprising a silicone. Unexpectedly it is possible to make compositions which are flowable in which the propellant forms part of the oil phase of the emulsion formulation but nevertheless surprisingly does not make the formulation substantially vulnerable to phase separation and or sedimentation. Moreover these compositions are stable and are able to form breakable foam of quality that spreads easily and is able to deliver an effective and measurable amount of active agent homogeneously to a target surface. By introducing an oil shakability is improved.
In one or more embodiments the active agent is dissolved in the composition and is dissolved in the expelled foam.
The invention is described with reference to the figures which are presented for the purpose of illustration and are not intended to be limiting.
This invention relates to foamable pharmaceutical and cosmetic vehicles or carriers; therapeutic compositions with active agents, therapeutic compositions where the active agent is encapsulated, for example, in microspheres, and delivery systems including cell delivery systems, comprising a Poloxamer.
In one or more embodiments no surfactant other than Poloxamer is required to make a gel or foam. The gel may be fixing such that it is liquid at room temperature and gel or semi gel like at or approaching body temperature, even at very low Poloxamer concentrations. In other embodiments other surfactants may be present. In further embodiments a combination of Poloxamer and polymer can be used.
There are provided polymer-based aqueous foams, especially very low density foams, where the main polymeric component is a Poloxamer and the foamable formulations include an active agent and are suitable for pharmaceutical or cosmetic administration with one or more propellants such that the resultant foams are easy to use, stable and non-irritating, with unique therapeutic properties which may include anti-infective properties and membrane transport properties. There are also provided such compositions in which the viscosity increases when the formulation is exposed to body temperature.
One important feature of topical products is the ability to deliver an effective amount of active agent intradermally with minimal transdermal penetration; and there are provided Poloxamer formulations with active agents, which provide improved intradermal penetration without significant transdermal penetration of such active agents.
An important feature of topical products is the solubility of active agents in the components of the composition and in the formulation as a whole. For example, the solubility can affect the rate of delivery of the active agent into the target site of treatment (such as the skin); and through membranes (such as the skin or mucosal membranes). There are provided formulations in which the Poloxamer improves the solubility of or acts to dissolve an active agent in an aqueous phase, wherein such an active agent is not fully soluble in said aqueous phase.
An important feature of topical products is the feel or sensation of the composition on application and there are provided Poloxamer based formulations which provide a mild cooling sensation without using large amounts of propellant.
There are provided new, improved, convenient to use, stable foam Poloxamer formulations, containing specific ingredients, which should effectively deliver and/or deposit various active agents into and onto the skin and/or other target sites and are relatively non-irritating and thus suitable for use by people having sensitive skin, mucosal areas and eyes.
According to one or more embodiments, the foamable composition includes the following essential components:
According to one or more embodiments, there is provided a pharmaceutical or cosmetic composition comprising:
According to one or more embodiments, there is provided a foamable or pharmaceutical or cosmetic composition, wherein the active agent is provided in microspheres, which are suspended in the composition.
In some embodiments, the concentration of Poloxamer is between about 0.1% to about 5% and the composition further includes a supporting agent, such as a non-ionic surface active agent. In some embodiments, the concentration of Poloxamer is between about 0.1% to about 5%; and the composition further includes a supporting agent such as a non surfactant polymer or polysaccharide. In some embodiments, such as when the composition includes a supporting agent, the Poloxamer is capable of the fixing the composition to a body surface.
In some embodiments, the composition is capable of forming a foam. For example, in some embodiments the composition is packaged in a packaging assembly. The assembly includes, for example, a container (e.g., an aerosol container), equipped with a valve and an actuator. Such assemblies are capable of releasing a foam and pressurized with a liquefied or compressed propellant. In some embodiments, the ratio of the foamable carrier to the propellant is about 100:1 to about 100:25.
According to one or more embodiments, there is also provided a pharmaceutical or cosmetic composition comprising:
According to one or more embodiments, there is also provided an aqueous foamable composition for application to a delivery site in a subject, the composition comprising:
In some embodiments, the Poloxamer and the polymeric agent when present together act synergistically so that the amount of Poloxamer required can be substantially reduced.
In some embodiments, the Poloxamer is in an amount capable of forming, upon exposure to body temperature, a gel either alone or in combination with a supporting agent. In certain embodiments, the supporting agent is selected from the group consisting of about 0.1% to about 0.5% surface active agent, about 0.1% to about 1% non surfactant polymer or polysaccharide or mixtures thereof.
In a preferred embodiment the Poloxamer is about 0.2% to about 2% in combination with a supporting agent.
All % values are provided on a weight (w/w) basis.
In the context of the present invention, the term “fixing” means a viscosity change of a formulation containing Poloxamer upon a temperature change such that the viscosity of a preparation comprising Poloxamer substantially increases when the temperature changes from room temperature of about 20° C. to a temperature of about 30° C. or more. In some embodiments “fixing” may also be induced by a change in the pH or in the ionic strength of the said solution. One consequence of fixing is that a liquid or semi liquid formulation turns viscous enough to remain substantially in the same place when applied to a body surface. The term “fixing Poloxamer” relates to a Poloxamer, which is capable, subject to exposure of elevated temperature, change in pH or ionic strength, of affording a “fixing” effect.
In an embodiment the composition comprises a Poloxamer in combination with a polysacharide to produce a synergistic gelling effect. This is a unique advantage, which enables much lower amounts of Poloxamer and polysaccharide to be used to achieve a gelling effect. Thus, whilst Poloxamer alone (e.g. Poloxamer 407) or polysaccharide alone (e.g., xantham gum) can produce aqueous gels, higher amounts are required than the total amount when they are in combination. Since Poloxamer has surfactant like properties, its presence in low concentrations is advantageous, for example, when the active agent of the composition comprises a therapeutic cell (as defined hereinbelow), and the cells are sensitive to surfactants. In an embodiment, in order to attain the fixing property, the Poloxamer is selected such that the formulation may be liquid or semi liquid at room temperature but upon warming to hand or body temperature the viscosity increases. In an embodiment the increase in viscosity is sufficient to have a gelling effect or to increase the retention time at the site of application or to increase the collapse time of a foam derived from the Poloxamer formulation.
In an embodiment the composition is packaged in an aerosol container, equipped with a valve and an actuator, capable of releasing a foam and pressurized with a liquefied or compressed propellant at a concentration of about 1% to about 25% by weight of the total composition. In an alternative embodiment the composition is packaged in a bag in aerosol or bag in valve delivery system in which the composition is stored in a bag separate from the propellant.
The foam released from the container is light and cosmetically-elegant. It is not a “quick-breaking” foam that collapses upon exposure to skin temperature; but rather it is breaks down upon application of very low sheer force, such as very easy movement of the fingers over the treated area.
The composition can contain one or more additional formulation additives, which can serve various functional purposes, including but not limited to one or more of the following purposes:
Thus, the composition may contain one or more additional formulation additives, as follows:
In an embodiment, the carrier comprises a Poloxamer. Poloxamer is a synthetic block copolymer of ethylene oxide and propylene, having the general formula of:
For the generic term “Poloxamer”, these copolymers are commonly named with the letter “P” (for Poloxamer) followed by three digits, the first two digits×100 give the approximate molecular mass of the polyoxypropylene core, and the last digit×10 gives the percentage polyoxyethylene content. For example, P407 is a Poloxamer with a polyoxypropylene molecular mass of 4,000 g/mol and a 70% polyoxyethylene content.
Poloxamers have several useful characteristics depending on the Poloxamer(s) selected. They can be thickeners and at higher concentrations gel forming in aqueous solution. They also have surfactant properties and can act as emulsifiers and wetting agents. Some are able to create thermo-sensitive solutions, such that their properties such as viscosity change with temperature. They are strongly hydrophilic and can help to improve solubility. Poloxamers are soluble in water and in alcohol. Poloxamers are used as emulsifying agents for intravenous fat emulsions, as solubilizing agents to maintain clarity in elixirs and syrups and as wetting agents for anti bacterials. They have been used in a variety of oral parenteral, and topical pharmaceutical formulations and are generally regarded as nontoxic and non irritant. Poloxamers are stable materials and aqueous solutions of Poloxamers are stable in the presence of acids, bases and metal ions. Poloxamers are not metabolized by the body.
Poloxamers are available in different grades which vary from liquids to solids. Table I, below exemplifies types of Poloxamers, conforming to the following requirements:
46.7 ± 1.9
0.020 ± 0.008
81.8 ± 1.9
0.026 ± 0.008
72.4 ± 1.9
0.034 ± 0.008
83.1 ± 1.7
0.031 ± 0.008
73.2 ± 1.7
0.048 ± 0.017
Examples of other Poloxamers are: 181, 182, 183, 184, 185, 212, 215, 217, 231, 234, 235, 238, 331, 333, 334, 335, 401, 402, and 403.
The successful restoration of membrane transport properties through surfactant Poloxamer 188 has been demonstrated. Poloxamer 188 (P188, mol wt=8400 g/mol), has the structure of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO, with 80 wt % PEO content). As a result of its amphiphilic nature, P188 has the capability to interact with a cell membrane and is found to alleviate as well as reverse damages caused by electrical trauma.
In an embodiment, the Poloxamer is included in the formulation, in an amount between about 0.1% and about 30%, preferably between about 0.5% and about 25% or more preferably between about 1% and about 10%.
In an embodiment, the Poloxamer is included in the formulation in an amount sufficient to dissolve an active agent in an aqueous phase, wherein such an active agent is not fully soluble in said aqueous phase.
In addition of their unique formulation properties, Poloxamers possess certain therapeutic effects. For example, Poloxamer 188 has been reported to improve capillary blood flow in burn injury (J Surg Res. 2001; 101(1):56-61); and Poloxamer 407 possesses immunomodulation and cytotoxicity-promoting properties (Pharmaceutical Res. 2006; 23(12): 2709-2728). Poloxamers have been reported to have anti-mycobacterial activity within macrophages (Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother). 1999 Sep. 26-29; 39:400) and they enhance the phagocytic activity of macrophases (Journal of the National Cancer Institute, Vol. 88, No. 11, Jun. 5, 1996). Thus, in certain embodiments, the Poloxamer acts not only as a formulation (vehicle) component, but also as an active agent of the composition, alone, or together with another active agent.
The sensory properties of foams containing a Poloxamer are favorable, as revealed by consumer panel tests.
It has been surprisingly discovered that Poloxamer 407 can be fixing at low levels of Poloxamer.
The composition may contain a surface-active agent in addition to Poloxamer. Surface-active agents (also termed “surfactants”) include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average). In certain cases HLB values can be found outside the standard range.
In many cases a single Poloxamer or a combination of Poloxamers suffice to facilitate producing a foam. Similarly where a liquid or semi liquid formulation which becomes gel like is desired a single fixing Poloxamer or a combination of Poloxamers at least one of which is a fixing Poloxamer may suffice to achieve effective fixing. In one or more embodiments the combination of poloxamers or poloxamers and another polymer or polysaccharide may act synergistically.
In other cases a combination of a Poloxamer with one or more surfactants other than Poloxamer) is desired. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. It has been further discovered that the generally thought HLB considerations are not always binding and that good quality foams can be produced with a surfactant or surfactant combination both where the HLB values are in or towards the lipophilic side of the scale and also where the HLB values are in or towards the hydrophilic side of the scale.
According to one or more embodiments in addition to Poloxamer the composition contains a single surface active agent having an HLB value between about 2 and about 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9. Lower HLB values may in certain embodiments be more applicable to water in oil emulsions.
According to one or more embodiments in addition to Poloxamer the composition contains a single surface active agent having an HLB value between about 7 and about 14, or more than one surface active agent and the weighted average of their HLB values is between about 7 and about 14. Mid range HLB values may, in certain embodiments, be more suitable for oil in water emulsions.
According to one or more other embodiments in addition to Poloxamer the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
According to one or more preferred embodiments the surface-active agent (other than Poloxamer) has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, or the composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
In one or more embodiments, the surface-active agent in addition to Poloxamer includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed.
Non limiting examples of possible non-ionic surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myrj 49, Myrj 52 and Myrj 59; poly(oxyethylene) alkyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol ether, brij 38, brij 52, brij 56, brij W1, ceteareth 20; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, and mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters including those having high monoester content, which have higher HLB values).
Mixtures of Non-Ionic Surfactants are Contemplated
In one or more embodiments the surface active agent is a complex or combination of two or more surface active agents (one of which may be poloxamer) that can be more effective than a single surfactant and provides a more stable emulsion or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant. Preferably, the complex comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters. In certain embodiments surfactants which tend to form liquid crystals may improve the quality of foams produced from compositions.
In one or more embodiments, the surfactant in addition to Poloxamer is a surfactant or surfactant combination that is capable of or which tends to form liquid crystals.
In one or more embodiments, the at least one surface active agent is solid, semi solid or waxy.
In certain cases, the surface active agent is ionic and is selected from the group of anionic, cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, alkyltrimethylammonium salts, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
Combination of Non-Ionic and Ionic Surfactants
In additional embodiments, the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1. In further embodiments, surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
In one or more embodiments, a combination of a non-ionic surfactant and an ionic surfactant (such as an anionic surfactant sodium lauryl sulphate or a zwitterionic surfactant cocamidopropyl betaine) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1. The resultant foam has a low specific gravity, e.g., less than 0.1 g/ml.
Where there is a combination of non-ionic and ionic surfactants then at least one non ionic surfactant is a Poloxamer.
The concentration of the surface active agent other than Poloxamer is between about 0.1% and about 5%. In a more preferred embodiment the concentration of surface active agent other than Poloxamer is between about 1% and about 4%.
Synergistic Foam Forming Effect
Surprisingly, it was found that while concentrations of less than about % or about 2% of a Poloxamer, are not sufficient to produce a composition that evolves an acceptable foam of quality, the addition of even small amounts of a non-ionic surface active agent affords an excellent foam with high expansion (density of less that 0.1 g/mL), easy spreadability and quick absorption into the skin upon application.
In an embodiment where there is a combination of (1) about 0.1% to about 5% of a Poloxamer; and (2) a non-ionic surface active agent, the ratio of Poloxamer to non ionic surface active agent is from about 1:2; about 1:1; about 2:1; about 4:1; about 8:1; about 10:1; about 15:1; about 20:1; about 30:1; about 40:1; to about 50:1.
In an embodiment where there is a combination of (i) about 0.1% to about 5% of a Poloxamer; and (2) an ionic surface active agent, the ratio of Poloxamer to ionic surface active agent is from about 1:2 to about 1:1; about 2:1; about 4:1; about 8:1; about 10:1; about 15:1; about 20:1; about 30:1; about 40:1; to about 50:1;
The foamable composition can be an emulsion, or microemulsion, including an aqueous phase and an organic carrier phase. In one or more embodiments the emulsion may comprise hydrophilic and hydrophobic ingredients combined in a predominately aqueous base, Thus, optionally, the foamable vehicle further includes at least one hydrophobic solvent, which constitutes the organic phase of the emulsion, at a concentration of about 1% to about 50% by weight. A “hydrophobic solvent” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is semi-solid or liquid at ambient temperature. The identification of a “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of such solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic component in the foamable compositions described herein. Examples of hydrophobic solvents include, but are not limited, to the following classes:
Triglycerides and Plant-Derived Oils
According to one or more embodiments, hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources, which are usually triglycerides. Suitable liquid oils include partially-saturated, unsaturated or polyunsaturated oils. By way of non limiting example, the partially saturated or unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, jojobo oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
Capric/Caprylic Triglycerides are Commonly used in Topical Formulations
Unsaturated and polyunsaturated oils are oils that contain unsaturated and/or poly-unsaturated fatty acids such as oleic acid, linoleic acid, linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid, and docosahexaenoic acid. Oils containing such unsaturated and ply-unsaturated fatty acids are known for their therapeutic benefits when applied topically.
Esters of Fatty Acids
Esters of fatty acids, suitable for use as a hydrophobic solvent, include but are not limited to isopropyl palmitate, isopropyl isostearate, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, cetyl acetate, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, maleated soybean oil,
Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenylsiloxane) copolymers. These are chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered as therapeutically active hydrophobic solvents, due to their barrier retaining and protective properties. In one or more embodiments, the hydrophobic carrier includes at least about 1%, about 2%, about 3%, about 4% by weight silicone oil or at least about 5% by weight.
Polypropylene Glycol Alkyl Ether
In an embodiment, the organic carrier is a polypropylene glycol alkyl ether (PPG alkyl ether). PPG alkyl ethers are liquid, water-insoluble propoxylated fatty alcohols, having the molecular formula of RO(CH2CHOCH3)n; wherein “R” is a straight-chained or branched C4 to C22 alkyl group; and “n” is in the range between 4 and about 50. They are organic liquids that function as skin-conditioning agent in pharmaceutical and cosmetic formulations. Non-limiting exemplary PPG alkyl ethers include PPG stearyl ethers and PPG Butyl Ether. Preferred PPG alky ethers according to the present invention include PPG-15 Stearyl Ether, PPG-2 Butyl Ether, PPG-9-13 Butyl Ether and PPG-40 Butyl Ether.
Fatty Acids and Fatty Alcohols as Hydrophobic Solvents
In an embodiment, the hydrophobic solvent is a fatty acid which are liquid of semi-solid at ambient temperatures. Exemplary liquid or semi-solid fatty acids include, but are not limited to unsaturated fatty acids, polyunsaturated fatty acids and branched fatty acids. Examples of unsaturated fatty acids include myristoleic acid, palmitoleic acid and oleic acid. Examples of polyunsaturated fatty acids include linoleic acid, α-linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid. An example for branched fatty acids is isostearic acid, which is a clear, oily liquid.
In an embodiment, the hydrophobic solvent is a fatty alcohol which are liquid of semi-solid at ambient temperatures. Examples of liquid or semi-solid fatty alcohols include, but are not limited to unsaturated fatty alcohols, polyunsaturated fatty alcohols and branched fatty alcohols. Exemplary unsaturated fatty alcohols include cis-6-octadecen-1-ol (petroselenyl alcohol), cis-9-octadecen-1-ol (oleyl alcohol) and cis-11-octadecen-1-ol (vaccenyl alcohol). Exemplary of polyunsaturated fatty alcohols include bombykol (tr-10,cis-12-hexadecadien-1-ol), and avocadene (16-heptadecene-1,2,4-triol). An example for branched fatty acids is isostearyl alcohol.
Mineral Oil and Petrolatum
Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. It is typically liquid; its viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C. In certain embodiments, the hydrophobic solvent comprises or contains petrolatum, which is also termed “white petrolatum” and “Vaseline”. Petrolatum depending on the amount in a formulation and the nature of the formulation can form an impermeable occlusive layer, which protects the skin and may facilitate enhanced penetration of active agents.
In an embodiment, the hydrophobic solvent is a wax, selected from the group consisting of (1) a fatty alcohol; (2) a fatty acid; and (3) certain naturally occurring waxes. Examples of waxes, suitable as hydrophobic solvents in accordance to the present invention include, but are not limited, to (1) a C8 to C22 fatty acid or fatty alcohol; (2) C16 to C20 fatty acid or fatty alcohol; (3) a branched chain fatty acid or fatty alcohol; (4) a straight chain fatty acid or fatty alcohol; (5) a saturated fatty acid or fatty alcohol (6) an unsaturated fatty acid or fatty alcohol; (7) a fatty acid or a fatty alcohol, selected from the group consisting of isostearic acid, oleic acid, oleyl alcohol, stearic acid, cetyl alcohol, stearyl alcohol, erucic acid, linoleic acid, arachidonic acid and linolenic acid; (8) a fatty acid or a fatty alcohol, selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, 12-hydroxystearic acid, undecylenic acid, tall acid, isostearic acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA); and (9) jojoba oil. In certain preferred embodiment, the wax is semi-solid or liquid at ambient temperature, such as oleyl alcohol, isostearic acid and jojoba oil.
Essential oils are plant oils extracted by distillation. Nonlimiting examples of essential oils include agar oil, ajwain oil, angelica root oil, anise oil, balsam oil, basil oil, bergamot oil, black Pepper essential oil, buchu oil, cannabis flower essential oil, caraway oil, cardamom seed oil, carrot seed oil, cedarwood oil, chamomile oil, cinnamon oil, cistus, citronella oil, clary Sage, clove leaf oil, coriander, costmary oil, cranberry seed oil, cumin oil/Black seed oil, cypress, davana oil, dill oil, eucalyptus oil, fennel seed oil, fenugreek oil, frankincense oil, galbanum, geranium oil, ginger oil, grapefruit oil, henna oil, jasmine oil, juniper berry oil, lavender oil, lemon oil, lemongrass oil, litsea cubeba oil, melissa oil (Lemon balm), mentha arvensis oil/Mint oil, mugwort oil, mustard oil, myrrh oil, neroli oil, orange oil, oregano oil, orris oil, parsley oil, patchouli oil, perilla essential oil, pennyroyal oil, peppermint oil, pine oil, rose oil, rosehip oil, rosemary oil, rosewood oil, sassafras oil, savory oil, schisandra oil, spearmint oil, star anise oil, tarragon oil, tea tree oil, thyme oil, vetiver oil, yarrow oil and ylang-ylang oil. Many essential oils are used as medical and aromatherapy applications, and thus, can be considered as therapeutically active hydrophobic solvents.
Emollients and “Therapeutically Active Hydrophobic Solvents”
Emollients are substances that soften and soothe the skin. They are used to correct dryness and scaling of the skin. Many of the hydrophobic solvents listed herein possess emollient properties and therefore, in addition to their contribution to the formulation texture, they provide an extra-benefit in the treatment of damaged skin and skin afflicted by a disorder that involves dry skin (such as psoriasis and atopic dermatitis).
Certain hydrophobic solvents listed herein further possess other properties which, which contribute to the therapeutic benefit of the present foamable composition, such as antibacterial, antifungal and anti-inflammatory properties. In the context, oils that possess therapeutically-beneficial properties are termed “therapeutically active solvent”.
Mixtures of various hydrophobic solvents are anticipated.
Optionally, the foamable vehicle further includes at least one polar solvent. A “polar solvent” is an organic solvent, typically soluble in both water and oil. Polar solvents, such as detailed below possess high solubilizing capacity and contribute to the skin penetration of an active agent. Examples of polar solvents include dimethyl isosorbide polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, other glycols, oleyl alcohol, alpha-hydroxy acids, such as lactic acid and glycolic acid, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformamide, methyl dodecyl sulfoxide, dimethylacetamide, azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, alkanols, such as dialkylamino acetates, and admixtures thereof. In certain preferred embodiments, the polar solvent is selected from the group consisting of dimethyl isosorbide glycerol (glycerin), propylene glycol, hexylene glycol, terpene-ol, oleyl alcohol, lactic acid and glycolic acid.
According to one or more embodiments, the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
Hydrophilic Emollients and “Therapeutically Active Solvents”
Certain hydrophilic solvents listed herein, such as glycerin, various glycols (for example propylene glycol_), α-hydroxy acids and PEGs (for example PEG, 200, 400, 600, 4000, 6000, 10,000) attract water and consequently possess emollient properties and therefore, in addition to their contribution to the formulation texture, they provide an extra-benefit in the treatment of damaged skin and skin afflicted by a disorder that involves dry skin (such as psoriasis and atopic dermatitis).
Certain hydrophobic solvents listed herein such glycerin, various glycols (for example propylene glycol), α-hydroxy acids, further possess other properties which, which contribute to the therapeutic benefit of the present foamable composition, such as antibacterial, antifungal, anti-inflammatory properties, anti-psoriasis and anti-aging effects. In the context, hydrophilic solvents that possess therapeutically-beneficial properties are termed “therapeutically active solvent”.
Non-limiting examples of alpha hydroxy acids include glycolic acid, lactic acid, malic acid, citric acid, alpha-hydroxyethanoic acid, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acidglycolic acid, tartaric acid, pyuric acid, citric acid, as well as their corresponding salts and pharmaceutically-acceptable derivatives; or any combination of any of the foregoing.
Hydroxy acids can help solubility and dermal penetration of a variety of drugs or cosmetic active agents.
“Polysaccharides” refer to agents which contain a backbone of repeating sugar (i.e., carbohydrate) units. Nonlimiting examples of polysaccharide gelling agents include xantham gum, agar, guar gum, locust bean gum, sodium alginate, sodium caseinate, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, tragacanth gum, cationic guars, hydroxypropyl guar gum, starch, a chemically modified starch, hydroxypropyl starch, hyaluronic acid, sodium hyaluronate, sodium stearyl fumarate, chitosan, ceratonia, pectin, calcium alginate, alginic acid, carrageenan and the like and those selected from cellulose, carboxymethycellulose sodium (NaCMC), carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, methylhydroxypropylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Also useful herein are the alkyl substituted celluloses. In these polymers, the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage. Typically these polymers are ethers of CloC30 straight or branched chain alcohols with hydroxyalkylcelluloses. Examples of alkyl groups useful herein include those selected from stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e. alkyl groups derived from the alcohols of coconut oil), paln-lityl, oleyl, linoleyl, linolenyl, ricinoleyl, behenyl, and mixtures thereof. Preferred among the alkyl hydroxyalkyl cellulose ethers is the material given the CTFA designation cetyl hydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose. This material is sold under the tradename Natrosol O CS Plus from Aqualon Corporation (Wilmington, Del.). Other useful polysaccharides include scleroglucans which are a linear chain of (1-3) linked glucose units with a Q-6) linked glucose every three units, a commercially available example of which is Clearogel™ CS 11 from Michel Mercier Products Inc. (Mountainside, N.J.).
Other useful polymeric agents include a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, acrylates/C10-C30 alkyl acrylates cross polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a cationic cellulose, polyvinylpyrrolidone (PVP), PEG 1000, PEG1500, PEG2000, PEG 4000, PEG 6000, PEG 8000, a polycarbophil, a carbomer, ASOS, and a pemulen. Some polymers are sensitive to pH like carbomers and may be used with a weak base such as trolamine (also known as triethanolamine or TEA) to aid or control their expansion.
It is thought that the polysaccharides and the other useful polymers act as stabilizers and thickeners. They are not considered surfactants except perhaps for pemulen, which can act as a non traditional emulsifier.
In an embodiment where there is a combination of (i) about 0.1% to about 5% of a Poloxamer; and (2) a non-ionic polymer or polysacharide, the ratio of Poloxamer to non ionic polymer or polysacharide is from about 1:1; about 2:1; about 4:1; about 8:1; about 10:1; about 15:1; about 20:1; about 30:1; about 40:1; to about 50:1;
Optionally, the foamable vehicle further includes a foam adjuvant selected from the group consisting of a fatty alcohol, which is solid at ambient temperature, having 15 or more carbons in their carbon chain; a fatty acid including straight-chain fatty acids, branched and substituted fatty acids, which is solid at ambient temperature, having 16 or more carbons in their carbon chain.
In an embodiment of the composition includes one or more additional components. Such additional components include but are not limited to one or more antioxidants, anti perspirants, anti-static agents, buffering agents, bulking agents, chelating agents, cleansers, colorants, conditioners, deodorants, diluents, dyes, emollients, flavanoids, fragrances, hair conditioners, humectants, ionization agents, moisturizers, occlusive agents, perfuming agents, pearlescent aids, perfuming agents, permeation enhancers, pH-adjusting agents, preservatives, protectants, skin penetration enhancers, softeners, solubilizers, sunscreens, sun blocking agents, sunless tanning agents, viscosity modifiers and vitamins. As is known to one skilled in the art, in some instances a specific additional component may have more than one activity, function or effect.
Preservatives, Anti-Oxidants/Radical Scavengers, Ionizing Agents, Buffering Agents and pH Modifying Agents
In one or more embodiments, the composition contains a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol. Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents. Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.
Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename TroloxR), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts may be used.
In one or more embodiments the antioxidant agent is a flavonoid. A non limiting list of flavonoid compounds is: benzquercin, diosmin, ethoxazorutoside, flavodate, sodium hesperidin, leucocianido, monoxerutin, oxerutin, quercetin, rutoside, rutin, rosmarinic acid.
Suitable buffering agents include but are not limited to acetic acid, adipic acid, calcium hydroxide, citric acid, glycine, hydrochloric acid, lactic acid, magnesium aluminometasilicates, phosphoric acid, sodium carbonate, sodium citrate, sodium hydroxide, sorbic acid, succinic acid, tartaric acid, and derivatives, salts and mixtures thereof.
In one or more embodiments of the present invention, a chelating agent is selected from the group consisting of acetyl trihexyl citrate, aminotrimethylene phosphonic acid, beta-alanine diacetic acid, bismuth citrate, EDTA and salts thereof, HEDTA and salts thereof, citric acid, cyclohexanediamine tetraacetic acid, diammonium citrate, dibutyl oxalate, diethyl oxalate, diisobutyl oxalate, diisopropyl oxalate, dilithium oxalate, dimethyl oxalate, dipotassium edta, dipotassium oxalate, dipropyl oxalate, disodium pyrophosphate, etidronic acid, methyl cyclodextrin, oxalic acid, pentapotassium, triphosphate, pentasodium aminotrimethylene phosphonate, pentasodium pentetate, pentasodium triphosphate, pentetic acid, phytic acid, potassium citrate, sodium citrate, sodium dihydroxyethylglycinate, sodium gluceptate, sodium gluconate, sodium hexametaphosphate, sodium metaphosphate, sodium metasilicate, sodium oxalate, sodium trimetaphosphate, tetrahydroxypropyl ethylenediamine, tetrapotassium etidronate, tetrapotassium pyrophosphate, tetrasodium etidronate, tetrasodium pyrophosphate, trisodium phosphate, malic acid, fumaric acid, maltol, succimer, penicillamine, dimercaprol, and desferrioxamine mesilate. Other authorized chelating agents are listed pursuant to annex 1, paragraph E.3.1 of regulation (EC) No 2003 (See Directive 67/548/EEC OJ 196, 16.8 1967, p 1) and are also incorporated herein by reference.
A humectant, is a substance that helps retain moisture and also prevents rapid evaporation. Non limiting examples of suitable heumectants are propylene glycol, propylene glycol derivatives, and glycerin. Further humectants include but are not limited to guanidine, urea, glycolic acid, glycolate salts, ammonium glycolate, quaternary alkyl ammonium glycolate, lactic acid, lactate salts, ammonium lactate, quaternary alkyl ammonium lactate, aloe vera, aloe vera gel, allantoin, urazole, alkoxylated glucose, hyaluronic acid, lactamide monoethanolamine, acetamide monoethanolamine and derivatives, esters, salts and mixtures thereof.
Other examples of humectants and moisturizers may be found in the Handbook of Pharmaceutical Additives published by Gower. Suitable ones for use with and soluble in the waterless compositions of the present invention may be selected as will be appreciated by a person skilled in the art.
A moisturizer, is a substance that helps retain moisture or add back moisture to the skin. Examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA. Glycerine and sodium pCA work in combination. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
Pharmaceutical compositions of the present invention may in one or more embodiments usefully comprise in addition a humectant or a moisturizer or combinations thereof.
In an embodiment, the propellant is a hydrocarbon propellant. Examples of suitable hydrocarbon propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof. Non limiting examples are AP70; AP46; and 1681. Alternatively, use of ether propellants, fluorocarbon propellants, as well as compressed gases (e.g., air, carbon dioxide, nitrous oxide, and nitrogen) is also possible. Examples of other optional propellants are dimethyl ether (DME), methyl ethyl ether and hydrofluoroalkanes (HFA), for example HFA 134a (1,1,1,2-tetrafluoroethane) and HFA 227 (1,1,1,2,3,3,3-heptafluoropropane). Mixtures of propellants can be useful. Typical concentrations of hydrocarbon and fluorocarbon propellants is between about 3% and about 25%, however, in various applications, higher concentrations, up to about 40% or in limited cases even up to about 70% can be used. The concentration of a compressed gas, such as carbon dioxide and nitrogen is restricted to up to about 5% to 10% due to their high pressure; however, it should be noted that even about 1% propellant depending upon the pressure and formulation may be sufficient to evolve a foam. In an embodiment, the ratio of the foamable carrier to the propellant is about 100:1 to about 100:25.
Composition and Foam Physical Characteristics and Advantages
A pharmaceutical or cosmetic composition manufactured using the foamable carrier is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
The foamable Poloxamer compositions are stable, such that they are capable of having an acceptable shelf-life of at least about six months, preferably about one year, or more preferably, at least about two years at ambient temperature The aqueous Poloxamer foams demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
The foamable composition should also be able to flow through the aperture of the container, e.g., aerosol valve and aerosol container, and create an acceptable foam.
Foam quality can be graded as follows:
Topically administrable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
Density is also a distinguishing factor in looking at the quality of foams. Poloxamers are used herein to form low density foams with good expansion having a density of less than about 0.2 g/ml, preferably with a density of less than about 0.1 g/ml. Where the Poloxamer formulations have a density of more than about 0.2 g/ml they do not form true foams and are considered to be aerated or bubble gels, being formed by expulsion with a propellant from a sealed canister under ambient conditions. Foam quality grading as above is not really appropriate for bubble gels which are mentioned herein since the bubble gel is not a foam or not a true foam and displays relatively high density (about 0.2 to about 0.9 g/cm3), much less expansion and slow drainage.
As further aspect of the foam is breakability. The breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
The breakable foam herein is not “quick breaking” and is not “thermolabile”, i.e., it does not collapse quickly upon expulsion and it does not readily collapse or melt upon exposure to body temperature environment. The breakable foam further does not display a long delayed expansion over minutes. Stability over a short time frame of minutes has advantages over foam which collapses quickly upon release. Similarly sheer-force breakability of the foam is clearly advantageous over thermally induced breakability. Both these factors allow for comfortable application and well directed administration to the target area. Breakable foam can break readily upon the application of shear force such as gentle rubbing to spread easily over a target surface. The sheer-force breakable foams herein are of low density, which further assists spreadability and contributes to a light pleasant feel. In certain embodiments the breakable foam is also fixing.
Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, Poloxamer foams have specific gravity of less than about 0.2 g/mL; or less than about 0.12 g/mL; or less than about 0.10 g/mL; or less than about 0.08 g/mL, depending on their composition and on the propellant concentration.
According to certain embodiments, the foamable composition is alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect. This disadvantage is particularly meaningful in the case of an antibiotic treatment, which is often directed to open wounds and damaged skin and mucosal tissues. In one or more other embodiments, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
The foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients. In the context, active pharmaceutical ingredients and active cosmetic ingredients are collectively termed “active agent” or “active agents”.
Suitable Active Agents
Suitable active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin D derivatives, wound healing agents and wart removers. As is known to one skilled in the art, in some instances a specific active agent may have more than one activity, function or effect.
Encapsulation of an Active Agent
In one or more embodiments, the active agent is encapsulated. The encapsulation may be, for example, in particles, microparticles, nanoparticles, microcapsules, microspheres, nanocapsules, nanospheres, liposomes, niosomes, polymer matrix, mineral bodies, silica-gel, graphite, nanocrystals, dendrimers or microsponges. Such particles etc., (hereinafter “encapsome”) can have various functions, such as (1) protection of the drug from degradation; (2) modification of the drug release rate from the composition; (3) control of skin penetration profile; and (4) mitigation of adverse effects, due to the controlled release of the active agent from the encapsulation particles.
An “encapsome” may be used to incorporate one or more active agents in a gel or foam. For example, it may retain within its structure or confines at least one active agent during storage, and yet release active agent at the delivery site responsive to a local temperature effect, a local pH effect, a local conductivity effect or any other local parameter or stimulus of the delivery site, which is different from that of the storage conditions.
Microsponges are macroporous beads, typically 10-25 microns in diameter, loaded with active agent. They consist of a copolymer, such as methyl methacrylate/glycol dimethacrylate crosspolymer. Examples of drugs that have been incorporated in microsponges include ibuprofen ketoprofen (non-steroidal anti-inflammatory agent), benzyl peroxide (an anti-acne agent), and fluconazole (an antifungal agent). Microsponges on application to skin release the active ingredient on a time mode and also in response to other stimuli (rubbing, temperature, pH, etc). In one or more embodiments microsponges may be incorporated into the formulations exemplified and described herein. In an embodiment the amount of microsponges may be varied from about 1% to about 25% of the formulation, preferably about 5% to 15%. Microsponge containing compositions are shown in Example 15. A person skilled in the art, will understand that the microsponge may be replaced by one or more other encapsomes in the compositions of the present invention.
In an embodiment any active agent suitable for loading in microsponges may be used, such as benzyl peroxide (BPO), tretinoin, hydroquinone, kotoprofen, vitamins, retinoids, such as retinoic acid isoretinoic acid and retinol, calcipotriol or calcitriol or tacalcitol (with or without a corticosteroid such as betmethasone or its esters (eg bmv)), flucinonide, hydrocortisone or clobetasol proprionate, flavanoids, fluconazole, ibuprofen, trolamine and the like. Where the active agent is oil soluble but not water soluble then formulations with minimal or no oil are preferred where the active agent is primarily to be located in the microsponges. So in an embodiment there is no oil in the formulations, only gels. In another embodiment, there are no significant amounts of true oils that solubilize the active ingredients and extract them from the microsponges. In an embodiment where the active ingredient is insoluble in water and is entrapped in the microsponges there is provided true oil in water emulsion, where the active ingredient is only exposed to the external water phase and does not access the internal oil phase. This may be achieved in an embodiment by formulating an aqueous oil gel foam with substantial water content. The methodology of loading microsponges with active agent and amounts that can be loaded are described in WO 01/85102, which is incorporated herein by way of reference. Where Drug Microsponge X % w/w is specified it refers to the microsponges including the trapped drug and any other ingredients incorporated when loading the microsponges.
“Dendrimers” are 3-dimensional polymeric materials of low polydispersity comprising repeatedly branched molecules, which are constructed by the successive addition of layers to the branching groups. Each new layer is called a generation. The final generation can incorporate additional active groups to tailor the functionality of the dendrimer. They can be neutral, anionic or cationic. The selection of core, branching and surface molecules gives the dendrimer the desired properties. Dendrimers are useful to prevent and to treat vaginal infections, sexually transmitted diseases, viral infections and HIV. They can be used against bacteria, yeast, fungi, or parasites.
Solubility of an Active Agent
In an embodiment, the active agent is not fully soluble in water or, is not fully soluble in the presence of a hydrophobic solvent in the formulation, or is not fully soluble in the oil phase of the emulsion. In an embodiment, the Poloxamer is present in the composition in an amount sufficient to solubilize the active agent in the composition. In one or more embodiments Poloxamer acts to improve the solubility of an active agent. In one or more embodiments Poloxamer enables the formulation to become clear. In a preferred embodiment the active agent to be solubilized is diclofenac or salicylic acid.
Exemplary Groups of Active Agents
In an embodiment, the active agent is a non-steroidal anti-inflammatory agent. In the context, a nonsteroidal antiinflammatory agent (also termed herein “NSAID”) is a pharmaceutically active compound, other than a corticosteroid, which affects the immune system in a fashion that results in a reduction, inhibition, prevention, amelioration or prevention of an inflammatory process and/or the symptoms of inflammation and or the production pro-inflammatory cytokines and other pro-inflammatory mediators, thereby treating or preventing a disease that involves inflammation.
In one or more embodiments, the NSAID is an inhibitor of the cyclooxygenase (COX) enzyme. Two forms of cyclooxygenase are known today: the constitutive cyclooxygenase (COX-1); and the inducible cyclooxygenase (COX-2), which is proinflammatory. Thus, in one or more embodiments, the NSAID is selected from the group consisting of a COX-1 inhibitor, a COX-2 inhibitor or a non-selective NSAID, which simultaneously inhibits both COX-1 and COX-2.
In one or more embodiments, the NSAID is salicylic acid a salicylic acid derivatives. Exemplary salicylic acid derivative include, in a non limiting fashion, aspirin, sodium salicylate, choline magnesium trislicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, olsalazine, esters of salicylic acid with a carboxylic acid, esters of salicylic acid with a dicarboxylic acid, esters of salicylic acid with a fatty acid, esters of salicylic acid with a hydroxyl fatty acid, esters of salicylic acid with an essential fatty acid, esters of salicylic acid with a polycarboxylic acid, and any compound wherein salicylic acid is linked to an organic moiety through a covalent bond.
In one or more embodiments, the NSAID is para-aminophenol (e.g., acetaminophen) and salts and derivatives thereof.
In one or more embodiments, the NSAID is an indole or an indole-acetic acid derivative (e.g., indomethacin, sulindac, etodolac) and salts and derivatives thereof.
In one or more embodiments, the NSAID is an aryl acetic acids (e.g., tolmetin, diclofenac, ketorolac) and salts and derivatives thereof.
In one or more embodiments, the NSAID is an arylpropionic acid and salts and derivatives thereof. Exemplary arylpropionic acid derivative include, in a non limiting fashion, are ibuprofen, naproxen, flubiprofen, ketoprofen, fenoprofen, oxaprozin.
In one or more embodiments, the NSAID is anthranilic acids or an anthranilic acid derivative, also termed “fenamates” (e.g., mefenamic acid, meclofenamic acid) and salts and derivatives thereof.
In one or more embodiments, the NSAID is selected from the group of enolic acids, enolic acid salts, enolic acid esters, amides, anhydrides and salts and derivatives thereof. Non-limiting examples of enolic acid derivatives include oxicams (piroxicam, tenoxicam) and pyrazolidinediones (phenylbutazone, oxyphenthratrazone)
Yet, in additional embodiments, the NSAID is an alkanone (e.g., nabumetone).
Selective COX-2 Inhibitors include, in an exemplary manner diaryl-substituted furanones (e.g., Rofecoxib); diaryl-substituted pyrazoles (e.g., Celecoxib); indole acetic acids (e.g., Etodolac); and sulfonanilides (e.g., Nimesulide) and salts and derivatives thereof. In an embodiment, the Poloxamer is present in the composition in an amount sufficient to solubilize the NSAID, as exemplified herein by the solubilization of both diclofenac and salicylic acid in both non-emulsion and emulsion based compositions.
In an embodiment, the active agent is a steroid. In certain embodiments the steroid is a corticosteroid, including but not limited to, hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethsone dipropionate, clobetasol valemate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters, chloroprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortmate, mepreddisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, as well as analogs, derivatives, salts, ions and complexes thereof.
In certain embodiments, the steroid is a hormone or a vitamin, as exemplified by pregnane, cholestane, ergostane, aldosterone, androsterone, calcidiol, calciol, calcitriol, calcipotriol, clomegestone, cholesterol, corticosterone, cortisol, cortisone, dihydrotestosterone, ergosterol, estradiol, estriol, estrone, ethinylestradiol, fusidic acid, lanosterol, prednisolone, prednisone, progesterone, spironolactone, timobesone and testosterone, as well as analogs, derivatives, salts, ions and complexes thereof.
In an embodiment, the Poloxamer is present in the composition in an amount sufficient to solubilize the steroid.
In an embodiment, the active agent is an immunomodulator. Immunomodulators are chemically or biologically-derived agents that modify the immune response or the functioning of the immune system. Immunomodulators suitable for use according to the present invention include, among other options, cyclic peptides, such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, laflunimus, laquinimod and imiquimod, as well as analogs, derivatives, salts, ions and complexes thereof. Such compounds, delivered in the foam, are especially advantageous in skin disorders such as psoriasis, eczema and atopic dermatitis, where the large skin areas are to be treated. In an embodiment, the Poloxamer is present in the composition in an amount sufficient to solubilize the immunomodulator.
In an embodiment, the active agent is a retinoid. The general formula of retinoids is:
where R is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, CH2OH, CH2NH2, CHO, CH═NOH, CO2H, CH═N[CH2]4CHNH2CO2H, CH3, CO2C2H5, CH2OCOCH3, a heteroatom, a saccharide and a polysaccharide.
Retinoids suitable for use according to the present invention include, among other options, include retinol, retinal, retinoic acid, isotretinoin, tazarotene, adapalene, 13-cis-retinoic acid, acitretin all-trans beta carotene, alpha carotene, lycopene, 9-cis-beta-carotene, lutein and zeaxanthin, as well as analogs, derivatives, salts, ions and complexes thereof.
Retinoids are known as sensitive agents, which tend to degrade in the presence of various formulation components, as well as oxygen, heat and light. Therefore, in certain embodiments, the retinoid is encapsulated in particles, microparticles, nanoparticles, microcapsules, microsphres, nanocapsules, nanospheres, liposomes, niosomes, polymer matrix, silica-gel, graphite, nanocrystals or microsponges. Such particles can have various functions, such as (1) protection of the retinoid from degradation; (2) modification of the retinoid release rate from the composition; (3) control of skin penetration profile; and (4) mitigation of adverse effects, due to the controlled release of the retinoid from the encapsulation particles.
In an embodiment, the active agent is an antiinfective agent. Such anti-infective agent can be selected from the group of an antibiotic agent, an antibacterial agent, an antifungal agent, an agent that controls yeast, an antiviral agent and an antiparasitic agent. Exemplary antiinfective agents are exemplified by beta-lactam antibiotic, an aminoglycoside, an ansa-type antibiotic, an anthraquinone, an azole, metronidazole, an antibiotic glycopeptide, a macrolide, erythromycin, clindamycin, an antibiotic nucleoside, an antibiotic peptide, polymyxin B, an antibiotic polyene, an antibiotic polyether, an antibiotic quinolone, an antibiotic steroid, fucidic acid, mupirocin, chloramphenicol, a sulfonamide, tetracycline, an antibiotic metal, silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium, an oxidizing agent, iodine, iodate, a periodate, a hypochlorite, a permanganate, a substance that release free radicals and/or active oxygen, a cationic antimicrobial agent, a quaternary ammonium compound, a biguanide, chlorohexidine, a triguanide, a bisbiguanide, a polymeric biguanide and a naturally occurring antibiotic compound, as well as analogs, derivatives, salts, ions and complexes thereof.
Cells as Active Agents
In an embodiment, the active agent is a therapeutic cell, or a mixture of therapeutic cells, or culture of therapeutic cells. In another embodiment the active agent is a fragment or fraction of a therapeutic cell, a mixture of therapeutic cells, or culture of therapeutic cells. In a further embodiment a fragment or fraction of the therapeutic cells can be one or more of cell organelles, such as mitochondria, golgi apparatus, endoplasmic reticulum, lysosomes, nucleus, cell membrane, and the like. The therapeutic cells, as provided in the present invention are cells that have a therapeutic benefit, through a variety of mechanisms, treatment modes and pathways. Without claiming specific mechanisms of action, the therapeutic cells, or fragments or fractions thereof can have an effect on microbial, bacteria, fungal or viral infection, autoimmune conditions, tumors, metastases, wound, burn, ulcer and post operative injury. The therapeutic cells can act directly on the condition, or via releasing signaling agents, such as cytokines, chemokines and the like. In one or more embodiments, therapeutic cells, fragments and fractions can include stem cells, blood cells, nerve cells or other cells of human origin. In an embodiment the cells produce antisense therapy. In a particular embodiment the therapeutic cells can be engineered to provide gene therapy. Genes are inserted into an individual's cells to treat a disease including hereditary diseases. The cells are then administered to the individual. The gene therapy may be somatic or it may be germ line gene therapy. In another embodiment the therapeutic cells may act to bolster or stimulate the subject's immune system. In an embodiment, the cells are selected from the group consisting of fibroblasts, langerhans cells, keratinocytes, leukocytes, phagocytes (such as macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. In other embodiments, the cells are skin cells, such as fibroblasts, langerhans cells and keratinocytes. Such cells may in one or more embodiments be in the early sages of development or differentiation. In one or more embodiments the cells may be inverted, for example, ghost cells. In other embodiments the cells are of plant, bacterial or viral origin and can include phages. In one or more embodiments the cells secrete an active agent such as a hormone or a neuro-transmitter or a cytokine or a chemokine or an interferon and the like. Cytokines have been variously named as lymphokines, interleukins, and chemokines. Cytokines are a category of signaling proteins and glycoproteins that, are used extensively in cellular communication. Cytokines are a diverse class of compounds in terms of origin and purpose. They are produced by a wide variety of hematopoietic and non-hematopoietic cell types and can have effects on both nearby cells or throughout the organism, sometimes strongly dependent on the presence of other chemicals. The cytokine family consists mainly of smaller, water-soluble proteins and glycoproteins with a mass of between 8 and 30 kDa. Chemokines can guide the migration of cells. Cells that are attracted by chemokines follow a signal of increasing chemokine concentration towards the source of the chemokine. Their activities include directing lymphocytes; promoting angiogenesis; guide cells to tissues that provide specific signals critical for cellular maturation; inflammatory in response to bacterial infection, viruses and agents that cause physical damage. Their release is often stimulated by pro-inflammatory cytokines such as interleukin 1. Inflammatory chemokines function mainly as chemoattractants for leukocytes, recruiting monocytes, neutrophils and other effector cells from the blood to sites of infection or tissue damage. Certain inflammatory chemokines activate cells to initiate an immune response or promote wound healing. They are released by many different cell types and serve to guide cells of both innate immune system and adaptive immune system. In an embodiment cells which secrete one or more of the following classes of cytokines is selected: CC cytokines; CXC cytokines; C cytokines; CX3C cytokines.
In an embodiment, the therapeutic cells are included in the composition in a concentration, suitable for an effective treatment of a disease or condition. Mixtures of different therapeutic cells are contemplated.
An exemplary composition which is suitable as a cell therapy composition includes:
A further exemplary composition which is suitable as a cell therapy composition includes:
In an embodiment, the Poloxamer/polymer system is included in the composition in a concentration which suitable to keep the cells in viable state. In an embodiment, the Poloxamer is included in the composition in a concentration which enhances the therapeutic effect of the therapeutic cells.
In a preferred embodiment the Poloxamer is a fixing Poloxamer. In a more preferred embodiment the fixing Poloxamer is Poloxamer 407.
In an embodiment, the Poloxamer/polymer system is included in the composition in a concentration or concentration ratio that, at low temperature, such as about 20° C. or lower, the composition is flowable, while upon application to a body surface, having temperature of more than about 30° C., it creates a more viscous composition. This can be achieved by selecting an effective amount of a suitable fixing Poloxamer.
In an embodiment the more viscous composition is semi-fluid. In a preferred embodiment the composition becomes a substantially non-flowable gel. This property is particularly important, in the event that it is desirable to deliver the composition, containing therapeutic cells to a target site as a liquid, but to fix it at the target site upon application or to improve the retention time. If the composition is to be delivered as a liquid to a body cavity it can be advantageous that it becomes a gel upon exposure to body temperature since this will facilitate or improve its retention in the body cavity. Likewise, if the composition is to be delivered as a foam, then upon application to a target site as the foams temperature increases its collapse time will increase and after the foam is broken by gentle mechanical force it may have gel or semi gel like properties so it conveniently remains at the target site. If the foam is applied to a body cavity then as indicated above upon exposure to body temperature this property will facilitate or improve its retention in the body cavity. In an unexpected discovery it has been found that fixing may occur at low concentrations of fixing Poloxamer synergistically in combination with a polysacharide.
Exemplary concentrations of a Poloxamer alone are about 20% or more, in the case of Poloxamer 407.
It was surprisingly discovered that while concentrations of less than about 20% of a Poloxamer, are not sufficient to produce a non-flowable gel upon application to a body surface, having temperature of more than about 30° C., a combination of a Poloxamer and a polymer affords synergistically a non-flowable gel upon application to a body surface, having temperature of more than about 30° C. at much lower concentrations. Exemplary concentrations of Poloxamer/polymer combination system is about 1% or more of Poloxamer 407 and about 0.5% or more or about 0.7% or more of a polymeric agent.
Exemplary suitable polymers include, in a non-limiting manner, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid and hyaluronic acid (which can also be obtained from biotechnological processes); chemically modified starches and the like, carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Additional exemplary polymeric agents include semi-synthetic polymeric materials such as cellulose ethers, such as methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, and cationic celluloses, carbomer (homopolymer of acrylic acid is crosslinked with an allyl ether pentaerythritol, an allyl ether of sucrose, or an allyl ether of propylene, such as Carbopol® 934, Carbopol® 940, Carbopol® 941, Carbopol® 980 and Carbopol® 981. Polyethylene glycol, having molecular weight of 1000 or more (e.g., PEG 1,000, PEG 4,000, PEG 6,000 and PEG 10,000) also have gelling capacity and while they are also considered herein as “polar solvents”, they are also considered polymeric agents. Mixtures of polymeric agents are contemplated.
In a preferred embodiment the polymer is a polysachharide, In a more preferred embodiment the polysachharide is a cell derived polysachharide like xantham gum or hyaluronic acid.
In an embodiment, the Poloxamer/polymer system is included in the composition in an optimized concentration or concentration ratio that, in one aspect, at low temperature, such as about 20° C. or lower, the composition is flowable, while upon application to a body surface, having temperature of more than about 30° C., it creates a non-flowable gel, and in an additional aspect, it is suitable to keep the cells in viable state.
In an embodiment, the composition provides a synergistic effect, resulting from the direct activity of the therapeutic cells, and the induction of release of signaling agents, such as cytokines, chemokines and the like, either from the therapeutic cells or from other cells present in the viable tissue of the target site.
In an embodiment, the composition, comprising a Poloxamer or a Poloxamer/polymer system and therapeutic cells, as described above, is packaged in an aerosol container, equipped with a valve and an actuator, capable of releasing a foam and pressurized with a liquefied or compressed propellant at a concentration of about 1% to about 25% by weight of the total composition.
Dual and Multi Chamber devices and heads suitable for use with the formulations described herein where a first formulation is stored in a first canister and a second formulation is stored in a second canister are described in U.S. Pat. No. 6,305,578 entitled DEVICE FOR MIXING, FOAMING AND DISPENSING LIQUIDS FROM SEPARATE COMPRESSED-GAS CONTAINERS and in US Publication 2007-0069046 and entitled APPARATUS AND METHOD FOR RELEASING A MEASURE OF CONTENT FROM A PLURALITY OF CONTAINERS all of which are incorporated herein by reference in their entirety. More particularly any of the devices and uses described are applicable herein and are incorporated by reference.
In an embodiment the dual chamber device is as described in U.S. Pat. No. 6,305,578 for example, a compressed gas container apparatus, having at least two compressed gas containers, disposed side by side, each for one foamable liquid product which contains a liquefied propellant gas, wherein both compressed gas containers are each provided with a valve, both valves are actuatable in common by a top fitting, and each valve is provided through the top fitting with a connecting conduit, the connecting conduits discharge into a mixing chamber, and an expansion conduit adjoins the mixing chamber and on its end has a foam dispensing opening, characterized in that the connecting conduits and the mixing chamber have such small cross-sectional areas that when a product is dispensed, the products flowing through the connecting conduits) and the mixing chamber remain in a liquid phase.
In an embodiment the dual dispenser head is as described in US Publication 2007-0069046 for example:
a dispenser head for use with a plurality of containers, comprising:
In one or more embodiments the dual canister kit may include a bag in canister or bag on valve system for one or both of the compositions.
In one or more embodiments the dual chamber system is adapted and arranged to provide mixing of the contents of the canisters in a mixing means connected to the canisters.
In one or more embodiments the dual chamber system is adapted and arranged to provide uniform dosing of the contents of each canister by a metered dosing means connected to the canisters.
In one or more embodiments there is provided a kit comprising a dual chamber device or dual dispenser head, a first canister comprising a first foamable formulation comprising a first API and a second canister comprising a second foamable formulation comprising a second API wherein each canister is connectable to the said device or head. The first foamable formulation may be any of the Poloxamer formulations described herein and the second foamable formulation may also be any of the Poloxamer formulations described herein. In an embodiment the first API is a steroid and the second API is a vitamin D derivative and the each formulation is adapted to carry an effective amount of steroid and vitamin D derivative, respectively, such that each formulation and API is sufficiently chemically and physically stable for pharmaceutical use.
In another embodiment the second foamable formulation is one of the therapeutic cell foamable compositions described Example 16 below. In another embodiment as indicated under example 16 the first formulation is a Poloxamer formulation and the second formulation is an aqueous formulation comprising therapeutic cells or cell fragments/fractions or mixtures thereof. Similarly In another embodiment the second foamable formulation can be one of the microsponge foamable compositions described Example 15 below.
Fields of Applications
The foamable composition is suitable for the treatment of any inflicted surface. In one or more embodiments, foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”). In the context herein “treatment” can mean any administration or application of a remedy to a patient that is intended to prevent, cure or decrease the symptoms of a disease or disorder, or to relieve pain, anxiety or any form of perceived discomfort.
By selecting a suitable active agent, or a combination of two or more active agents, the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, eethyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, granuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo.
Likewise, the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranuloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
In an embodiment, the disorder is a dermatological disorder, which can be treated by a Poloxamer.
In an embodiment, the disorder is a dermatological disorder, which can be synergistically treated by an active agent, together with a Poloxamer.
In an embodiment, the disorder is a dermatological disorder, which can be treated by a topical steroid.
In an embodiment, the disorder is a dermatological disorder, which can be treated by an immunomodulator.
In an embodiment, the disorder is a dermatological disorder, which can be treated by a retinoid.
In an embodiment, the disorder is a dermatological disorder, which can be treated by cell therapy.
In an embodiment, the disorder is a dermatological disorder, which can be treated by gene therapy.
In an embodiment, the disorder is a dermatological disorder, which can be treated by cytochine.
In an embodiment, the disorder is a dermatological disorder, which can be treated by chemotherapy.
In an embodiment, the disorder is a dermatological disorder, which can be treated by an anti-infective agent, such as an antibacterial agent, and antibiotic, an antifungal agent and an antiviral agent.
In an embodiment, the disorder is a dermatological disorder, which is common in children. Foam is advantageous in the topical treatment of children, who are sensitive to treatment with a cream or ointment.
In an embodiment, the disorder is atopic dermatitis and the active agent is a steroid, a NSAID or an immunomodulator.
In an embodiment, the disorder is psoriasis and the active agent is a steroid, a NSAID, a retinoid or an immunomodulator.
In an embodiment, the disorder is selected from psoriasis and atopic dermatitis and the active agent comprises a steroid, together with an additional non-steroidal active agent, such as a vitamin D derivative.
In an embodiment, the active agent a NSAID, and the disorder is selected from the group consisting of acne, rosacea, actinic keratoses, joint pain, back pain, superficial pain and the like and osteoarthritis.
In an embodiment, the composition is useful for the treatment of an infection. In one or more embodiments, the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
In an embodiment, the composition is useful for the treatment of wound, ulcer and burn.
The composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
In an embodiment, the Poloxamer composition can be applied to protect the skin prior to exposure to radiation or to help or accelerate the healing after exposure to radiation. In a preferred embodiment the polymer in the Poloxamer/polymer aqueous composition is hyaluronic acid.
Each aerosol canister is filled with the pre-foam formulation (“PFF”) and crimped with valve using vacuum crimping machine and then pressurized with propellant. The process of applying a vacuum will cause most of the oxygen present to be eliminated. Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
Pressurizing is carried out using a hydrocarbon gas or gas mixture. Canisters are filled and then warmed for 30 sec in a warm bath at 50° C. and well shaken immediately thereafter.
Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60° C. water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
In an embodiment, where there are therapeutic cells the propellant is separate from the therapeutic cells Poloxamer formulation and the product is assembled using a bag on valve system or bag in can canister assembly in which the product is in a sealed bag inside the sealed canister which has been filled with propellant. Upon actuation the propellant exerts pressure on the bag to expel its contents. In a further embodiment the propellant mixes with the product as it is being released from the canister. In another embodiment a dual canister assembly is used wherein the therapeutic cells are in bag in can or bag in valve system and the Poloxamer formulation is in a second canister and they are mixed either externally or in a mixing chamber connected to both canisters as is known in the art and or as described above. Where therapeutic cells are used the propellant will be selected such that an effective amount of therapeutic cells will be available after expulsion from the canister/bag in valve. Suitable propellants include compressed air, CO2 nitrogen, helium, argon, or nitrous oxide.
Production Under Vacuum
Optionally, the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid. Preferably the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
Tests to Characterize Foam Products
By way of non limiting example the objectives of hardness, collapse time, FTC stability tests and aging are briefly set out below as would be appreciated by a person skilled in the art.
Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36° C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 minute. Thus foams which are structurally stable on the skin for at least one minute are termed “short term stable” compositions or foams.
Drainage: A simple indication of the rate of drainage or whether there is any significant drainage can be obtained from the collapse time method and results. In the collapse time method the foam is observed and filmed for a period of time, say 180 secs. The height of the foam is measured against a marked ruler and any changes recorded and plotted as a graph. Also the foam quality is observed. If during the measurement there is a change in quality it is noted. So simply if there is a reduction in quality say from Good to Fairly Good or from Excellent to Good then significant drainage is considered to have occurred and the approximate time point when this change has been noted is said to be the drainage time. A slow drainage is a drainage of about or more than 180 secs preferably more than 300 seconds.
In this procedure, the foam product is dispensed into vessels (including dishes or tubes) of a known volume and weight. Replicate measurements of the mass of foam filling the vessels are made and the density is calculated. The canister and contents are allowed to reach room temperature. Shake the canister to mix the contents and dispense and discard 5-10 mL. Then dispense foam into a preweighed tube, filling it until excess is extruded. Immediately remove (level off) excess foam at both ends and then weigh the filled tube on the weighing balance.
LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
Viscosity is measured with Brookfield LVDV-II+PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10 RPM. However, at about the apparent upper limit for the spindle of ˜>50,000 CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude. Unless otherwise stated viscosity of the pre-foam formulation (PFF) is provided. It is not practical to try and measure the viscosity of the foamable formulation with regular propellants since they have to be stored in sealed pressurized canisters or bottles. In order to simulate the viscosity in the foamable formulations with propellant an equivalent weight of pentane (a low volatile hydrocarbon) is added to and mixed with the pre-foam formulation and left overnight. The viscosity is then measured as above.
Freeze Thaw Cycles (FTC)
To check the foam appearance under extreme conditions of repeated cycles of cooling, heating (first cycle) cooling, heating (second cycle) etc., commencing with −10° C. (24 hours) followed by +40° C. (24 hours) measuring the appearance and again repeating the cycle for up to three times.
Healthy volunteers selected at random were give a sample of foam formulation and applied it to the skin on their hand or forearm and were asked for their observations.
Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software. The camera used was a Nikon D40X Camera (resolution 10 MP) equipped with Sigma Macro Lens (ref: APO MACRO 150 mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels×400 pixels.
The light microscope enables observing and measuring particles from few millimeters down to one micron. Light microscope is limited by the visible light wavelength and therefore is useful to measuring size of particles above 800 nanometers and practically from 1 micron (1,000 nanometers).
“Shakability” represents the degree to which the user is able to feel/hear the presence of the liquid contents when the filled pressurized canister is shaken. Shaking is with normal mild force without vigorous shaking or excessive force. When the user cannot sense the motion of the contents during shaking the product may be considered to be non shakable. This property may be of particular importance in cases where shaking is required for affecting proper dispersion of the contents.
Good shakability (conforms to required quality specification) 2 Moderate shakability (conforms to required quality specification) 1 Not or hardly shakable but may still be flowable and allow foam 0 formation of quality Is substantially not able to pass through valve Block
Aging or Creaming by Centrifugation:
1. Principle of Test
The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
In the case of waterless silicone emulsion compositions which are inherently more susceptible to creaming by virtue of the silicone and by virtue of the waterless solvent, the presence of some creaming at the enormous centrifugal forces imposed on the formulations does not derogate from the fact that the compositions have not phase separated and can still be understood as being resistant to creaming and provides a good indication of the long term stability of the formulations. To the extent that good quality stable formulations are achieved, which are resistant to creaming or such that no creaming is observed, the formulations are considered as exceptionally stable. The procedure is as follows:
The amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter. The canisters are stored in controlled temperature incubators at one or more of 5 C, at 25 C, at, 40 C and at 50 C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
The ingredients listed in the Examples are Xanthan, Poloxamer 188, Poloxmar 124, Poloxamer 407, Pemulen TR2, Carbomer 974 Methocel, PVP, NaCMC, PEG 100 stearate, Laureth 23, Polysorbate 60, Polysorbate 80, Sorbitan oleate, Sorbitan laurate, Cyclomethicone, Dimethicone, Dimethicone cyclomethicone copolyol, Glycerin, Propylene glycol, Heavy mineral oil, Salycilic acid, Clindomycin, Acyclovir, Minoxid, Benzoyl peroxide, Sodium diclofenac.
Part A—Xantham at 0.3% by Weight
Propellant AP-70 %
Viscosity (+8% pentane)
Bubble size (above 500 μm)
Procedure: Xanthan was dissolved in water and mixed until fully dissolved at room temperature.
Comments: xanthan a polysaccharide is only able to produce a bubbled semi liquid gel of high density.
Part B—Polymeric Agents at 5% in Water with Propellant
Foam Vehicle Composition, Containing Poloxamer 188
Ingredient 5% Poloxamer (188) Poloxamer 188 5.00 Purified water 95.00 Total 100.00 Propellant (AP-70) 8.00
Cooling Sensation on Hand
Procedure: Poloxamer 188 was dissolved in water and mixed until fully dissolved at room temperature
Comments: Unexpectedly, 5% Poloxamer 188, with no further ingredients, is sufficient to produce good foam at room temperature with high expansion (density of less that 0.1 g/mL), easily spreadable and quick absorption into the skin upon application.
Part C—Polymeric Agents at Different % s in Water with Propellant
Foam Vehicle Composition Containing 1% to 15% Poloxamer 407
Shakability of PF
Visual inspection in
NM = Not measured.
Procedure: A stock solution of 20% Poloxamer was prepared by dissolving the poloxamer in water at 5° C. overnight until fully dissolved. 1% Poloxamer was prepared by dissolving 1 g solid Poloxamer in water at room temperature. Higher levels of Poloxamer (about 2% and above) do not dissolve readily and therefore require the preparation of a stock solution overnight with cooling. Poloxamer stock solution was mixed with water at room temperature.
Comments: Interestingly, it was observed that formulations were of enhanced quality when they were prepared using stock Poloxamer solution instead of adding Poloxamer powder directly. In high concentrations, difficulty was encountered in dissolving Poloxamer 407 in water. Therefore the use of stock solution was employed. Viscosity of PFF was seen to be about zero due to the very high aqueous content.
The quality of the foam was seen to be concentration dependant and improved with increased concentration. The fact foam was produced was unexpected due to the following reasons. First the formulation is of hydrophilic nature and the hydrophobic propellant is likely not to dissolve in the aqueous solution. This may be explained by the fact that Poloxamer is comprised of a polyoxyethylene segment which is hydrophilic while the polyoxypropylene segment is hydrophobic. Secondly there is no foam booster present such as surfactant. Poloxamers overall are known to be used as mild emulsifiers. In one case when the formulation was made in a pressurized glass bottle it appeared to be non homogenous yet surprisingly the foam quality was excellent and dispense weight satisfactory. More particularly, the foamable carrier demonstrated good quality foam when above 2% Poloxamer was used. When 1% was dissolved in water, foam quality was determined as fairly good (FG). Total dispense weight was high. The 3% poloxamer foam demonstrated total lower dispense weight (91%) in comparison to other formulations. Bubble size was somewhat higher than expected with excellent quality foam formulations and the dispensing rate was not always homogenous. All foams reduced from high quality to low (FG) when collapse time was evaluated. About 3% to about 4% Poloxamer foam appeared to provide the best foam quality. Using stock solution improved foam quality since solubility was improved. Due to the gelling characteristics of Poloxamer formulations shakability was minimal to none and yet viscosity was low due to large quantity of water. This may be explained by the expansion ability of the polymer.
It appears that the propellant is not fully dissolved in the foam due to the hydrophobic nature of the propellant. This was demonstrated by visual inspection of pentane addition to the pre foam formulation (PFF). Pentane can simulate the effect of volatile propellant. Interestingly although the propellant was not dissolved in the formulation, the dispense weight was high, indicating the propellant was able to dispense the formulation from the canister.
Procedure: Carpobol 974 was mixed vigorously with water at room temperature until fully dissolved followed by the addition of trolamine to reach the required pH. Poloxamer 407 stock solution was added to the carbopol solution and mixed at room temperature.
to pH ~4
to pH ~5
to pH ~6
to pH ~7
Shakability of PF after
Total dispense weight
Comments: Carbopol in combination with Poloxamer produced excellent foam with long collapse and drainage times. Viscosity and density were increased as pH was elevated. At each pH the viscosity was not significantly different in the presence or absence of pentane, suggesting better solubility of the propellant in the formulation. When the formulations were mixed with pentane large bubbles trapping the pentane were observed.
Foam demonstrated high stability and shakability was improved. Bubble size was similar for all formulations. However, total dispense weight was reduced when tested for formulations 02 and 05 suggesting in these two cases lesser homogeneity with the propellant.
Carboxamer/Poloxamer Concentration in Foamable Polymer Compositions
Carbomer 974P, NF
Propellant AP-70 %
Shakability of PF
Comments: A combination of Carbomer with Poloxamer provides the preparation of shakable foamable compositions with 96-98% water, with good foam quality. The density of these compositions is low and ranges from 0.06-0.12 g/cm3. It is thought that there is some form of synergism between Poloxamer and carbomer such that the combination provides enhanced foam quality.
Procedure: Carbopol is dissolved in water followed by the addition of trolamine and at room temperature. When a gel is formed, Poloxamer is slowly added to the mixture.
Propellant AP-70 %
3000 rpm/10 min
10000 rpm/10 min
Foam density, g/mL
Collapse time, sec
Foam drainage, sec
Shakability of PF after
pH diluted 1:5
Mean bubble size mcm
Drainage time approx. [min]
Comments: Interestingly, a combination of pemulen and 2%-5% of a Poloxamer compound, resulted in a foam composition of excellent quality, exhibiting a density of 0.04-0.06 g/cm3 It is thought that there is some form of synergism between the Poloxamer and the pemulen to enhance the foam quality and stability. It may be—without being bound by any theory—that solubility of the propellant is enhanced in the presence of pemulen. The presence of trolamine increases the pH, causing the uncoiling and expansion of the polymers, assisting with a synergistic effect of those reagents.
Poloxamer 407 % W/W
Poloxamer 407 (20%
Viscosity (+8% pentane)
Total dispense weight
Procedure: Methocel was dissolved in cold water 5° C. with mixing. PVP and NaCMC were dissolved at room temperature. Poloxamer 407 was added to the mixture until fully dissolved.
Comments: 1% Poloxamer failed to produce foam of quality therefore addition of polymers such as PVP and cellulose was tested. Methocel and CMC which are cellulose polymers produced foam of high quality which was stable over 3 mins, demonstrating the synergistic effect. PVP in comparison produced foam, which demonstrated lower stability.
Note: When the foam using CMC was dispensed on an inert dish at room temperature the resultant foam was of good quality. When the foam was applied to the hand, foam quality became fairly good.
Poloxamer/water compositions were tested in order to assess the behavior of Poloxamer formulations in the absence of propellant with and without a non surfactant polymer such as xanthan gum.
Procedure: 20% poloxamer stock solution was mixed with water at room temperature.
a) Poloxamer alone is a fluid below 20%
Poloxamer 407 20% 15% Water To 100% To 100% Behavior on hand (PFF at RT) Gel Fluid Behavior on hand (PFF at 36° C.) Gel Fluid Behavior on glass at 36° C. (PFF at RT) Gel Fluid Behavior on glass at 36° C. (PFF at 36° C.) Gel Fluid
b) Poloxamer 407 and polysaccharide xantham gum
Poloxamer 407 15% 15% 10% 5% 2.5% 1.0% Xanthan gum 0.12% 0.5% 0.5% 0.5% 0.7% 0.7% Water To 100% To 100% To 100% To 100% To 100% To 100% Behavior on hand Fluid Gel Gel Gel Gel Gel (PFF at RT) Behavior on glass Fluid Semi- Fluid Fluid Semi- Semi- at 36° C. (PFF at Fluid Fluid Fluid RT) Behavior on hand Fluid Semi- Fluid Fluid Semi- Semi- (PFF at 36° C.) Fluid Fluid Fluid Behavior on glass Fluid Semi- Fluid Fluid Semi- Fluid at 36° C. (PFF at Fluid Fluid 36° C.)
c) Poloxamer 188 and a non surfactant polysaccharide xantham gum
Poloxamer 188 5% 1.0% Xanthan gum 0.5% 0.7% Water To 100% To 100% Behavior on hand (PFF at RT) Gel Gel Behavior on glass at 36 C. (PFF at RT) Gel Gel
d) A non surfactant polysaccharide xantham gum alone
Behavior on hand (PFF at RT)
It was observed when 20% Poloxamer 407 PFF is at a relatively low temperature, such as about 20° C. or lower, the viscosity is lower and the composition is flowable, As the temperature increases to that of body temperature the viscosity increases such that upon application to a body surface, having temperature of more than about 30° C., it creates a non-flowable gel.
The above compositions were placed in transparent vials and were observed to be liquid at 20° C. Each one of the compositions was subsequently dripped on the palm of the hand (having temperature of about 32-35° C.; and the flowability was assessed by visual observation.
At 20% Poloxamer 407 alone the formulation was a gel at room and at body temperature. When the concentration of Poloxamer alone was reduced to 15% it became fluid.
It was found that the addition of a small amount of non surfactant polymer (xanthan gum) can act synergistically with 5% or 2.5% or 1% Poloxamer 407 a surfactant like polymer in order to achieve the gel like properties seen at 20% Poloxamer concentration alone,
Poloxamer 188 (5%), in contrast 407, did not show a change in state and remained a gel when contacted with a surface at 36 C. Thus, the body temperature sensitive rheology of 407 is not observed with 188.
Xantham on its own remains fluid at concentrations at which it is a gel when combined with Poloxamer. Much higher amounts of xantham gum are required to form a gel without Poloxamer.
These vehicles are suitable as carriers of various active agents, including therapeutic cells. These vehicles are suitable for application onto any body surface, including for example the skin, any body cavity and any mucosal surface such as the vagina.
Procedure: The compositions were prepared as follows:
1. A stock solution of Poloxamer was prepared as follows: 20 gr. of Poloxamer (407 or 188) was added to 80 gr. of cold water and mixed until dissolved.
2. 5 gr. from stock solution was taken and mixed with 94.3 gr. water at RT and then 0.7 gr. of xanthan gum was added and mixed until dissolved.
Propellant (AP-70) propane, butane
and isobutane mixture
Collapse time (sec.)
Comments: It was unexpectedly noted that foams derived from compositions of two types of Poloxamers in combination with xantham gum caused a mild cooling sensation when applied to the hand with relatively low amounts of propellant. Such amounts of propellant do not normally result in a noticeable cooling effect in other foam formulations. The observation was then tested quantitatively. Without being limited by any theory this may be due to the unique properties of the Poloxamers to moderate the expansion rate of the foam so that some evaporation/release of propellant continues for a short period after expulsion from the canister.
Room temperature (RT) was ˜20.5° C., which means both Poloxamer/polymer formulations have a similar “cooling effect”.
Ingredient 24 01 25 26 Poloxamer 407 1.00 1.00 2.00 Poloxamer 124 1.00 1.00 2.00 Purified water 99.00 99.00 98.00 94.00 Total 100.00 100.00 100.00 100.00 Propellant A70 8.00 8.00 8.00 8.00
Shakability of PF
Procedure: Polymers were mixed with water until fully dissolved. Liquid poloxamer was mixed with water at room temperature.
Comments: Foam quality was poor when liquid Poloxamer was used. A mixture of two Poloxamers, one liquid and the other solid, was able to produce foam of high quality. The formulation, however was not stable and was drained following 50 seconds. Surprisingly, the bubble size of the formulations with the liquid lower molecular weight Poloxamer was smaller compared to previous formulations using solid higher molecular weight Poloxamers. Total dispense weight was relatively high suggesting that PFF was dispensed using the propellant.
Ingredient 09 10 XXX Poloxamer 407 % W/W 1.00 1.00 1.00 Poloxamer 407 (20%) 5.00 5.00 5.00 PEG100 stearate 1.00 Laureth 23 1.00 Polysorbate 60 (surfactant) 1.00 Purified water 94.00 94.00 94.00 Total 100.00 100.00 100.00 Propellant A70 8.00 8.00 8.00
Viscosity (+8% pentane)
Shakability of PF after
Total dispense weight
Procedure: Surfactant was dissolved in water with mixing at 50° C. The mixture was cooled to RT. Poloxamer 407 was added to the mixture with stirring until fully dissolved.
Comments: 1% Poloxamer 407 combined with 1% polysorbate 60 or Laureth 23, is sufficient to make high quality foam. The formulation has a synergistic foam forming effect since neither Poloxamer nor the surfactant at their current concentrations are sufficient to produce an acceptable foam, but their combination provides an excellent foam with high expansion (density of less that 0.1 g/mL), easy spreadability and quick absorption into the skin upon application. PEG 100 stearate which is a polyoxyethylene ester however failed to produce high quality foam in comparison to the alkyl ether (Laureth) and fatty acid esters (polysorbate).
Low concentrations of surfactant are an advantage, especially where the composition is to be applied to sensitive skin or mucosal surfaces in order to minimize skin or mucosal irritation. Repeated application of surfactants to the skin can result in depletion of fatty substances causing drying of the skin. So another advantage of very low surfactant levels is that even with repeated use drying of the skin is minimized or eliminated. Notably, in certain cases the concentration of 1% Poloxamer 407 is a limiting factor, due to both the FDA inactive ingredient list for topical administration which currently sets 1% as an upper limit; and secondly since the viscosity of the pressurized composition can interfere with shakability. By utilizing low polymer concentrations it can be easier to achieve greater shakability. Nevertheless, unexpectedly elsewhere formulations have been achieved with acceptable shakability despite formulations having high viscosity after the addition of propellant (See Examples 2A and 1F).
Actual % W/W
Solution of Carbomer
947P 0.4% and
Poloxamer 407 20%
3000 rpm/10 min
10000 rpm/10 min
Collapse time, sec
Foam drainage, sec
Shakability of PF after
pH diluted 1:5
Mean bubble size
Procedure: For procedure, see Example 10.
Comments: Surprisingly, despite the presence of silicone which is a defoaming agent the resultant compositions were of good to excellent quality. These compositions had improved stability. As is seen above and in Example 10 these compositions were all stable to the centrifugation test at 3000 rpm. At 10,000 rpm there appears to be some propellant separation when silicone was present. Interestingly and unexpectedly, the foam quality was also improved in the presence of the different silicones. Although silicones are known to be defoamers—without being bound by any theory—it may be assumed that they assist with propellant dissolution forming an emulsion formulation. It is noteworthy that whilst significant drainage occurs in the foam it nevertheless, has a collapse time of greater than 300 secs.
Sol. Of Pemulen TR2
0.5% and Trolamine
Poloxamer 407 % W/W
Poloxamer 407 20% sol
Propellant AP-70 %
Foam density, g/mL
Collapse time, sec
Foam drainage, sec
Shakability of PF after
pH diluted 1:5
3000 rpm/10 min
10000 rpm/10 min
Mean bubble size
Comments: Good to excellent foam compositions were formed. These compositions were all stable to the centrifugation test at 3000 rpm. At 10,000 rpm there appears to be some propellant separation. Interestingly and unexpectedly, the foam quality was improved in the presence of the different silicones. Although silicones are known to be defoamers perhaps they assist with propellant dissolution and or Poloxamer interaction providing the formulation with an emulsion type format. It is noteworthy that drainage occurs in the foam even though it has a collapse time of greater than 300 secs. Interestingly, although, there is no major difference in bubble size of the foams and the bubbled gel (See Example 1), with the former perhaps having the larger average size, there is huge difference in quality of the foam released, which apparently is due to factors other than bubble size.
Ingredient Function % w/w Poloxamer 407 75.00 (15% (20% solution) Poloxamer) Glycerin Hydrophilic solvent, therapeutically 3.00 effective solvent, emollient Propylene glycol hydrophilic solvent, therapeutically 3.00 effective solvent, emollient Polysorbate 80 surfactant 2.00 Cyclomethicone hydrophobic solvent; therapeutically 1.00 effective solvent Purified water To 100%
Comments: Interestingly, whilst polysorbate does not work well with carbopol (see Example 8A) it is successful with a hydrophobic/hydrophilic formulation comprising a silicone, a penetration enhancer (PG) and a humectant (glycerin)
Ingredient Function % w/w Heavy mineral oil hydrophobic solvent, emollient 6.00 Poloxamer 407 75.00 (15% (20% solution) poloxamer) Glycerin Hydrophilic solvent, therapeutically 3.00 effective solvent, emollient Propylene glycol hydrophilic solvent, therapeutically 3.00 effective solvent, emollient Sorbitan oleate surfactant 2.00 Cyclomethicone hydrophobic solvent; therapeutically 1.00 effective solvent Purified water To 100%
Comments: The addition of mineral oil did not affect foam quality.
Poloxamer 407 (20% solution)
Procedure (to make 100 gr):
Centrifugation (10,000 RPM)
Comments: The vehicle of Example 11A with active ingredient is stable on centrifugation indicating good resistance to aging.
Heavy mineral oil
Poloxamer 407 (20% solution)
Centrifugation (10,000 RPM)
Comments: The vehicle of Example 11B with active ingredient is stable on centrifugation indicating good resistance to aging.
Poloxamer 407 functions as co-solubilizer ingredient of sodium diclofenac. When included in the formulation at 15% concentration, crystals were not observed under the microscope.
Ingredient 001 002 Sodium diclofenac 3.00 3.00 Poloxamer 407 15.00 15.00 Heavy mineral oil 6.00 Glycerine 3.00 3.00 Propylene glycol 3.00 3.00 Polysorbate 80 2.00 Sorbitan laurate 2.00 Cyclomethicone 1.00 Purified water 73.00 68.00 Total 100.00 100.00 Propellant (AP-70) 8 8
Foam properties (T-0)
Assay (by HPLC) 2.95 3.03 Foam quality Excellent Good Color White White Odor No odor No odor Collapse time (sec) >300/G >300/G Density 0.047 0.052 Bubble size 106.00 75.00 Bubble size (above 500)μm 0.0 0.0 Microscope for NaDiclofenac crystals Not observed Not observed
Stability: Foam Properties Following Four Freeze & Thaw Cycles
Foam quality Excellent Good Color White White Odor Very faint Very faint Microscope for NaDiclofenac crystals Not observed Not observed
Stability: Foam Properties Following 1 Month at 5° C.
Assay (by HPLC) 3.04 3.07 Foam quality Excellent Good Color White White Odor No odor No odor Collapse time >300/G >300/G Density 0.047 0.052 Microscope for NaDiclofenac crystals Not observed Not observed pH 3.04 3.07
Stability: Foam Properties Following 1 Month at 40° C.
Foam quality Excellent Good Color White White Odor No odor No odor Microscope for NaDiclofenac crystals Not observed Not observed
Stability: Foam Properties Following 2 Months at 5° C.
Foam quality Excellent Good Color White White Odor No odor No odor Microscope for NaDiclofenac crystals Not observed Not observed
Stability: Foam Properties Following 1 Month at 40° C.
Foam quality Excellent Good Color White White Odor No odor Very faint odor Collapse time >300/G >300/G Density 0.065 0.068 Microscope for NaDiclofenac crystals Not observed Not observed pH 3.09 3.29
Stability: Foam Properties Following 3 Months at 5° C.
Foam quality Excellent Good Color White White Odor No odor No odor Microscope for NaDiclofenac crystals Not observed Not observed
Stability: Foam Properties Following 3 Months at 40° C.
Very faint odor
Microscope for NaDiclofenac crystals
Comments: Both pharmaceutical formulations with and without mineral oil were observed to be chemically and physically stable over a period of three months in accelerated stability studies even at an elevated temperature of 40° C. Note: In order to assess the concentration of Poloxamer 407 which is required to afford full solubility of the active agent, 3% sodium diclofenac was added to 5, 7 and 10 percent of Poloxamer in water. All 3 concentrations were heated to 75° C. to dissolution and cooled. In all cases, after 24 h, crystals were visually observed
The aim of this study was to compare the in vitro penetration of Diclofenac Foam formulated at 3% (w/w) to one commercial reference product (Solaraze® Gel, 3% w/w) across ear pig skin.
Absorption studies were conducted using excised pig ear skin mounted onto a flow-through diffusion cell over a 24-hour period. Four skin samples for each foam formulation and three skin samples of Solaraze gel were used. A target amount of 1 g of each formulation (30 mg of Diclofenac) was applied to a skin surface of 1.77 cm2. Concentrations of Diclofenac in receptor fluid fractions over time and remaining in the skin at the end of the study were assayed using an HPLC method with UV detection. The limit of quantification was 20 ng/mL−1.
Samples analyzed for Diclofenac content:
As shown in
Diclofenac foam, 3% (w/w)—Prototype 001
Penetrated amount: 338.4 μg/cm2 for Stratum Corneum and 7.4 μg/cm2 for Skin Extraction (Total Skin content=345.8 μg/cm2)
Transdermal Delivery: 81.44 μg/cm2
Diclofenac foam, 3% (w/w)—Prototype 002
Penetrated amount: 360.2 μg/cm2 for Stratum Corneum and 4.0 μg/cm2 for Skin Extraction (Total Skin content=364.2 μg/cm2)
Transdermal Delivery: 55.12 μg/cm2
Solaraze Gel, 3% (w/w)
Intradermal penetration: 128.6 μg/cm2 for Stratum Corneum and 34.7 μg/cm2 for Skin Extraction (Total Skin content=163.3 μg/cm2)
Transdermal Delivery: 50.49 μg/cm2.
1. Intradermal Penetration:
Ingredient % w/w Sodium diclofenac 3.00 Poloxamer 188 (20% solution) 75.00 Glycerin 3.00 Propylene glycol 3.00 Polysorbate 80 2.00 Cyclomethicone 1.00 Purified water 13.00 Total: 100.00
Shakability of PF after propellant addition
Bubble size (above 500) μm
Microscope (crystals only)
Microscope (crystals only)
Ingredient % w/w Heavy mineral oil 6.00 Glycerin 3.00 Propylene glycol 3.00 Sorbitan oleate 2.00 Poloxamer 188 (20% solution) 75.00 Sodium diclofenac 3.00 Purified water 7.00 Cyclomethicone 1.00 Total: 100.00
Shakability of PF after propellant addition
Bubble size (above 500) μm
Microscope (crystals only)
Microscope (crystals only)
Comments: Whilst lower average molecular weight Poloxamer 188 produces a therapeutic foam formulation of excellent quality that can withstand FTC testing for hydrophilic hydrophobic formulations with and without mineral oil, higher average molecular weight Poloxamer 407 produces therapeutic foam formulations that have improved collapse times.
In both vials, 1 & 2, there are 12.5 gr. of 20% Poloxamer 188/purified water stock solution (2.5 gr. Poloxamer 188+10 gr. purified water).
In vial #1, 0.25 gr. of salicylic acid was dissolved (1:10 ratio API/Poloxamer 188, 1:40 ratio API/purified water).
In vial #2, 0.50 gr. of salicylic acid was dissolved (1:5 ratio API/Poloxamer 188, 1:20 ratio API/purified water).
Comments: As shown clearly in
According to literature (USP 29), Salicylic acid's solubility in water is 1 gr. in 460 gr. (˜0.2% at 20° C.). Unexpectedly, Poloxamer 188 multiplied solubility of Salicylic acid in water by about 25.
Comments: The poloxamer carriers are suitable for use both with active agents that can be solubilized and also with suspensions of active agents.
(&) Poloxamer 407
974P 0.4% (&)
(&) Poloxamer 407
Made up with
water to 100%:
974P 0.4% (&)
Made up with
water to 100%:
Comments: The prophetic foam formulations may have properties not too dissimilar to the carrier formulations to which the microsponges have been added.
The following table provides possible compositions of a therapeutic cell and two exemplary Poloxamer/polymer systems. The compositions are suitable for application onto any body surface, including for example the skin, the vagina, any body cavity and any mucosal surface. They can be suitable as carriers of various therapeutic cells including but not limited to fibroblasts, langerhans cells, keratinocytes, leukocytes, phagocytes (such as macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. Without limiting the scope of this invention, by selecting certain therapeutic cells, the compositions are useful for the treatment of a disease or disorder, which involve microbial, bacteria, fungal or viral infection, autoimmune conditions, tumors, metastases, wound, burn, ulcer, post operative injury and any further disease or disorder, which is responsive to treatment with such therapeutic cells.
Macrophage*/suitable aqueous medium
Prophetic Behavior on hand (PFF at RT)
*or any other therapeutic cell. In another embodiment fractions or fragments of therapeutic cells may be used.
The compositions are packaged in a container, suitable for delivering a flowable composition to a target site. Alternatively, the compositions can be packaged in an aerosol container, equipped with a valve and an actuator, capable of releasing a foam and pressurized with a liquefied or compressed propellant at a concentration of about 1% to about 25% by weight of the total composition. In other embodiments a bag in can or bag on valve system is used. In further embodiments a dual chamber system is used where the cells are in one chamber (bag in canister where the propellant is separate from the cells) and the Poloxamer formulation is in a separate canister in the other chamber. Upon actuation the two compositions are expelled and are mixed either in a mixing chamber or in the passage connected to the canisters or outside the dual canister system.
Preparation of Formulations with therapeutic cells and Poloxamer.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US1159250||1 May 1914||2 Nov 1915||Frank Moulton||Vaginal irrigator.|
|US1666684||15 Jan 1926||17 Apr 1928||Carstens Mfg Co H||Vaginal douche|
|US1924972||15 Apr 1929||29 Aug 1933||Beckert Carl J||Stabilized egg product|
|US2085733||15 Jul 1935||6 Jul 1937||Bird John C||Shaving cream|
|US2390921||23 Mar 1943||11 Dec 1945||Ethel Hudson Clark||Applicator for facial creams|
|US2524590||22 Apr 1946||3 Oct 1950||Carsten F Boe||Emulsion containing a liquefied propellant gas under pressure and method of spraying same|
|US2586287||26 Oct 1950||19 Feb 1952||Colagte Palmolive Peet Company||Aluminum sulfamate antiperspirant preparation|
|US2617754||29 Aug 1949||11 Nov 1952||Procter & Gamble||Cosmetic cream|
|US2767712||1 Mar 1954||23 Oct 1956||Waterman Neil S||Medicinal applicator|
|US2968628||17 Oct 1958||17 Jan 1961||Shulton Inc||Propellant composition|
|US3004894||7 Apr 1959||17 Oct 1961||Upjohn Co||Therapeutic composition comprising tetracycline and a dioxolane|
|US3062715||18 Nov 1953||6 Nov 1962||George S Pfaus||Vaginal tablet|
|US3067784||14 Apr 1960||11 Dec 1962||Esta Medical Lab Inc||Adapter connecting aerosol container valve stem to dispenser for filling said dispenser|
|US3092255||5 Feb 1960||4 Jun 1963||Hohman Robert F||Sorting apparatus|
|US3092555||21 Apr 1958||4 Jun 1963||Roy H Horn||Relatively collapsible aerosol foam compositions|
|US3141821||17 Mar 1959||21 Jul 1964||Lehn & Fink Products Corp||Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis|
|US3142420||26 Apr 1962||28 Jul 1964||Neotechnic Eng Ltd||Metering dispenser for aerosol with fluid pressure operated piston|
|US3144386||9 May 1958||11 Aug 1964||Merck & Co Inc||Mastitis aerosol foam|
|US3149543||4 Mar 1963||22 Sep 1964||Ingersoll Rand Co||Non-lubricated piston|
|US3154075||2 Nov 1960||27 Oct 1964||Norwich Pharma Co||Vaginal applicator|
|US3178352||27 Feb 1959||13 Apr 1965||Roy Erickson||Shaving method and composition therefor|
|US3236457||21 Aug 1963||22 Feb 1966||John R Kennedy||Composite spray container assembly|
|US3244589||26 Oct 1962||5 Apr 1966||Sunnen||Alkyl phenoxy polyethoxy ether spermicidal aerosol|
|US3252859||24 Oct 1962||24 May 1966||Masti Kure Company Inc||Colloidal silica-oil composition and method of using same|
|US3261695||24 Dec 1962||19 Jul 1966||Gen Foods Corp||Process for preparing dehydrated foods|
|US3263867||26 Dec 1963||2 Aug 1966||Valve Corp Of America||Metering button-type aerosol actuator|
|US3263869||3 Nov 1964||2 Aug 1966||Calmar Inc||Liquid dispenser with overcap|
|US3298919||26 Dec 1962||17 Jan 1967||Dow Corning||Shaving cream containing polysiloxanes|
|US3301444||12 Aug 1965||31 Jan 1967||Oel Inc||Aerosol metering valve|
|US3303970||14 Jul 1964||14 Feb 1967||Kurtz Constance||Device for simultaneously dispensing from plural sources|
|US3330730||3 Aug 1962||11 Jul 1967||Colgate Palmolive Co||Pressurized emulsion quick breaking foam compositions|
|US3333333||14 Aug 1963||1 Aug 1967||Rca Corp||Method of making magnetic material with pattern of embedded non-magnetic material|
|US3346451||27 Jan 1965||10 Oct 1967||S E Massengill Company||Concentrated liquid lactic acid douche preparation containing aromatics|
|US3366494||15 Feb 1967||30 Jan 1968||Du Pont||Pressurized aerosol food emulsions|
|US3369034||27 Apr 1964||13 Feb 1968||Eversharp Inc||Process for separating saponifiables and unsaponifiables in marine animal oils|
|US3377004||3 Oct 1966||9 Apr 1968||Gen Mills Inc||Metered dispensing container|
|US3384541||28 Oct 1964||21 May 1968||William G. Clark||Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants|
|US3395214||9 Jan 1964||30 Jul 1968||Scholl Mfg Co Inc||Antiperspirant composition providing a readily collapsible sprayable foam|
|US3395215||15 Oct 1964||30 Jul 1968||Colgate Palmolive Co||Pressurized lotion composition|
|US3401849||24 May 1966||17 Sep 1968||Robert L. Weber||Low force metering valve|
|US3419658||25 Jan 1965||31 Dec 1968||Du Pont||Nonaqueous aerosol foams containing mineral oil|
|US3456052||28 Sep 1965||15 Jul 1969||Garrett Lab Inc||Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol|
|US3527559||5 Jan 1967||8 Sep 1970||Standard Pharmacal Corp||Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent|
|US3540448||17 Jan 1968||17 Nov 1970||Sunnen Joseph||Rechargeable applicator for dispensing substances in a foam condition|
|US3559890||3 Sep 1968||2 Feb 1971||William R Brooks||Foam dispenser|
|US3561262||26 Oct 1967||9 Feb 1971||Magnaflux Corp||Water soluble developer|
|US3563098||28 Jun 1968||16 Feb 1971||Rex Chainbelt Inc||Automatic quick release mechanism|
|US3574821||23 Oct 1967||13 Apr 1971||Mediline Ag||Feminine hygiene spray deodorant compositions|
|US3577518||18 Jul 1969||4 May 1971||Nat Patent Dev Corp||Hydrophilic hairspray and hair setting preparations|
|US3667461||7 Dec 1970||6 Jun 1972||Zamarra Paul A||Disposable syringe|
|US3751562||22 Sep 1972||7 Aug 1973||Princeton Biomedix||Medicated gelled oils|
|US3770648||12 Jul 1971||6 Nov 1973||Bristol Myers Co||Anhydrous aerosol foam|
|US3787566||29 Mar 1971||22 Jan 1974||Holliston Labor Inc||Disinfecting aerosol compositions|
|US3819524||7 Dec 1972||25 Jun 1974||Colgate Palmolive Co||Cosmetic composition for thermal dispensing|
|US3841525||14 Jun 1972||15 Oct 1974||Siegel N||Aerosol spray device with cam activator|
|US3849580||5 Sep 1972||19 Nov 1974||American Home Prod||Aerosol dispensing system for anhydrous edible fat compositions|
|US3865275||30 Jul 1973||11 Feb 1975||Raymond Lee Organization Inc||Apparatus for operating an aerosol can|
|US3866800||12 Feb 1969||18 Feb 1975||Alberto Culver Co||Non-pressurized package containing self-heating products|
|US3882228||23 Nov 1970||6 May 1975||Aspro Nicholas Ltd||Analgesic formulations|
|US3886084||23 Aug 1971||27 May 1975||Champion Int Corp||Microencapsulation system|
|US3890305||18 Dec 1972||17 Jun 1975||Ciba Geigy Ag||Divinyldiphenyl compounds|
|US3912665||17 Jan 1973||14 Oct 1975||Spitzer Joseph G||Emulsified propellant compositions for foamed structures such as applicator pads, and process|
|US3923970||29 Mar 1974||2 Dec 1975||Carter Wallace||Stable aerosol shaving foams containing mineral oil|
|US3929985||18 Jan 1974||30 Dec 1975||Richardson Merrell Inc||Anhydrous candicidin foam compositions|
|US3952916||6 Jan 1975||27 Apr 1976||Warner-Lambert Company||Automatic dispenser for periodically actuating an aerosol container|
|US3959160||13 May 1974||25 May 1976||Wilkinson Sword Limited||Aerosol shaving foam compositions|
|US3962150||10 Apr 1974||8 Jun 1976||Richardson-Merrell Inc.||Foam producing cleansing compositions|
|US3963833||27 Jun 1974||15 Jun 1976||Colgate-Palmolive Company||Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt|
|US3966090||19 Jun 1972||29 Jun 1976||Dart Industries Inc.||Package for dispensing an antiseptic composition|
|US3966632||6 Jun 1974||29 Jun 1976||G. D. Searle & Co.||Vegetable oil emulsion|
|US3970219||3 Mar 1975||20 Jul 1976||Spitzer Joseph G||Aerosol containers for foaming and delivering aerosols and process|
|US3970584||14 Feb 1973||20 Jul 1976||S. C. Johnson & Son, Inc.||Aerosol package containing a foam-forming emulsion and propellent system|
|US3993224||8 Sep 1975||23 Nov 1976||Aerosol Investments, Ltd.||Spout for two-component resin dispenser|
|US3997467||21 May 1974||14 Dec 1976||Pharmacia Aktiebolag||Foam forming composition|
|US4001391||16 Sep 1971||4 Jan 1977||Plough, Inc.||Means for depositing aerosol sprays in buttery form|
|US4001442||17 Jul 1974||4 Jan 1977||Elastin-Werk Aktiengesellschaft||Collagen-containing preparations|
|US4018396||5 May 1975||19 Apr 1977||Bechtel International Corporation||Embedded housing for ore crusher|
|US4019657||26 Mar 1976||26 Apr 1977||Spitzer Joseph G||Aerosol containers for foaming and delivering aerosols|
|US4083974||7 Mar 1977||11 Apr 1978||The Upjohn Company||Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether|
|US4102995||13 May 1976||25 Jul 1978||Westwood Pharmaceuticals Inc.||Tar gel formulation|
|US4110426||4 Mar 1976||29 Aug 1978||Colgate-Palmolive Company||Method of treating skin and hair with a self-heated cosmetic|
|US4124149||27 Dec 1976||7 Nov 1978||Spitzer Joseph G||Aerosol container with position-sensitive shut-off valve|
|US4145411||23 Feb 1976||20 Mar 1979||Colgate-Palmolive Company||Pressurized foaming shaving composition|
|US4151272||13 Jan 1978||24 Apr 1979||American Cyanamid Company||Wax-like antiperspirant stick compositions|
|US4160827||6 Feb 1978||10 Jul 1979||The Upjohn Company||Metronidazole phosphate and salts|
|US4213979||18 Dec 1978||22 Jul 1980||Plough, Inc.||Stable sprayable hydrocortisone product|
|US4214000||30 Oct 1978||22 Jul 1980||Johnson & Johnson||Zinc salt of all-trans-retinoic acid for the treatment of acne|
|US4226344||6 Feb 1979||7 Oct 1980||Booth, Inc.||Constant flow valve actuator|
|US4229432||19 Apr 1978||21 Oct 1980||Bristol-Myers Company||Antiperspirant stick composition|
|US4230701||21 Mar 1979||28 Oct 1980||Hoffmann-La Roche Inc.||Administration of biologically active vitamin D3 and vitamin D2 materials|
|US4241048||1 May 1979||23 Dec 1980||Bristol-Myers Company||Suspension composition of benzocaine|
|US4241149||20 Jul 1979||23 Dec 1980||Temple University||Canal clathrate complex solid electrolyte cell|
|US4252787||27 Dec 1976||24 Feb 1981||Cambridge Research And Development Group||Anti-fertility composition and method|
|US4254104||12 Nov 1975||3 Mar 1981||Shiseido Co., Ltd.||Process for preparing stable oil-in-water emulsions|
|US4268499||7 Jun 1979||19 May 1981||Dow Corning Corporation||Antiperspirant emulsion compositions|
|US4271149||21 Sep 1979||2 Jun 1981||West Agro-Chemical, Inc.||Germicidal iodine compositions with enhanced iodine stability|
|US4292250||17 Nov 1980||29 Sep 1981||Wisconsin Alumni Research Foundation||Vitamin D derivatives|
|US4292326||1 Dec 1978||29 Sep 1981||Nazzaro Porro Marcella||Process for treatment of hyperpigmentary dermatoses|
|US4299826||12 Oct 1979||10 Nov 1981||The Procter & Gamble Company||Anti-acne composition|
|US4305936||9 Oct 1980||15 Dec 1981||Dermik Laboratories||Topical corticosteroid formulations|
|US4309995||28 Jan 1980||12 Jan 1982||Sacco Susan M||Vaginal irrigation apparatus|
|US4310510||3 Oct 1980||12 Jan 1982||Sherman Kenneth N||Self administrable anti-fertility composition|
|US4323694||29 Apr 1981||6 Apr 1982||Finetex, Inc.||Benzoic acid esters|
|US4325939||22 Sep 1980||20 Apr 1982||Richardson-Vicks Inc.||Zinc derivatives and their use in dental compositions|
|US4329990||7 Aug 1980||18 May 1982||Sneider Vincent R||Expanding swab applicator|
|US4335120||3 Nov 1980||15 Jun 1982||Hoffmann-La Roche Inc.||Administration of biologically active vitamin D3 and vitamin D2 materials|
|US4352808||12 Dec 1980||5 Oct 1982||Schering Corporation||3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore|
|US4385161||6 Jan 1981||24 May 1983||Imperial Chemical Industries Limited||Olefine polymerization process|
|US4386104||29 Jun 1981||31 May 1983||Nazzaro Porro Marcella||Process for the treatment of acne|
|US4393066||5 Jun 1981||12 Jul 1983||Garrett David M||Method for treatment of herpetic lesions|
|US4427670||10 Feb 1982||24 Jan 1984||Mitsubishi Chemical Industries Limited||Skin preparation|
|US4439416||5 Mar 1979||27 Mar 1984||Colgate-Palmolive Company||Self-heating shaving composition|
|US4439441||19 Jul 1982||27 Mar 1984||Syntex (U.S.A.) Inc.||Contraceptive compositions and methods employing 1-substituted imidazole derivatives|
|US4440320||30 Nov 1981||3 Apr 1984||Wernicke Steven A||Foam dispensing apparatus|
|US4447486||21 Sep 1981||8 May 1984||Bayer Aktiengesellschaft||Surface-sealed moldings of cellular polyurethane elastomers and a process for their production|
|US4469674||2 May 1983||4 Sep 1984||Richardson-Vicks Inc.||Stable oral compositions containing zinc and fluoride compounds|
|US4508705||2 Jul 1980||2 Apr 1985||Lever Brothers Company||Skin treatment composition|
|US4522948||24 Apr 1981||11 Jun 1985||Syntex (U.S.A.) Inc.||Spermicidal substituted 1-(cycloalkyl)alkylimidazoles|
|US4529601||26 Aug 1982||16 Jul 1985||Astra Lakemedel Aktiebolag||Local anesthetic mixture for topical application and method for obtaining local anesthesia|
|US4529605||12 Jan 1983||16 Jul 1985||Una E. Lynch||Bathing oil composition|
|US4552872||1 Feb 1984||12 Nov 1985||The Procter & Gamble Company||Penetrating topical pharmaceutical compositions containing corticosteroids|
|US4574052||31 May 1984||4 Mar 1986||Richardson-Vicks Inc.||Crackling aerosol foam|
|US4576961||30 Aug 1983||18 Mar 1986||Lorck Henning O B||Antibiotic heterocyclic oxygen compounds and use|
|US4595526||28 Sep 1984||17 Jun 1986||Colgate-Palmolive Company||High foaming nonionic surfacant based liquid detergent|
|US4603812||21 May 1984||5 Aug 1986||The Dow Chemical Company||Foam-generating pump sprayer|
|US4627973||14 Dec 1984||9 Dec 1986||Charles Of The Ritz Group Ltd.||Skin mousse|
|US4628063||8 Mar 1984||9 Dec 1986||Dana P. Brigham||Antiviral pharmaceutical preparations and methods for their use|
|US4661524||27 Dec 1985||28 Apr 1987||Beecham Group P.L.C.||Topical treatment and composition|
|US4672078||3 Jul 1985||9 Jun 1987||Schering-Plough Corporation||Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations|
|US4673569||12 Feb 1985||16 Jun 1987||Faberge Incorporated||Mousse hair composition|
|US4678463||16 Sep 1986||7 Jul 1987||Millar Thomas D||Devices for insertion into a body cavity of an animal and/or applicators therefor|
|US4701320||26 Nov 1985||20 Oct 1987||Lederle (Japan), Ltd.||Composition stably containing minocycline for treating periodontal diseases|
|US4725609||20 Nov 1984||16 Feb 1988||Burroughs Wellcome Co.||Method of promoting healing|
|US4738396||4 Jun 1987||19 Apr 1988||Matsuda K. K.||Vehicle air conditioner|
|US4741855||31 Jul 1987||3 May 1988||The Procter & Gamble Company||Shampoo compositions|
|US4752465||21 Jan 1987||21 Jun 1988||Product Resources International, Inc.||Aerosol foam|
|US4770634||11 Jun 1986||13 Sep 1988||Pellico Michael A||Method for treating teeth with foamable fluoride compositions|
|US4780309||16 Jun 1987||25 Oct 1988||Warner-Lambert Company||Edible aerosol foam compositions and method of preparing same|
|US4784842||25 Sep 1987||15 Nov 1988||Jean London||Therapeutic composition for treatment of cuts, burns and abrasions|
|US4792062||8 May 1987||20 Dec 1988||L'oreal||Package for two pressurized receptacles|
|US4798682||6 Jun 1986||17 Jan 1989||Henkel Kommanditgesellschaft Auf Aktien||Oil-in-water emulsions with increased viscosity under shear stress|
|US4804674||19 Mar 1987||14 Feb 1989||Euroceltique, S.A.||Vaginal pharmaceutical composition|
|US4806262||9 Nov 1987||21 Feb 1989||The Procter & Gamble Company||Nonlathering cleansing mousse with skin conditioning benefits|
|US4808388||18 Aug 1987||28 Feb 1989||Merz + Co. Gmbh & Co.||Foamable creams|
|US4822613||15 Dec 1986||18 Apr 1989||S. C. Johnson & Son, Inc.||Water-soluble foamable insecticidally-active compositions|
|US4822614||19 Dec 1986||18 Apr 1989||S. C. Johnson & Son, Inc.||Bioactive film-forming composition for control of crawling insects and the like|
|US4826048||29 Oct 1987||2 May 1989||Ing. Erich Pfeiffer Gmbh & Co. Kg||Dispenser for manually discharging plural media|
|US4827378||15 Jun 1988||2 May 1989||Rockwell International Corporation||Jack coaxial connector EMI shielding apparatus|
|US4828837||30 Mar 1987||9 May 1989||Liposome Technology, Inc.||Non-crystalline minoxidil composition, its production and application|
|US4836217||23 Sep 1985||6 Jun 1989||Fischer Torkel I||Hypersensitivity test means|
|US4837019||11 Aug 1986||6 Jun 1989||Charles Of The Ritz Group Ltd.||Skin treatment composition and method for treating burned skin|
|US4837378||15 Jan 1988||6 Jun 1989||Curatek Pharmaceuticals, Inc.||Topical metronidazole formulations and therapeutic uses thereof|
|US4844902||11 Feb 1988||4 Jul 1989||Bayer Aktiengesellschaft||Topically applicable formulations of gyrase inhibitors in combination with corticosteroids|
|US4847068||6 Aug 1987||11 Jul 1989||Johnson & Johnson Consumer Products, Inc.||Skin care compositions|
|US4849117||17 Jun 1987||18 Jul 1989||Sanitek Products, Inc.||Concentrated composition for forming an aqueous foam|
|US4855294||6 Sep 1988||8 Aug 1989||Theratech, Inc.||Method for reducing skin irritation associated with drug/penetration enhancer compositions|
|US4863900||15 Jan 1987||5 Sep 1989||The Research Foundation Of State University Of New York||Method for reducing viral transmission with poly-L-histidine|
|US4867967||4 Jun 1987||19 Sep 1989||Crutcher Wilbert L||Method for the treatment of pseudofolliculitis barbae|
|US4873078||22 Apr 1988||10 Oct 1989||Plough, Inc.||High-gloss, high-shine lipstick|
|US4874794||28 Apr 1989||17 Oct 1989||Lidak Biopharmaceuticals||Inflammatory disease treatment|
|US4877805||3 Jun 1988||31 Oct 1989||Kligman Albert M||Methods for treatment of sundamaged human skin with retinoids|
|US4885282||8 Mar 1988||5 Dec 1989||Thornfeldt Carl R||Treatment of hyperhidrosis, ichthyosis and wrinkling|
|US4897262||22 Mar 1988||30 Jan 1990||Playtex Jhirmack, Inc.||Non-aerosol hair spray composition|
|US4902281||16 Aug 1988||20 Feb 1990||Corus Medical Corporation||Fibrinogen dispensing kit|
|US4906453||26 Oct 1988||6 Mar 1990||Jumpeer Nails, Inc.||Mousse product|
|US4913893||28 Aug 1987||3 Apr 1990||Clairol Incorporated||Aerosol hair setting composition containing an alginate|
|US4919934||2 Mar 1989||24 Apr 1990||Richardson-Vicks Inc.||Cosmetic sticks|
|US4954487||15 Feb 1989||4 Sep 1990||The Procter & Gamble Company||Penetrating topical pharmaceutical compositions|
|US4956049||23 Jun 1989||11 Sep 1990||Ciba-Geigy Corporation||Process for sizing paper with anionic hydrophobic sizing agents and cationic retention aids|
|US4957732||28 Dec 1989||18 Sep 1990||L'oreal||Shaving composition for the skin based on polyorgano-siloxanes containing an acyloxyalkyl group and process for use|
|US4963351||26 Dec 1989||16 Oct 1990||Bhn Associates||Shaving aid|
|US4966779||21 Dec 1989||30 Oct 1990||Basf Corporation||Stable, water miscible emulsion comprising a fat-soluble vitamin|
|US4970067||12 Dec 1988||13 Nov 1990||Helene Curtis, Inc.||Method and composition to condition hair and impart semi-permanent hair set retention properties|
|US4975466||7 Dec 1988||4 Dec 1990||Ciba-Geigy Corporation||Pharmaceutical preparations for topical application and their use in the treatment of inflammatory skin diseases|
|US4981367||28 Jul 1989||1 Jan 1991||Stranco, Inc.||Portable mixing apparatus|
|US4981677||15 Nov 1988||1 Jan 1991||L'oreal||Petrolatum-containing aerosol foam concentrate|
|US4981679||27 Sep 1988||1 Jan 1991||Briggs Joseph H||Method and composition for the treatment of burns|
|US4981845||25 Aug 1989||1 Jan 1991||Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc.||Cosmetic composition|
|US4985459||13 Oct 1989||15 Jan 1991||Richardson-Vicks, Inc.||Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same|
|US4992478||4 Apr 1988||12 Feb 1991||Warner-Lambert Company||Antiinflammatory skin moisturizing composition and method of preparing same|
|US4993496||8 Jan 1990||19 Feb 1991||Total Walther Feuerschutz Gmbh||Quick release valve for sprinkler head|
|US5002540||22 May 1989||26 Mar 1991||Warren Kirschbaum||Intravaginal device and method for delivering a medicament|
|US5002680||12 Jul 1989||26 Mar 1991||The Procter & Gamble Company||Mild skin cleansing aerosol mousse with skin feel and moisturization benefits|
|US5007556||18 Apr 1990||16 Apr 1991||Block Drug Company, Inc.||Metering dispenser|
|US5013297||12 Dec 1988||7 May 1991||Cattanach John F||Vaginal douche|
|US5015471||29 Nov 1989||14 May 1991||Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.||Topical composition|
|US5019375||14 Mar 1989||28 May 1991||The Procter & Gamble Company||Low residue antiperspirant creams|
|US5034220||20 Jun 1990||23 Jul 1991||Gaf Chemicals Corporation||Non-aerosol shaving gel|
|US5035895||20 Jan 1989||30 Jul 1991||Eisai Co., Ltd.||Emulsified and solubilized pharmaceutical preparation|
|US5053228||13 Jul 1990||1 Oct 1991||W. R. Grace & Co.-Conn.||Polymeric temperature sensitive drug carrier|
|US5071648||29 Mar 1990||10 Dec 1991||Merocel Corporation||Polymeric broad-spectrum antimicrobial materials|
|US5071881||22 May 1990||10 Dec 1991||Imperial Chemical Industries Plc||Co2 blown integral skin foams|
|US5073371||30 Nov 1990||17 Dec 1991||Richardson-Vicks, Inc.||Leave-on facial emulsion compositions|
|US5082651||25 Apr 1990||21 Jan 1992||Smith Kline & French Laboratories Limited||Pharmaceutical compositions|
|US5087618||11 Jan 1989||11 Feb 1992||University Of Florida||Redox carriers for brain-specific drug delivery|
|US5089252||30 Aug 1989||18 Feb 1992||L'oreal||Cosmetic composition for treating keratin fibres, and process for treating the latter|
|US5091111||19 Sep 1990||25 Feb 1992||S. C. Johnson & Son, Inc.||Aqueous emulsion and aersol delivery system using same|
|US5094853||27 Jul 1990||10 Mar 1992||S. C. Johnson & Son, Inc.||Method of preparing a water-soluble stable arthropodicidally-active foam matrix|
|US5100917||11 Sep 1990||31 Mar 1992||Merrell Dow Pharmaceuticals Inc.||Novel a-nor-steroid-3-carboxylic acid derivatives|
|US5104645||2 Feb 1990||14 Apr 1992||The Proctor & Gamble Company||Antidandruff shampoo compositions|
|US5112359||4 Jun 1990||12 May 1992||Clairol, Inc.||Hair colorants|
|US5114718||20 Sep 1990||19 May 1992||The Procter & Gamble Company||Sustained release compositions for treating periodontol disease|
|US5122519||27 Jun 1989||16 Jun 1992||American Cyanamid Company||Stable, cosmetically acceptable topical gel formulation and method of treatment for acne|
|US5130121||8 Jan 1991||14 Jul 1992||Isp Investments Inc.||Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer|
|US5133972||29 Jun 1990||28 Jul 1992||Ciba-Geigy Corporation||Topically administrable pharmaceutical preparations|
|US5135915||14 Oct 1988||4 Aug 1992||Genentech, Inc.||Method for the treatment of grafts prior to transplantation using TGF-.beta.|
|US5137714||11 Apr 1991||11 Aug 1992||Unilever Patent Holdings B.V.||Anhydrous cosmetic composition comprising stable lower alkyl esters of pyroglutamic acid|
|US5143717||2 Aug 1989||1 Sep 1992||Code Blue Medical Corporation||Burn foam and delivery system|
|US5156765||15 May 1990||20 Oct 1992||Fox Valley Systems, Inc.||Aerosol foam marking compositions|
|US5164357||5 Jun 1991||17 Nov 1992||Appleton Papers Inc.||Thermally-responsive record material|
|US5164367||26 Mar 1990||17 Nov 1992||Procyte Corporation||Method of using copper(ii) containing compounds to accelerate wound healing|
|US5167950||28 Mar 1991||1 Dec 1992||S. C. Johnson & Son||High alcohol content aerosol antimicrobial mousse|
|US5171577||6 Feb 1990||15 Dec 1992||L'oreal||Process for the preparation of foams which can be used in the cosmetics and pharmaceutical field and foams obtained by this process|
|US5196405||27 Feb 1990||23 Mar 1993||Norman H. Oskman||Compositions and methods of treating hemorrhoids and wounds|
|US5204093||2 Jul 1991||20 Apr 1993||Victor Steven A||Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same|
|US5208031||29 Jul 1991||4 May 1993||Kelly Patrick D||Sexual lubricants containing zinc as an anti-viral agent|
|US5217707||14 Feb 1992||8 Jun 1993||Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.||Pharmaceutical composition and process for the preparation thereof|
|US5219877||25 Sep 1989||15 Jun 1993||Bristol-Myers Squibb Company||Lauryl alcohol as skin penetration enhancer for topical imidazole agents|
|US5221696||7 Feb 1991||22 Jun 1993||Alcon Laboratories, Inc.||Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs|
|US5230897||31 Oct 1991||27 Jul 1993||G. D. Searle & Co.||Transdermal pentamidine|
|US5236707||8 Nov 1991||17 Aug 1993||Dallas Biotherapeutics, Inc.||Stabilization of human interferon|
|US5252246||10 Jan 1992||12 Oct 1993||Allergan, Inc.||Nonirritating nonionic surfactant compositions|
|US5254334||4 May 1992||19 Oct 1993||Imaginative Research Associates, Inc.||Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters|
|US5262407||21 Oct 1991||16 Nov 1993||L'oreal||Use of salicylic derivatives for the treatment of skin aging|
|US5266592||3 Apr 1992||30 Nov 1993||Haarmann & Reimer Gmbh||Compositions which have a physiological cooling effect, and active compounds suitable for these compositions|
|US5279819||21 Sep 1992||18 Jan 1994||The Gillette Company||Shaving compositions|
|US5286475||8 Nov 1991||15 Feb 1994||L'oreal||Anhydrous cosmetic composition in the aerosol form forming a foam|
|US5300286||14 Jul 1992||5 Apr 1994||Dow Corning Corporation||Silicone emulsion for personal care application|
|US5301841||29 Jan 1992||12 Apr 1994||Ing. Erich Pfeiffer Gmbh & Co. Kg||Media discharge apparatus for housing a movable reservoir|
|US5308643||30 Nov 1992||3 May 1994||Osipow Lloyd I||Self-lather generating shaving compositions|
|US5314904||16 Jun 1992||24 May 1994||Alfa Wassermann S.P.A.||Pharmaceutical compositions containing rifaximin for treatment of vaginal infections|
|US5322683||1 May 1989||21 Jun 1994||Leonard Mackles||Anhydrous aerosol foam|
|US5326557||6 Apr 1993||5 Jul 1994||Dow Corning Corporation||Moisturizing compositions containing organosilicon compounds|
|US5344051||27 Apr 1992||6 Sep 1994||Insta-Foam Products, Inc.||Two-component foam dispensing apparatus|
|US5346135||16 Jun 1992||13 Sep 1994||Vincent Edward C||Spraying apparatus for blending liquids in a gaseous spray system|
|US5352437||23 Jul 1990||4 Oct 1994||Hisamitsu Pharmaceutical Co., Inc.||Foamable aerosol preparation|
|US5369131||20 May 1993||29 Nov 1994||Poli Industria Chimica S.P.A.||Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam|
|US5378451||27 Sep 1993||3 Jan 1995||Dow B. Hickam, Inc.||Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof|
|US5378730||3 Dec 1992||3 Jan 1995||Alza Corporation||Permeation enhancer comprising ethanol and monoglycerides|
|US5380761||20 Oct 1993||10 Jan 1995||Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt.||Transdermal compositions|
|US5384308||14 Jun 1993||24 Jan 1995||Henkin; R. I.||Composition and method for enhancing wound healing|
|US5385943||7 Apr 1993||31 Jan 1995||Schering Aktiengesellschaft||Use of topically applicable preparations for treatment of presbyderma|
|US5389676||13 Sep 1993||14 Feb 1995||E. B. Michaels Research Associates, Inc.||Viscous surfactant emulsion compositions|
|US5397312||13 May 1993||14 Mar 1995||Akzo N.V.||Applicator for introducing a cream-type substance into a woman's vagina|
|US5398846||20 Aug 1993||21 Mar 1995||S. C. Johnson & Son, Inc.||Assembly for simultaneous dispensing of multiple fluids|
|US5399205||22 Dec 1993||21 Mar 1995||Taiho Industries Co., Ltd.||Method for cleansing and lustering a surface|
|US5411992||29 Apr 1993||2 May 1995||Clilco Ltd.||Lice repellant composition|
|US5422361||14 Dec 1990||6 Jun 1995||Schering Corporation||Stable cream and lotion bases for lipophilic drug compositions|
|US5429815||11 Apr 1994||4 Jul 1995||Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.||Stable single-phase self-foaming cleanser|
|US5435996||7 Feb 1994||25 Jul 1995||Dow Corning Corporation||Moisturizing compositions containing organosilicon compounds|
|US5447725||11 Jun 1993||5 Sep 1995||The Procter & Gamble Company||Methods for aiding periodontal tissue regeneration|
|US5449520||1 Oct 1993||12 Sep 1995||Giuliani S.P.A.||Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level|
|US5451404||28 Jun 1993||19 Sep 1995||The Procter & Gamble Company||Coolant compositions|
|US5482965||3 Sep 1993||9 Jan 1996||Rajadhyaksha; Vithal J.||Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents|
|US5491245||15 Mar 1994||13 Feb 1996||Th. Goldschmidt Ag||Method for the synthesis of amphoteric surfactants|
|US5500211||22 Sep 1994||19 Mar 1996||The Gillette Company||Soap-free self-foaming shave gel composition|
|US5508033||14 Feb 1995||16 Apr 1996||Societe D'engrais Composes Mineraux Et Amendments||Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions|
|US5512555||21 Jul 1994||30 Apr 1996||Merck & Co., Inc.||Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one|
|US5514367||28 Feb 1994||7 May 1996||Estee Lauder, Inc.||Skin tanning compositions and methods for their preparation and use|
|US5514369||8 May 1995||7 May 1996||Henkel Corporation||Mild shampoo composition|
|US5520918||15 Mar 1994||28 May 1996||Mary Kay Cosmetics, Inc.||Low irritant skin-cosmetic composition for daily topical use, its application and manufacture|
|US5523078||3 Feb 1995||4 Jun 1996||Michael E. Baylin||Method of preparing and composition for treatment of hair and scalp|
|US5527534||21 Oct 1993||18 Jun 1996||Gynetech Laboratories, Ltd.||Vaginal sponge delivery system|
|US5527822||29 Dec 1993||18 Jun 1996||Forest Laboratories, Inc.||Method of treatment of traumatic brain injury|
|US5529770||9 Dec 1994||25 Jun 1996||West Agro, Inc.||Viscous liquid conditioning topical germicides|
|US5531703||28 Apr 1993||2 Jul 1996||Schering-Plough Healthcare Products, Inc.||Applicator for semisolid medications|
|US5534261||17 Jan 1995||9 Jul 1996||University Of Southern California||Retinoid-based compositions and method for preventing adhesion formation using the same|
|US5536743||24 Aug 1994||16 Jul 1996||Curatek Pharmaceuticals Limited Partnership||Intravaginal treatment of vaginal infections with buffered metronidazole compositions|
|US5540853||20 Oct 1994||30 Jul 1996||The Procter & Gamble Company||Personal treatment compositions and/or cosmetic compositions containing enduring perfume|
|US5545401||2 Jun 1994||13 Aug 1996||Shanbrom; Edward||Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine|
|US5567420||16 Nov 1994||22 Oct 1996||Mceleney; John||Lotion which is temporarily colored upon application|
|US5576016||18 May 1993||19 Nov 1996||Pharmos Corporation||Solid fat nanoemulsions as drug delivery vehicles|
|US5578315||1 Dec 1993||26 Nov 1996||Rutgers, The State University Of New Jersey||Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity|
|US5585104||12 Apr 1995||17 Dec 1996||The Procter & Gamble Company||Cleansing emulsions|
|US5589157||8 May 1995||31 Dec 1996||Amerchol Corporation||Hairsprays and acrylic polymer compositions for use therein|
|US5589515||25 Sep 1992||31 Dec 1996||Nof Corporation||Cosmetic composition and an emulsion composition|
|US5597560||10 Apr 1995||28 Jan 1997||Laboratorios Cusi, S.A.||Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse|
|US5603940||27 Sep 1994||18 Feb 1997||L'oreal||Oil-in-water emulsion which may be used for obtaining a cream|
|US5605679||5 Jun 1995||25 Feb 1997||L'oreal||Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor|
|US5608119||5 Jun 1995||4 Mar 1997||Takasago International Corporation||(2S)-3-[(1R, 2S, 5R)-[5-methyl-2-(1-methylethyl)-cyclohexyl]oxy]-1, 2-propanediol, process for producing the same, and compositions containing the same|
|US5611463||12 Jul 1995||18 Mar 1997||Lir France, S.A.||Double dispenser for fluid products|
|US5612056||21 Aug 1992||18 Mar 1997||The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Gt. Britain & Northern Ireland||Transdermal formulations|
|US5613583||18 Jul 1995||25 Mar 1997||Toyota Jidosha Kabushiki Kaisha||Slip control apparatus for motor vehicle lock-up clutch|
|US5613623||19 Jul 1995||25 Mar 1997||Wella Aktiengesellschaft||Two-chamber container|
|US5614171||22 Feb 1994||25 Mar 1997||Domp e Farmaceutici SpA||Hydrophilic pharmaceutical composition containing ketoprofen lysine salt for topical use|
|US5614178||27 Jun 1994||25 Mar 1997||The Procter & Gamble Company||Compositions for topical delivery of drugs comprising a mixture of high and low HLB surfactants and alkoxylated ether|
|US5635469||10 Oct 1996||3 Jun 1997||The Procter & Gamble Company||Foaming cleansing products|
|US5641480||8 Dec 1994||24 Jun 1997||Lever Brothers Company, Division Of Conopco, Inc.||Hair care compositions comprising heteroatom containing alkyl aldonamide compounds|
|US5643600||5 Jan 1996||1 Jul 1997||Micro-Pak, Inc.||Lipid vesicles containing avocado oil unsaponifiables|
|US5645842||18 Jul 1996||8 Jul 1997||Th. Goldschmidt Ag.||Cosmetic or pharmaceutical preparations|
|US5650554||30 Dec 1994||22 Jul 1997||Sembiosys Genetics Inc.||Oil-body proteins as carriers of high-value peptides in plants|
|US5658575||7 Sep 1994||19 Aug 1997||L'oreal||Cosmetic or dermatological composition comprising an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating|
|US5658749||23 Feb 1995||19 Aug 1997||Corning Clinical Laboratories, Inc.||Method for processing mycobacteria|
|US5658956||22 May 1995||19 Aug 1997||Warner-Lambert Company||Bioadhesive-wound healing compositions and methods for preparing and using same|
|US5663208||22 May 1995||2 Sep 1997||Warner-Lambert Company||Antifungal wound healing compositions and methods for preparing and using same|
|US5672634||23 Dec 1996||30 Sep 1997||Isp Investments Inc.||Crosslinked PVP-I2 foam product|
|US5679324||17 Oct 1995||21 Oct 1997||The Procter & Gamble Co.||Aerosol foamable fragrance composition|
|US5683710||13 Sep 1995||4 Nov 1997||Nitto Denko Corporation||Percutaneous absorption preparation|
|US5686088||22 Jan 1996||11 Nov 1997||The Procter & Gamble Company||Antimicrobial wipe compositions|
|US5693258||30 Mar 1994||2 Dec 1997||Kao Corporation||Method for improving foaming properties and foaming composition|
|US5695551||9 Dec 1996||9 Dec 1997||Dow Corning Corporation||Water repellent composition|
|US5700396||18 Oct 1996||23 Dec 1997||Nof Corporation||Cosmetic compositions and an emulsion composition|
|US5716611||2 Jan 1996||10 Feb 1998||Euro-Celtique, S.A.||Emollient antimicrobial formulations containing povidone iodine|
|US5716621||3 Jul 1996||10 Feb 1998||Pharmadyn, Inc.||Nonocclusive drug delivery device and process for its manufacture|
|US5719122||15 Oct 1993||17 Feb 1998||Smithkline Beecham Farmaceutici S.P.A.||Pharmaceutical compositions containing a calcitonin|
|US5719197||7 Jun 1995||17 Feb 1998||Noven Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5725872||17 Sep 1996||10 Mar 1998||Ferring Bv||Composition for foams, notably rectal foams, and foams thus obtained|
|US5725874||18 May 1994||10 Mar 1998||Hisamitsu Pharmaceutical Co., Inc.||Solubilizer and external preparations containing the same|
|US5730964||2 Jun 1995||24 Mar 1998||Merck & Co., Inc.||Method of treating sweat-related conditions|
|US5733558||22 Apr 1996||31 Mar 1998||L'oreal||Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same|
|US5733572||29 Nov 1994||31 Mar 1998||Imarx Pharmaceutical Corp.||Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles|
|US5747049||18 Sep 1995||5 May 1998||Shiseido Company, Ltd.||Cosmetic composition|
|US5753241||26 Feb 1996||19 May 1998||L'oreal||Transparent nanoemulsion less than 100 NM based on fluid non-ionic amphiphilic lipids and use in cosmetic or in dermopharmaceuticals|
|US5753245||19 Feb 1997||19 May 1998||The Procter & Gamble Company||Personal cleansing compositions|
|US5759520||21 Jul 1995||2 Jun 1998||Tillotts Pharma Ag||Aqueous foamable composition|
|US5759579||5 Dec 1996||2 Jun 1998||American Home Products Corporation||Pharmaceutical suspension systems|
|US5767104||2 Jun 1995||16 Jun 1998||Bar-Shalom; Daniel||Use of sulfated saccharides to treat baldness|
|US5773410||24 Jul 1995||30 Jun 1998||Takasago International Corporation||Method for purifying (-)-N-isopulegol and citrus perfume composition containing (-)-N-isopulegol obtained by the method|
|US5783202||14 Mar 1995||21 Jul 1998||Soltec Research Pty. Ltd.||Pediculicidal mousse composition for killing head lice|
|US5788664||2 Apr 1996||4 Aug 1998||Scalise; Gaspare||Suppository applicator|
|US5792448||30 May 1997||11 Aug 1998||L'oreal||Use of flavonoids for preserving and/or enhancing the mechanical properties of the hair and process for protecting the hair using these compounds|
|US5792922||2 Apr 1993||11 Aug 1998||Sembiosys Genetics Inc.||Oil-body protein cis-elements as regulatory signals|
|US5797955||9 Jun 1997||25 Aug 1998||Walters; David J.||Pressure application unit for positioning vertebra|
|US5804546||23 May 1996||8 Sep 1998||Cussons (International) Limited||Cleaning composition|
|US5817322||22 Mar 1996||6 Oct 1998||Xu; Rongxiang||Pharmaceutical base and the use of the same|
|US5824650||19 Dec 1995||20 Oct 1998||L'oreal||Topical composition containing a substance P antagoinst|
|US5833960||29 Jul 1997||10 Nov 1998||Beiersdorf Ag||Foaming light protection preparations containing water-soluble light protection filters and surface-active substances|
|US5833961||25 Jun 1996||10 Nov 1998||Inolex Investment Corporation||Polyester-based suncreen formulations|
|US5837270||26 Aug 1996||17 Nov 1998||Burgess; Nelson Leon||Topical anti-acne composition|
|US5840744||15 Jul 1996||24 Nov 1998||Minnesota Mining And Manufacturing Co.||Intravaginal treatment of vaginal infections with buffered metronidazole compositions|
|US5840771||26 Sep 1997||24 Nov 1998||Legere Pharmaceuticals, Ltd.||Prophylaxis against diseases tramsmittable by sexual contact, and therapy of such diseases|
|US5843411||6 Feb 1997||1 Dec 1998||Topix Pharmaceuticals Inc.||Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use|
|US5846983||9 Feb 1996||8 Dec 1998||Mayo Foundation For Medical Education And Research||Colonic delivery of nicotine to treat inflammatory bowel disease|
|US5849042||19 Nov 1997||15 Dec 1998||Bristol-Myers Squibb||Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol|
|US5856452||16 Dec 1996||5 Jan 1999||Sembiosys Genetics Inc.||Oil bodies and associated proteins as affinity matrices|
|US5858371||21 Apr 1997||12 Jan 1999||Panacea Biotech Limited||Pharmaceutical composition for the control and treatment of anorectal and colonic diseases|
|US5865347||27 Oct 1997||2 Feb 1999||William T. Wilkinson||Multi-chamber dispenser for flowable materials|
|US5866040||27 Jul 1994||2 Feb 1999||Shiseido Company, Ltd.||Complex and emulsified composition|
|US5869529||6 Feb 1996||9 Feb 1999||Agis Industries (1983) Ltd.||Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus|
|US5871720||20 Nov 1997||16 Feb 1999||Colgate-Palmolive Company||Cosmetic compositions with DBS and functionalized silicones|
|US5877216||28 Oct 1997||2 Mar 1999||Vivus, Incorporated||Treatment of female sexual dysfunction|
|US5879469||6 Jan 1997||9 Mar 1999||Deeay Technologies Ltd.||Dishwashing method and detergent composition therefor|
|US5881493||14 Sep 1995||16 Mar 1999||D. B. Smith & Co. Inc.||Methods for applying foam|
|US5885581||11 Sep 1997||23 Mar 1999||Merz, Incorporated||Composition and method for improvement of the appearance of scars|
|US5889028||7 Aug 1997||30 Mar 1999||Mayo Foundation For Medical Education And Research||Colonic delivery of nicotine to treat inflammatory bowel disease|
|US5889054||8 Sep 1997||30 Mar 1999||Tristrata Technology, Inc.||Method of using beta hydroxy acids for treating wrinkles|
|US5891458||15 Sep 1997||6 Apr 1999||Britton; Peter||Bioerodible device for administering active ingredients|
|US5902574||27 Nov 1996||11 May 1999||The Gillette Company||Shaving preparation for improved shaving comfort|
|US5902789||26 May 1995||11 May 1999||Fisons Corporation||Nasal administration of drugs|
|US5905092||6 Feb 1997||18 May 1999||Virotex Corporation Reel/Frame||Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction|
|US5910382||21 Apr 1997||8 Jun 1999||Board Of Regents, University Of Texas Systems||Cathode materials for secondary (rechargeable) lithium batteries|
|US5911981||24 Oct 1997||15 Jun 1999||R.I.T.A. Corporation||Surfactant blends for generating a stable wet foam|
|US5912007||6 Dec 1996||15 Jun 1999||Warner-Lambert Company||Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same|
|US5914122||27 Jun 1997||22 Jun 1999||Dr. Falk Pharma Gmbh||Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams|
|US5914310||30 Jul 1997||22 Jun 1999||Rhodia Inc.||Amphoteric surfactants having multiple hydrophobic and hydrophilic groups|
|US5922331||26 Mar 1997||13 Jul 1999||Chanel, Inc.||Skin cream composition|
|US5925669||17 Jul 1995||20 Jul 1999||Molecular/Structural Bio Technologies, Inc.||Carrier compositions for anti-neoplastic drugs|
|US5948682||25 Apr 1997||7 Sep 1999||Sembiosys Genetics Inc.||Preparation of heterologous proteins on oil bodies|
|US5951544||4 Dec 1996||14 Sep 1999||Laser Industries Ltd.||Handpiece assembly for laser apparatus|
|US5951989||7 Apr 1997||14 Sep 1999||Heymann; Warren R.||Method for the treatment of dry skin|
|US5951993||9 Jan 1997||14 Sep 1999||Minnesota Mining And Manufacturing Company||Stable hydroalcoholic compositions|
|US5952373||12 Dec 1995||14 Sep 1999||Beiersdorf Ag||Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides|
|US5952392||22 Aug 1997||14 Sep 1999||Avanir Pharmaceuticals||Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition|
|US5955414||5 Oct 1995||21 Sep 1999||S. C. Johnson & Son, Inc.||Cleaning foam having fluorinated stain repellent and low flammability|
|US5959161||27 Oct 1998||28 Sep 1999||Takasago International Corporation||Method for producing para-menthane-3,8-diol|
|US5961957||19 Oct 1998||5 Oct 1999||Mcanalley; Bill H.||Foam compositions|
|US5961998||8 Jul 1998||5 Oct 1999||L'oreal||Glossy composition containing aromatic oils thickened by a polysaccharide ether|
|US5972310||29 May 1998||26 Oct 1999||Tillotts Pharma Ag||Aqueous foamable composition|
|US5976555||1 Mar 1996||2 Nov 1999||Johnson & Johnson Consumer Products, Inc.||Topical oil-in-water emulsions containing retinoids|
|US5980904||18 Nov 1998||9 Nov 1999||Amway Corporation||Skin whitening composition containing bearberry extract and a reducing agent|
|US5990100||28 Aug 1998||23 Nov 1999||Panda Pharmaceuticals, L.L.C.||Composition and method for treatment of psoriasis|
|US5993846||21 Apr 1998||30 Nov 1999||Pharmos Corporation||Bioadhesive emulsion preparations for enhanced drug delivery|
|US6001341||21 May 1997||14 Dec 1999||Condea Augusta S.P.A.||Deodorant and/or antiperspirant cosmetic compositions|
|US6006948||14 Aug 1998||28 Dec 1999||Raimund Andris Gmbh & Co. Kg||Two-chamber metering dispenser|
|US6019967||26 Jan 1996||1 Feb 2000||Societe L'oreal S.A.||Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin|
|US6024942||8 Dec 1997||15 Feb 2000||The Procter & Gamble Company||Photoprotective compositions|
|US6030630||27 Dec 1996||29 Feb 2000||Rhodia Chimie||Cosmetic compositions for the hair or skin based on sulfone copolyesters with polyorganosiloxane units|
|US6033647||14 Oct 1997||7 Mar 2000||L'oreal||Self-foaming cream|
|US6039936||13 Nov 1997||21 Mar 2000||L'oreal||Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof|
|US6042848||15 Aug 1997||28 Mar 2000||The Board Of Trustees Of Southern Illinois University||Enhancement of antimicrobial peptide activity by metal ions|
|US6045779||9 Feb 1995||4 Apr 2000||Henkel Kommanditgesellschaft Auf Aktien||Skin and hair aerosol foam preparations containing an alkyl polyglycoside and vegetable oil|
|US6071536||21 Mar 1996||6 Jun 2000||Shionogi & Co., Ltd.||Gelatin capsule having adjusted water activity|
|US6075056||3 Oct 1997||13 Jun 2000||Penederm, Inc.||Antifungal/steroid topical compositions|
|US6080394||8 Nov 1999||27 Jun 2000||Dow Corning Corporation||Polar solvent-in-oil emulsions and multiple emulsions|
|US6087317||10 Dec 1998||11 Jul 2000||Dow Corning Corporation||Particle size stable silicone emulsions|
|US6090772||23 Jul 1999||18 Jul 2000||Steris Inc||Triclosan skin wash with enhanced efficacy|
|US6093408||25 Oct 1996||25 Jul 2000||The Procter & Gamble Company||Skin care compositions|
|US6096756||16 Jun 1998||1 Aug 2000||Albert Einstein College Of Medicine Of Yeshiva University||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists|
|US6110477||30 Oct 1998||29 Aug 2000||Topix Pharmaceuticals Inc.||Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use|
|US6110966||18 Feb 1999||29 Aug 2000||Medi-Cell Laboratories, Inc.||Triple action complex|
|US6113888||15 Jun 1999||5 Sep 2000||Neutrogena Corporation||Self-tanning mousse|
|US6116466||5 Oct 1998||12 Sep 2000||L'oreal S.A.||Two-product dispensing unit|
|US6121210||2 Mar 1999||19 Sep 2000||Dap Products Inc.||Foamable silicone oil compositions and methods of use thereof|
|US6126920||1 Mar 1996||3 Oct 2000||Medeva Europe Plc||Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition|
|US6140355||13 Jan 1994||31 Oct 2000||Alfa Wassermann S.P.A.||Pharmaceutical compositions containing rifaximin for treatment of vaginal infections|
|US6146645||27 May 1998||14 Nov 2000||Sembiosys Genetics Inc.||Uses of oil bodies|
|US6146664||10 Jul 1998||14 Nov 2000||Shaklee Corporation||Stable topical ascorbic acid compositions|
|US6162834||6 Nov 1998||19 Dec 2000||L'oreal||Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications|
|US6165455||21 Jul 1997||26 Dec 2000||The Procter & Gamble Company||Personal care compositions containing thermoplastic elastomeric graft copolymers|
|US6168576||24 May 1999||2 Jan 2001||Irene N. Reynolds||Device for dispensing vaginal medication|
|US6171347||29 Aug 1997||9 Jan 2001||Wella Aktiengesellschaft||Compositions, methods and kits for reductively removing color from dyed hair|
|US6180669||5 Apr 1999||30 Jan 2001||Tamarkin Pharmaceutical Innovation Ltd.||Method for treatment of dermatological disorders|
|US6183762||24 Nov 1999||6 Feb 2001||Sembiosys Genetics Inc.||Oil body based personal care products|
|US6186367||19 Oct 1999||13 Feb 2001||Valley Design Inc.||Metered liquid squeeze dispenser|
|US6187290||5 Dec 1995||13 Feb 2001||Giltech Limited||Physiologically acceptable foamable formulation and foam|
|US6189810||22 Sep 1999||20 Feb 2001||Sergei Alexeevich Nerushai||Method for aerosol spraying liquid perfume products|
|US6190365||21 Jun 1999||20 Feb 2001||Chun Lim Abbott||Vaginal douche applicator and method of vaginal deodorization using the same|
|US6204285||27 Jun 1997||20 Mar 2001||Sepracor Inc.||Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate|
|US6210656||15 Apr 1999||3 Apr 2001||L'oreal||Self-foaming cream|
|US6210742||5 Jul 2000||3 Apr 2001||Sembiosys Genetics Inc.||Uses of oil bodies|
|US6214318||30 Mar 1999||10 Apr 2001||Oms Holdings Llc||Aerosol ointment compositions for topical use|
|US6214788||28 Mar 2000||10 Apr 2001||Firmenich Sa||Use of cubebol as a flavoring ingredient|
|US6221381||24 Sep 1999||24 Apr 2001||The University Of British Columbia||Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier|
|US6221823||9 Sep 1996||24 Apr 2001||Reckitt Benckiser Inc.||Germicidal, acidic hard surface cleaning compositions|
|US6224888||12 Feb 1999||1 May 2001||The Procter & Gamble Company||Cosmetic compositions|
|US6231837||18 Apr 2000||15 May 2001||Schering-Plough Healthcare Products, Inc.||Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery|
|US6232315||28 Sep 1999||15 May 2001||Merck & Co., Inc.||Method for treating inflammatory diseases by administering a thrombin inhibitor|
|US6251369||19 Oct 1998||26 Jun 2001||Sultan Dental Products||Dental fluoride foam|
|US6258374||3 Sep 1998||10 Jul 2001||Astra Aktiebolag||Foam-forming pharmaceutical composition|
|US6271295||3 Mar 1998||7 Aug 2001||General Electric Company||Emulsions of silicones with non-aqueous hydroxylic solvents|
|US6274150||21 Dec 1999||14 Aug 2001||L'oreal||Nanoemulsion based on phosphoric acid fatty acid esters and its uses in the cosmetics, dermatological, pharmaceutical, and/or ophthalmological fields|
|US6287546||27 Sep 1999||11 Sep 2001||Colgate-Palmolive Company||Shampoos with stabilizers|
|US6294550||9 Feb 2000||25 Sep 2001||Asivi, Llc||Treatment of female sexual dysfunction|
|US6299023||24 Aug 2000||9 Oct 2001||Miles Arnone||Device for dispensing two substances in a user selectable ratio with replaceable cartridges|
|US6299032||27 Nov 2000||9 Oct 2001||George W. Hamilton||Disposable actuator with cap opener for aerosol cans|
|US6299900||19 Feb 1997||9 Oct 2001||Monash University||Dermal penetration enhancers and drug delivery systems involving same|
|US6305578||28 Feb 2000||23 Oct 2001||Wella Aktiengesellshaft||Device for mixing, foaming and dispensing liquids from separate compressed-gas containers|
|US6306841||30 Mar 2000||23 Oct 2001||Asivi, Llc||Treatment of female sexual dysfunction|
|US6308863||2 Sep 1999||30 Oct 2001||Owens-Brockway Plastic Products Inc.||Dual chamber package for pressurized products|
|US6319913||9 Nov 1998||20 Nov 2001||Cellegy Pharmaceuticals, Inc.||Penetration enhancing and irritation reducing systems|
|US6328950||24 Nov 1999||11 Dec 2001||Wella Aktiengesellschaft||Pigment-containing foamable gel and device producing a foam from said gel|
|US6328982||4 Aug 1999||11 Dec 2001||Takasago International Corporation||Cool feeling composition|
|US6333362||6 Mar 1997||25 Dec 2001||L'oreal||Pressurized device comprising an ultrafine foaming oil-in-water emulsion and use of this emulsion in cleansing and care of skin|
|US6335022||13 Dec 1999||1 Jan 2002||L'oreal||Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields|
|US6341717||28 Mar 2001||29 Jan 2002||Megaplast Gmbh & Co. Kg||Metering pump dispenser with at least two metering pumps|
|US6344218||27 May 1999||5 Feb 2002||The Procter & Gamble Company||Skin deodorizing and santizing compositions|
|US6348229||16 Mar 2000||19 Feb 2002||Thixo Ltd.||Food comprising thixotropic composition of unsaturated fat and process for manufacture thereof|
|US6358541||3 May 2000||19 Mar 2002||David S. Goodman||Topical preparation for the treatment of hair loss|
|US6364854||6 Feb 1998||2 Apr 2002||J. Uriach & Cia. S. A.||Applicator for semi-solid medications|
|US6372234||24 May 2000||16 Apr 2002||Sembiosys Genetics Inc.||Products for topical applications comprising oil bodies|
|US6375960||29 Dec 1999||23 Apr 2002||L'oreal||Nanoemulsion based on ethoxylated fatty ethers or on ethoxylated fatty esters and its uses in the cosmetics, dermatological and/or ophthalmological fields|
|US6383471||6 Apr 1999||7 May 2002||Lipocine, Inc.||Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents|
|US6395258||26 Apr 2000||28 May 2002||Unilever Home & Personal Care Usa A Division Of Conopco, Inc.||Mousse forming hair treatment composition containing n-methyl alkyl glucamide surfactant|
|US6395300||4 Nov 1999||28 May 2002||Acusphere, Inc.||Porous drug matrices and methods of manufacture thereof|
|US6403061||23 Oct 2000||11 Jun 2002||Societe L'oreal||UV-photoprotecting W/O emulsions comprising micronized insoluble screening agents & nonscreening oxyalkylenated silicones|
|US6403069||20 Oct 2000||11 Jun 2002||Colgate-Palmolive Company||High oil clear emulsion with elastomer|
|US6410036||4 May 2000||25 Jun 2002||E-L Management Corp.||Eutectic mixtures in cosmetic compositions|
|US6423323||18 Aug 1998||23 Jul 2002||Stephanie Neubourg||Foam skin cream, uses of the foam skin protection cream and a process for its preparation|
|US6428772||25 Jun 2001||6 Aug 2002||Blistex Inc.||Acne treatment composition with cooling effect|
|US6433003||19 Apr 2000||13 Aug 2002||Arthur M. Bobrove||Method for treating hyperhidrosis in mammals|
|US6433024||8 May 2000||13 Aug 2002||Karl F. Popp||Topical anti-acne composition|
|US6433033||10 Feb 2000||13 Aug 2002||Mitsui Chemicals, Inc.||High-durability flexible polyurethane cold cure molded foam and process for producing the same|
|US6437006||25 Sep 2000||20 Aug 2002||American Cyanamid Company||Pharmaceutical carrier formulation|
|US6440429||6 Sep 1996||27 Aug 2002||Kao Corporation||Emulsified, water-in-oil type composition and skin cosmetic preparation|
|US6447801||1 Apr 1999||10 Sep 2002||Bernard Salafsky||Anti-parasitic action of N,N-diethyl-m-toluamide (deet) and formulations that prolong its activity in the skin|
|US6455076||21 Dec 1995||24 Sep 2002||Gary S. Hahn||Formulations and methods for reducing skin irritation|
|US6468989||13 Jul 2000||22 Oct 2002||Dow Pharmaceutical Sciences||Gel compositions containing metronidazole|
|US6479058||31 Aug 2000||12 Nov 2002||Mccadden Michael E.||Composition for the topical treatment of poison ivy and other forms of contact dermatitis|
|US6486168||29 Sep 2000||26 Nov 2002||3M Innovative Properties Company||Formulations and methods for treatment of mucosal associated conditions with an immune response modifier|
|US6488947||6 Mar 2002||3 Dec 2002||The Procter & Gamble Company||Topical composition comprising a functional aromatic derivative cosmetic bonding agent|
|US6511655||11 Aug 2000||28 Jan 2003||Beiersdorf Ag||Cosmetic or dermatological preparations of the oil-in-water type|
|US6514487||3 Aug 2001||4 Feb 2003||Teresa Leigh Barr||Foam and gel oat protein complex and method of use|
|US6524594||26 May 2000||25 Feb 2003||Johnson & Johnson Consumer Companies, Inc.||Foaming oil gel compositions|
|US6531118||11 Dec 2001||11 Mar 2003||Avon Products, Inc.||Topical compositions with a reversible photochromic ingredient|
|US6534455||28 Sep 2000||18 Mar 2003||L'oreal||Composition for washing keratin materials, based on a detergent surfactant, a dialkyldiallylammonium homopolymer and an acrylic terpolymer|
|US6536629||20 Dec 2001||25 Mar 2003||Airspray N.V.||Aerosol for dispensing a liquid|
|US6544530||9 Mar 2000||8 Apr 2003||J.P.M.E.D. Ltd.||Stable oil-in-glycerin emulsion|
|US6544562||25 Jun 2001||8 Apr 2003||Blistex Inc.||Acne treatment including dual-package system|
|US6547063||10 Oct 2000||15 Apr 2003||The Procter & Gamble Company||Article for the delivery of foam products|
|US6548074||22 Mar 2000||15 Apr 2003||Elizabeth Arden Co., Division Of Conopco, Inc.||Silicone elastomer emulsions stabilized with pentylene glycol|
|US6562355||10 Oct 2000||13 May 2003||Societe L'oreal S.A.||Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin|
|US6566350||21 May 2001||20 May 2003||Showa Yakuhin Kako Co., Ltd.||Minocycline-containing compositions|
|US6582679||1 Oct 2001||24 Jun 2003||Wella Ag||Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials|
|US6582710||29 Jan 2002||24 Jun 2003||Sembiosys Genetics Inc.||Products for topical applications comprising oil bodies|
|US6589509||5 Jul 2001||8 Jul 2003||Wella Ag||Clear, two-phase, foam-forming aerosol hair care product|
|US6596287||24 Oct 2001||22 Jul 2003||Semibiosys Genetics Inc.||Products for topical applications comprising oil bodies|
|US6599513||24 Oct 2001||29 Jul 2003||Sembiosys Genetics Inc.||Products for topical applications comprising oil bodies|
|US6620773||3 Aug 1999||16 Sep 2003||Johnson & Johnson Gmbh||Foaming oil preparation and its use|
|US6638981||17 Aug 2001||28 Oct 2003||Epicept Corporation||Topical compositions and methods for treating pain|
|US6649571||4 Apr 2000||18 Nov 2003||Masi Technologies, L.L.C.||Method of generating gas bubbles in oleaginous liquids|
|US6649574||8 Oct 2002||18 Nov 2003||Exxonmobil Research And Engineering Company||Biodegradable non-toxic gear oil|
|US6672483||3 Feb 2000||6 Jan 2004||Rexam Sofab||Dispenser for chemically unstable products|
|US6682726||30 Apr 2001||27 Jan 2004||The Gillette Company||Self-foaming shaving lotion|
|US6691898||27 Feb 2002||17 Feb 2004||Fomo Products, Inc.||Push button foam dispensing device|
|US6709663||31 Aug 2001||23 Mar 2004||Healthpoint, Ltd.||Multivesicular emulsion drug delivery systems|
|US6723309||10 Jun 2002||20 Apr 2004||Jeffrey Alan Deane||Hair cleansing conditioner|
|US6730288||8 Sep 1999||4 May 2004||Connetics Australia Pty Ltd||Mousse composition|
|US6753000||19 Aug 2002||22 Jun 2004||L'oreal||Hydroxystilbene/ascorbic acid compositions for treating skin afflictions|
|US6753167||29 Jun 2001||22 Jun 2004||Sembiosys Genetics Inc.||Preparation of heterologous proteins on oil bodies|
|US6762158||21 Dec 2000||13 Jul 2004||Johnson & Johnson Consumer Companies, Inc.||Personal care compositions comprising liquid ester mixtures|
|US6765001||21 Dec 2001||20 Jul 2004||Medicis Pharmaceutical Corporation||Compositions and methods for enhancing corticosteroid delivery|
|US6774114||30 Apr 2003||10 Aug 2004||L'oreal||Topical application of immixture of ascorbic acid + ascorbic acid compounds for augmenting the synthesis of epidermal ceramides|
|US6777591||25 Aug 2000||17 Aug 2004||Sembiosys Genetics Inc.||Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter|
|US6790435||18 Sep 2000||14 Sep 2004||Unilever Home & Personal Care Usa Division Of Conopco, Inc.||Antiperspirant compositions comprising microemulsions|
|US6796973||21 Mar 1994||28 Sep 2004||Instead, Inc.||Vaginal discharge collection device and intravaginal drug delivery system|
|US6811767||19 Jun 2000||2 Nov 2004||Elan Pharma International Limited||Liquid droplet aerosols of nanoparticulate drugs|
|US6834778||24 Nov 2003||28 Dec 2004||Kanebo, Limited||Mixing and discharge device|
|US6843390||17 Mar 2003||18 Jan 2005||Joe G. Bristor||Multiple fluid closed system dispensing device|
|US6875438||24 Apr 2003||5 Apr 2005||Aventis Pharma Deutschland Gmbh||Preparations for topical administration of substances having antiandrogenic activity|
|US6881271||4 May 2004||19 Apr 2005||Sanyo Electric Co., Ltd.||Fixing member for evaporation apparatus|
|US6890567||22 Jul 2003||10 May 2005||Takasago International Corporation||Sensate composition imparting initial sensation upon contact|
|US6902737||14 Jan 2002||7 Jun 2005||L'oreal||Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields|
|US6911211||10 Jan 2001||28 Jun 2005||Foamix Ltd.||Pharmaceutical and cosmetic carrier or composition for topical application|
|US6946120||16 Apr 2002||20 Sep 2005||Connetics Australia Pty. Ltd.||Pharmaceutical composition|
|US6946139||3 Dec 2002||20 Sep 2005||Clariant Gmbh||Methods for producing foam from multiphase compositions|
|US6951654||27 Mar 2002||4 Oct 2005||Galen (Chemicals) Limited||Intravaginal drug delivery devices for the administration of an antimicrobial agent|
|US6955816||14 Nov 2002||18 Oct 2005||Klysz Beatrice M||Anti-aging skin care composition and uses thereof|
|US6956062||17 May 2001||18 Oct 2005||Air Liquide Santé (International)||Storage-stable compositions of glycerol monoalkyl ethers|
|US6958154||14 Jul 2003||25 Oct 2005||3M Innovative Properties Company||Spray on bandage and drug delivery system|
|US6967023||31 Aug 2000||22 Nov 2005||Foamix, Ltd.||Pharmaceutical and cosmetic carrier or composition for topical application|
|US6968982||18 Sep 2002||29 Nov 2005||Burns Caleb E S||Multiple-mist dispenser|
|US6969521||28 Nov 2000||29 Nov 2005||Avon Products, Inc.||Aerosol insect repellent composition having low VOC content and method of applying same to the skin|
|US6994863||19 Mar 2003||7 Feb 2006||Foamix Ltd.||Pharmaceutical and cosmetic carrier and composition for topical application|
|US7002486||11 Dec 2001||21 Feb 2006||Lawrence Malcolm G||Highway vehicular traffic flow control|
|US7014844||13 Dec 2002||21 Mar 2006||Avon Products, Inc.||Lightening compositions and methods of use|
|US7021499||21 Sep 2004||4 Apr 2006||Bissell Homecare, Inc.||Aerosol package|
|US7029659||27 Jan 2004||18 Apr 2006||Connetics Australia Pty Ltd.||Mousse composition|
|US7060253||20 Sep 1996||13 Jun 2006||Mundschenk David D||Topical formulations and delivery systems|
|US7078058||27 Sep 2002||18 Jul 2006||Connetics Australia Pty Ltd||Corticosteroid-containing pharmaceutical composition|
|US7083799||26 Feb 1996||1 Aug 2006||L'oreal||No-synthase inhibitors|
|US7137536||22 Jul 2002||21 Nov 2006||Seaquist Perfect Dispensing Foreign, Inc.||Inverted aerosol dispenser|
|US7195135||26 Jul 2000||27 Mar 2007||Valois S.A.S||Dispenser having a hinged dispensing head|
|US7222802||28 Apr 2004||29 May 2007||Meadwestvaco Corporation||Dual sprayer with external mixing chamber|
|US7225518||23 Feb 2004||5 Jun 2007||Boston Scientific Scimed, Inc.||Apparatus for crimping a stent assembly|
|US7226230||30 Dec 2003||5 Jun 2007||Raymond Liberatore||Spreader|
|US7235251||27 Aug 2003||26 Jun 2007||Beiersdorf Ag||Cosmetic or dermatological oil/water emulsions with reduced lipid content|
|US7270828||18 Dec 2003||18 Sep 2007||The Procter & Gamble Company||Personal care composition comprising hydrophobic gel|
|US7455195||26 Jun 2003||25 Nov 2008||Daizo Co., Ltd.||Container for discharging plural contents, a dispenser using the container, and a process for producing the dispenser|
|US7497354||6 Oct 2003||3 Mar 2009||Airlessystems||Fluid dispenser|
|US7575739 *||28 Apr 2004||18 Aug 2009||Foamix Ltd.||Foamable iodine composition|
|US7645803||9 May 2006||12 Jan 2010||Foamix Ltd.||Saccharide foamable compositions|
|US7654415||11 Mar 2003||2 Feb 2010||Airspray International B.V.||Dispensing unit|
|US7682623||5 Dec 2005||23 Mar 2010||Foamix Ltd.||Pharmaceutical composition for topical application|
|US7700076||20 Aug 2004||20 Apr 2010||Foamix, Ltd.||Penetrating pharmaceutical foam|
|US7704518||9 May 2006||27 Apr 2010||Foamix, Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US7793807||4 Oct 2004||14 Sep 2010||Valois S.A.S.||Metering valve and a fluid dispenser device including such a valve|
|US7820145 *||28 Apr 2004||26 Oct 2010||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US7960416||3 Aug 2001||14 Jun 2011||Takeda Pharmaceutical Company Limited||Stable emulsion composition|
|US20010006654||9 Dec 1998||5 Jul 2001||L'oreal||Compositions and methods for treating hair and skin using aqueous delivery systems|
|US20010027218||15 May 2001||4 Oct 2001||3M Innovative Properties Company||Aqueous foaming compositions, foam compoitions, and preparation of foam compositions|
|US20010027981||2 Feb 2001||11 Oct 2001||Jean-Pierre Yquel||Dispenser for selectively dispensing separately stored components|
|US20010036450||22 Jan 2001||1 Nov 2001||Claude Verite||Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one poly ethylene glycol (PEG) ester, and uses thereof|
|US20020002151||21 May 2001||3 Jan 2002||Showa Yakuhin Kako Co., Ltd.||Minocycline-containing compositions|
|US20020004063||28 Sep 1999||10 Jan 2002||Jie Zhang||Methods and apparatus for drug delivery involving phase changing formulations|
|US20020013481||3 Feb 1999||31 Jan 2002||Uwe Schonrock||Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation|
|US20020015721||5 Jan 2000||7 Feb 2002||Jean-Thierry Simonnet||Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields|
|US20020032171||8 Jun 2001||14 Mar 2002||Feng-Jing Chen||Clear oil-containing pharmaceutical compositions containing a therapeutic agent|
|US20020035046||21 Dec 2000||21 Mar 2002||Lukenbach Elvin R.||Personal care compositions|
|US20020035070||19 Jul 2001||21 Mar 2002||The Procter & Gamble Company||Method of regulating hair growth using metal complexes of oxidized carbohydrates|
|US20020035087||6 Jul 2001||21 Mar 2002||Barclay Barry J.||B complex vitamin compositions that protect against cellular damage caused by ultraviolet light|
|US20020035182||13 Jul 2001||21 Mar 2002||L'oreal||Nanoemulsion containing nonionic polymers, and its uses|
|US20020039591||1 Oct 1999||4 Apr 2002||Joseph Scott Dahle||Topical applications for skin treatment|
|US20020044659||15 May 2001||18 Apr 2002||Nec Corporation||Broadcast verification system, broadcast verification method, broadcast verification apparatus and storage medium storing broadcast verification program|
|US20020045659||30 Jul 2001||18 Apr 2002||Michelet Jean Francois||Use, in cosmetic preparations, of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs|
|US20020048798||14 Mar 2001||25 Apr 2002||Avery Mitchell Allen||Novel antioxidants|
|US20020058010||30 Aug 2001||16 May 2002||L'oreal||Foaming cosmetic cream for treating greasy skin and methods for using the same|
|US20020072544||20 Jul 2001||13 Jun 2002||Clariant Gmbh||Fine emulsions|
|US20020090386||10 Jan 2002||11 Jul 2002||Haslwanter Joseph A.||Skin barrier composition|
|US20020098215||22 Jan 2001||25 Jul 2002||Veronique Douin||Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof|
|US20020111281||6 Dec 2000||15 Aug 2002||Mohan Vishnupad||Anhydrous creams, lotions and gels|
|US20020117516||19 Oct 2001||29 Aug 2002||L'oreal||Dispenser unit for simultaneously dispensing the contents of two containers|
|US20020134376||19 Mar 2002||26 Sep 2002||3M Innovative Properties Company||Metering valve for a metered dose inhaler having improved flow|
|US20020136755||22 Dec 2000||26 Sep 2002||Tyrrell David John||Absorbent articles with non-aqueous compositions containing botanicals|
|US20020143188||28 May 2002||3 Oct 2002||Garvey David S.||Nitrosated and nitrosylated potassium channel activators, compositions and methods of use|
|US20020153390||18 Apr 2002||24 Oct 2002||Vlodek James A.||Methods and apparatus for extruding foam through orifices|
|US20020165170||26 Mar 2002||7 Nov 2002||Wilson S. Brian||Method of attenuating reactions to skin irritants|
|US20020182162||7 Aug 2002||5 Dec 2002||Mohsen Shahinpoor||Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth|
|US20020187181||14 May 2001||12 Dec 2002||3M Innovative Properties Company||System for delivering cosmetics and pharmaceuticals|
|US20020198136||6 Mar 2002||26 Dec 2002||Cellegy Pharmaceuticals, Inc.||Compounds and methods for the treatment of urogenital disorders|
|US20030006193||6 Sep 2002||9 Jan 2003||Katsunori Ikeda||Apparatus for purifying nucleic acids and proteins|
|US20030031693||19 Aug 2002||13 Feb 2003||Lionel Breton||Hydroxystilbene/ascorbic acid compositions for treating skin afflictions|
|US20030053961||12 Jul 2002||20 Mar 2003||Eccard Wayne Ellis||Mousse forming compositions comprising quaternary ammonium agents|
|US20030077297||11 Feb 2002||24 Apr 2003||Feng-Jing Chen||Pharmaceutical formulations and systems for improved absorption and multistage release of active agents|
|US20030078172||18 Sep 2002||24 Apr 2003||L'oreal||Foaming cosmetic cream|
|US20030114520||9 Aug 2002||19 Jun 2003||Croda, Inc.||Anti-irritants|
|US20030118515||21 Dec 2001||26 Jun 2003||Robert Jew||Cosmetic composition containing carbon dioxide|
|US20030130247||21 Dec 2001||10 Jul 2003||Medicis Pharmaceutical Corporation||Compositions and methods for enhancing corticosteroid delivery|
|US20030175232||12 Nov 2002||18 Sep 2003||The Procter & Gamble Company||Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care|
|US20030175315||3 Jan 2003||18 Sep 2003||Yoo Byung Hee||Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same|
|US20030180347||13 Mar 2003||25 Sep 2003||W.F. Young, Incorporated||Patch for the delivery of topical agents|
|US20030185839||9 May 2003||2 Oct 2003||Podolsky Daniel K.||Methods and compositions for treating dermal lesions|
|US20030194379||28 Apr 2003||16 Oct 2003||Francois Brugger||Aerosol container and a method for storage and administration of a pre-determined amount of a pharmaceutically active aerosol|
|US20030195128||28 Jan 2003||16 Oct 2003||Deckman Douglas E.||Lubricating oil compositions|
|US20030206955||21 May 2001||6 Nov 2003||L'oreal||Nanoemulsions, compositions comprising such nanoemulsions, and methods of using such nanoemulsions|
|US20030215472||31 Dec 2002||20 Nov 2003||Bonda Craig A||Methods and compositions employing a dialkyl amide|
|US20040018228||7 May 2003||29 Jan 2004||Afmedica, Inc.||Compositions and methods for reducing scar tissue formation|
|US20040028752||8 Aug 2002||12 Feb 2004||S.L.A. Pharma Ag.||Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker|
|US20040038912||12 Jun 2003||26 Feb 2004||Jean-Francois Michelet||Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process|
|US20040053797||12 Sep 2002||18 Mar 2004||Unilever Home & Personal Products Usa, Division Of Conopco, Inc.||Viscoelastic cleansing gel with micellar surfactant solutions|
|US20040058878||16 Jan 2003||25 Mar 2004||Walker Edward B.||Antimicrobial and sporicidal composition|
|US20040063787||19 Sep 2002||1 Apr 2004||Villanueva Julie M.||Vaginal health products|
|US20040067970||17 Sep 2003||8 Apr 2004||Unilever Home & Personal Care Usa, Division Of Conopco, Inc.||Novel compounds and their uses|
|US20040072638||26 Aug 2003||15 Apr 2004||Enos Richard A.||Quick-release fastener for releasably attaching lacrosse stick head to shaft|
|US20040076651||18 Oct 2001||22 Apr 2004||Werner Brocks||Cosmetic or dermatological agent in the form of a creamy permanent mousse or a stable foamed cream|
|US20040078896||14 Apr 2003||29 Apr 2004||Dreamwell, Ltd.||Cassette bedding system|
|US20040079361||16 Jan 2002||29 Apr 2004||Clayton Colin D.||Medicinal aerosols|
|US20040105825||3 Dec 2002||3 Jun 2004||Clariant Gmbh||Methods for producing foam from multiphase compositions|
|US20040120917||7 Feb 2003||24 Jun 2004||Coletica||Cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium, as well as its uses|
|US20040127554||15 May 2002||1 Jul 2004||Carlo Ghisalberti||Dermatological and cosmetic compositions|
|US20040138179||23 Oct 2003||15 Jul 2004||Goldstein Jay A.||Antifungal formulations|
|US20040151671||23 Jan 2004||5 Aug 2004||Connetics Australia Pty Ltd.||Pharmaceutical foam|
|US20040151756||4 Feb 2003||5 Aug 2004||Richards Anthony P.||Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle|
|US20040161447||11 Feb 2004||19 Aug 2004||Leonard Paul||Liquid foam producing compositions and dispensing system therefor|
|US20040184992||27 Jan 2004||23 Sep 2004||Connetics Australia Pty Ltd||Mousse composition|
|US20040185123||16 Mar 2004||23 Sep 2004||Mazzio Elizabeth A.||Topical treatment for dyshidrosis (pompholyx) and dry skin disorders|
|US20040191196||16 Dec 2003||30 Sep 2004||Dov Tamarkin||Novel conjugate compounds and dermatological compositions thereof|
|US20040192754||24 Mar 2004||30 Sep 2004||Shapira Nathan Andrew||Methods for treating idiopathic hyperhidrosis and associated conditions|
|US20040195276||1 Apr 2004||7 Oct 2004||Karl-Heinz Fuchs||Discharge device for at least one medium|
|US20040197276||24 Oct 2002||7 Oct 2004||Yoshihiko Takase||Composition for oily foamable aerosol|
|US20040197295||16 Jan 2004||7 Oct 2004||Beiersdorf Ag||Foamable preparations|
|US20040219122||18 Dec 2003||4 Nov 2004||The Procter & Gamble Company||Personal care composition comprising hydrophobic gel|
|US20040219176||6 Feb 2004||4 Nov 2004||Dominguez Maria Antonia Garcia||Injectables in foam. new pharmaceutical applications|
|US20040220187||21 Apr 2004||4 Nov 2004||Pharmacia Corporation||Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders|
|US20040229813||2 Jan 2004||18 Nov 2004||Femme Pharma, Inc.||Pharmaceutical preparations for treatments of diseases and disorders of the breast|
|US20040234475||24 Jun 2002||25 Nov 2004||Helene Lannibois-Drean||Oil-in-oil emulsions comprising a silicone, dispersions and use of said emulsions|
|US20040241099||28 May 2003||2 Dec 2004||Popp Karl F.||Foamable pharmaceutical compositions and methods for treating a disorder|
|US20040247531||26 Mar 2004||9 Dec 2004||Beiersdorf Ag||Self-foaming, foam-like, after-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids that are solid or semi-solid at room temperature|
|US20040253275||10 Jan 2001||16 Dec 2004||Meir Eini||Pharmaceutical and cosmetic carrier or composition for topical application|
|US20040258627||10 May 2004||23 Dec 2004||Beiersdorf Ag||Self-foaming, foam-like, after-foaming or foamable cosmetic or dermatological preparation|
|US20040265240||28 Apr 2004||30 Dec 2004||Foamix Ltd.||Foamable iodine composition|
|US20050002976||14 Jun 2004||6 Jan 2005||The Procter & Gamble Company||Polyol-in-silicone emulsions|
|US20050013853||10 Feb 2004||20 Jan 2005||Irit Gil-Ad||Anti-proliferative drugs|
|US20050031547 *||28 Apr 2004||10 Feb 2005||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US20050042182||21 May 2004||24 Feb 2005||Moshe Arkin||Topical compositions of urea|
|US20050054991||28 Aug 2002||10 Mar 2005||Tobyn Michael John||Topical administration device|
|US20050069566||4 Aug 2004||31 Mar 2005||Foamix Ltd.||Foam carrier containing amphiphilic copolymeric gelling agent|
|US20050074414||20 Aug 2004||7 Apr 2005||Foamix Ltd.||Penetrating pharmaceutical foam|
|US20050075407||20 Aug 2004||7 Apr 2005||Foamix Ltd.||Foam incorporating eutetic mixture|
|US20050079139||8 Oct 2004||14 Apr 2005||Jacques Elizabeth Joan||Minoxidil pharmaceutical foam formulation|
|US20050084551||23 Sep 2004||21 Apr 2005||Jensen Claude J.||Morinda citrifolia-based oral care compositions and methods|
|US20050085843||17 Sep 2004||21 Apr 2005||Nmt Medical, Inc.||Quick release knot attachment system|
|US20050101936||6 Nov 2003||12 May 2005||Pediamed Pharmaceuticals, Inc.||Multi-site drug delivery platform|
|US20050106197||27 Sep 2004||19 May 2005||Xavier Blin||Cosmetic composition comprising a block polymer and a non-volatile silicone oil|
|US20050123494||17 Nov 2004||9 Jun 2005||Swaile David F.||Antiperspirant composition and applicator therefor|
|US20050123496||8 Dec 2003||9 Jun 2005||Unilever Home & Personal Care Usa, Division Of Conopco, Inc.||Self foaming non-aqueous personal wash cleansers with little or no surfactant|
|US20050186142||24 Jan 2005||25 Aug 2005||Foamix Ltd.||Kit and composition of imidazole with enhanced bioavailability|
|US20050186147||4 Feb 2005||25 Aug 2005||Foamix Ltd.||Cosmetic and pharmaceutical foam with solid matter|
|US20050189377||17 Nov 2004||1 Sep 2005||Beiersdorf Ag||Dispenser and cosmetic or dermatological preparation comprising an auxiliary for use with dispenser|
|US20050196414||3 Mar 2005||8 Sep 2005||Essentia Biosystems, Inc.||Compositions and methods for topical application and transdermal delivery of botulinum toxins|
|US20050205086||11 Mar 2005||22 Sep 2005||Foamix Ltd.||Retinoid immunomodulating kit and composition and uses thereof|
|US20050207837||18 Mar 2005||22 Sep 2005||Bodypoint Designs, Inc.||Quick release assembly|
|US20050222090||29 Dec 2004||6 Oct 2005||Gilead Sciences, Inc.||Anti-proliferative compounds, compositions, and methods of use thereof|
|US20050232869||11 Mar 2005||20 Oct 2005||Foamix Ltd.||Nonsteroidal immunomodulating kit and composition and uses thereof|
|US20050244342||6 Apr 2005||3 Nov 2005||Foamix Ltd.||Moisturizing foam containing lanolin|
|US20050244354||30 Apr 2004||3 Nov 2005||Sam Speron||Oxygenated personal care products|
|US20050245902||10 Feb 2003||3 Nov 2005||Brian Cornish||Substance delivery device|
|US20050252995||17 May 2004||17 Nov 2005||Westphal Nathan R||Detachable tube assembly|
|US20050255048||13 May 2005||17 Nov 2005||Collegium Pharmaceutical, Inc.||Sprayable formulations for the treatment of acute inflammatory skin conditions|
|US20050258189||21 May 2004||24 Nov 2005||Scott Peterson||Reconfigurable metered material dispenser|
|US20050266035||11 Aug 2005||1 Dec 2005||Pfizer Inc.||Skin protectant spray compositions|
|US20050268416||25 Apr 2005||8 Dec 2005||Sommers J E||Foldable lotion applicator|
|US20050271596||9 May 2005||8 Dec 2005||Foamix Ltd.||Vasoactive kit and composition and uses thereof|
|US20050271598||28 Apr 2005||8 Dec 2005||Foamix Ltd.||Body cavity foams|
|US20050276836||12 Jul 2005||15 Dec 2005||Michelle Wilson||Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents|
|US20050281755||15 Oct 2004||22 Dec 2005||Galderma S.A.||Topical foam/mousse compositions for treating psoriasis|
|US20050281766||6 Jul 2005||22 Dec 2005||Avon Products, Inc.||Method of improving the aesthetic appearance of epithelia|
|US20050285912||28 Jun 2004||29 Dec 2005||Eastman Kodak Company||Latency stirring in fluid ejection mechanisms|
|US20050287081||24 Jun 2004||29 Dec 2005||Dpt Laboratories, Ltd.||Pharmaceutically elegant, topical anhydrous aerosol foam|
|US20060008432||7 Jul 2004||12 Jan 2006||Sebastiano Scarampi||Gilsonite derived pharmaceutical delivery compositions and methods: nail applications|
|US20060018937||26 Apr 2005||26 Jan 2006||Foamix Ltd.||Steroid kit and foamable composition and uses thereof|
|US20060018938||14 Jul 2005||26 Jan 2006||Stephanie Neubourg||Foam skin cream, use of the foam skin protection cream and a process of its preparation|
|US20060029565||9 Aug 2004||9 Feb 2006||The Gillette Company||Self-heating shave foam product|
|US20060051301||27 Oct 2003||9 Mar 2006||Givaudan Sa||Coolant solutions and compositions comprising the same|
|US20060054634||26 Jun 2003||16 Mar 2006||Satoshi Mekata||Packaging container for discharge of plurality of contents, packaging product including the packaging container and process for producing the packaging product|
|US20060057168||31 Aug 2005||16 Mar 2006||Connetics Australia Pty Ltd||Microemulsion process and composition|
|US20060088561||5 Dec 2005||27 Apr 2006||Foamix Ltd.||Pharmaceutical composition for topical application|
|US20060099151||12 Dec 2003||11 May 2006||Fritz Neubourg||Stable foam cream|
|US20060108377||19 Nov 2004||25 May 2006||Glynn Kenneth P||Metered dose squeeze dispenser|
|US20060110418||23 Nov 2005||25 May 2006||Nanocluster Technologies, Llc||Water-in-oil emulsions and methods|
|US20060114745||1 Nov 2005||1 Jun 2006||Ute Ollmann||Apparatus for blending two different components|
|US20060121073||12 Jul 2005||8 Jun 2006||Sandhya Goyal||Topical gel formulation comprising insecticide and its preparation thereof|
|US20060140984||24 Oct 2003||29 Jun 2006||Foamix Ltd.||Cosmetic and pharmaceutical foam|
|US20060140990||5 Jan 2006||29 Jun 2006||Drugtech Corporation||Composition for topical treatment of mixed vaginal infections|
|US20060160713||16 Jun 2004||20 Jul 2006||Takasago International Corporation||Shampoo and body detergent composition|
|US20060165616||22 Jul 2003||27 Jul 2006||Michael Brock||Microemulsion containing anti-uv filters and/or anti-dandruff agents|
|US20060177392||5 Dec 2005||10 Aug 2006||William Walden||Oil-based composition for acne|
|US20060193789||23 Jan 2006||31 Aug 2006||Foamix Ltd.||Film forming foamable composition|
|US20060193813||10 Feb 2006||31 Aug 2006||L'oreal||Nanoemulsion containing a hydroxylated urea compound|
|US20060204446||6 Feb 2004||14 Sep 2006||Cipla Ltd||Topical immunotherapy and compositions for use therein|
|US20060222675||28 Mar 2006||5 Oct 2006||Sabnis Ram W||Personal care compositions with color changing indicator|
|US20060233721||27 Mar 2006||19 Oct 2006||Foamix Ltd.||Foam containing unique oil globules|
|US20060239937||12 Dec 2003||26 Oct 2006||Neubourg Skin Care Gmbh And Co Kg||Stable foam cream|
|US20060251684||16 Mar 2005||9 Nov 2006||Nanobio Corporation||Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof|
|US20060254597||7 Jul 2006||16 Nov 2006||40J's Llc||Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound|
|US20060263323||24 Mar 2004||23 Nov 2006||Becton, Dickinson And Company||Invisible antimicrobial glove and hand antiseptic|
|US20060269485||7 Jun 2006||30 Nov 2006||Foamix Ltd.||Antibiotic kit and composition and uses thereof|
|US20060272199||2 Jun 2005||7 Dec 2006||Bmc Manufacturing, Llc||Aqueous gel candle for use with a warming device|
|US20060275218||9 May 2006||7 Dec 2006||Foamix Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US20060275221||9 May 2006||7 Dec 2006||Foamix Ltd.||Saccharide foamable compositions|
|US20060285912||18 Apr 2006||21 Dec 2006||Foamix Ltd.||Apparatus and method for releasing a measured amount of content from a container|
|US20060292080||26 May 2006||28 Dec 2006||Connetics Australia Pty Ltd||Vitamin formulation|
|US20070009607||11 Jul 2005||11 Jan 2007||George Jones||Antibacterial/anti-infalmmatory composition and method|
|US20070017696||18 Jul 2006||25 Jan 2007||Hon Hai Precision Industry Co., Ltd.||Multi-layer printed circuit board|
|US20070020213||19 Jul 2006||25 Jan 2007||Foamix Ltd.||Foamable composition combining a polar solvent and a hydrophobic carrier|
|US20070020304||6 Jul 2006||25 Jan 2007||Foamix Ltd.||Non-flammable insecticide composition and uses thereof|
|US20070027055||22 Aug 2006||1 Feb 2007||Koivisto Bruce M||High alcohol content gel-like and foaming compositions|
|US20070036831||9 Aug 2006||15 Feb 2007||Nanobio Corporation||Nanoemulsion compositions having anti-inflammatory activity|
|US20070059253||13 Nov 2006||15 Mar 2007||Stiefel Laboratories, Inc.||Foamable pharmaceutical compositions and methods for treating a disorder|
|US20070069046||12 Sep 2006||29 Mar 2007||Foamix Ltd.||Apparatus and method for releasing a measure of content from a plurality of containers|
|US20070071688||13 Oct 2006||29 Mar 2007||Sanofi-Aventis||Pharmaceutical compositions for transdermal administration of anti-inflammatory agents|
|US20070098647||27 Sep 2006||3 May 2007||Neubourg Skin Care Gmbh & Co. Kg||Skin care products|
|US20070134174||1 Nov 2006||14 Jun 2007||Christopher Irwin||Personal care composition|
|US20070140999||29 Jan 2007||21 Jun 2007||Hill Dermaceuticals, Inc.||Topical skin care composition containing refined peanut oil|
|US20070142263||15 Dec 2005||21 Jun 2007||Stahl Katherine D||Color changing cleansing composition|
|US20070148112||28 Dec 2005||28 Jun 2007||Avon Products, Inc.||Foaming, color-changing topical composition and method of imparting a cosmetic effect|
|US20070148194||29 Nov 2006||28 Jun 2007||Amiji Mansoor M||Novel nanoemulsion formulations|
|US20070154402||24 Oct 2006||5 Jul 2007||Collegium Pharmaceutical, Inc.||Topical Pharmaceutical Foam Composition|
|US20070160548||13 Dec 2006||12 Jul 2007||Playtex Products, Inc.||Moisturizing sunless tanning composition|
|US20070237724||29 Mar 2007||11 Oct 2007||Abram Albert Z||Foamable suspension gel|
|US20070253911||13 Mar 2007||1 Nov 2007||Foamix Ltd.||Foamable compositions, kits and methods for hyperhidrosis|
|US20070264317||15 May 2006||15 Nov 2007||Perrigo Israel Pharmaceuticals Ltd.||Imiquimod cream formulation|
|US20070271235||2 Oct 2006||22 Nov 2007||Metacarta, Inc.||Geotext Searching and Displaying Results|
|US20070280891||26 Dec 2006||6 Dec 2007||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US20070281999||30 May 2007||6 Dec 2007||The Dial Corporation||Alcohol-containing antimicrobial compositions having improved efficacy|
|US20070292355||4 Apr 2007||20 Dec 2007||Foamix Ltd.||Anti-infection augmentation foamable compositions and kit and uses thereof|
|US20070292359||7 Jun 2007||20 Dec 2007||Foamix Ltd.||Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof|
|US20070292461||12 Jan 2007||20 Dec 2007||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US20080008397||4 Jul 2006||10 Jan 2008||Pavel Kisilev||Feature-aware image defect removal|
|US20080015263||21 Jun 2007||17 Jan 2008||Bolotin Elijah M||Compositions for delivery of therapeutics and other materials|
|US20080015271||12 Jul 2007||17 Jan 2008||Stiefel Research Austrialia Pty Ltd||Fatty acid pharmaceutical foam|
|US20080031907||28 Jun 2007||7 Feb 2008||Foamix Ltd.||Cosmetic and pharmaceutical foam|
|US20080031908||25 Jul 2007||7 Feb 2008||L'oreal||Oily cosmetic composition in aerosol form|
|US20080035155||1 Jul 2005||14 Feb 2008||Gilead Sciences, Inc.||Topical Antiviral Formulations|
|US20080044444||5 Jul 2007||21 Feb 2008||Foamix Ltd.||Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof|
|US20080058055||31 Oct 2007||6 Mar 2008||Igt||Game development architecture that decouples the game logic from the graphics logic|
|US20080063682||23 Mar 2007||13 Mar 2008||Johanne Cashman||Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans|
|US20080069779||10 Sep 2007||20 Mar 2008||Foamix Ltd.||Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof|
|US20080131378||17 Jan 2008||5 Jun 2008||Walter Keller||Aerosol Cream Mousse and Method of Treating Hair|
|US20080138293||20 Aug 2007||12 Jun 2008||Foamix Ltd||Cosmetic and pharmaceutical foam|
|US20080138296||19 Oct 2007||12 Jun 2008||Foamix Ltd.||Foam prepared from nanoemulsions and uses|
|US20080152596||20 Aug 2007||26 Jun 2008||Foamix Ltd.||Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof|
|US20080153789||26 Dec 2007||26 Jun 2008||Femmepharma Holding Company, Inc.||Topical administration of danazol|
|US20080166303||10 Sep 2007||10 Jul 2008||Dov Tamarkin||Colored or colorable foamable composition and foam|
|US20080167376||28 Dec 2007||10 Jul 2008||Dmi Biosciences, Inc.||Methods and products which utilize N-acyl-L-aspartic acid|
|US20080181854||7 Apr 2005||31 Jul 2008||Novartis Ag||Pimecrolimus Foam Composition Containing Hexylene Glycol, Optionally Oleyl Alcohol, Dimethylisosorbide and/or Medium Chain Triglycerides|
|US20080188445||1 Feb 2008||7 Aug 2008||Warner Chilcott Company Inc.||Tetracycline compositions for topical administration|
|US20080188446||1 Feb 2008||7 Aug 2008||Warner Chilcott Company Inc.||Tetracycline compositions for topical administration|
|US20080193762||31 Oct 2007||14 Aug 2008||The Rockefeller University||Water soluble metal and semiconductor nanoparticle complexes|
|US20080206155||14 Nov 2007||28 Aug 2008||Foamix Ltd.||Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses|
|US20080206159||29 Nov 2007||28 Aug 2008||Foamix Ltd.||Compositions with modulating agents|
|US20080206161||25 Jan 2008||28 Aug 2008||Dov Tamarkin||Quiescent foamable compositions, steroids, kits and uses thereof|
|US20080241079||21 Jul 2006||2 Oct 2008||Neubourg Skin Care Gmbh & Co. Kg||Skin Care Products|
|US20080253973||8 Jan 2008||16 Oct 2008||Foamix Ltd.||Sensation modifying topical composition foam|
|US20080255498||25 Feb 2008||16 Oct 2008||Houle Philip R||Sensitizer Solutions, Systems, and Methods of Use|
|US20080260655||4 Feb 2008||23 Oct 2008||Dov Tamarkin||Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses|
|US20080292560||14 Mar 2008||27 Nov 2008||Dov Tamarkin||Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent|
|US20080299220||14 Jan 2008||4 Dec 2008||Dov Tamarkin||Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses|
|US20080311167||6 Sep 2007||18 Dec 2008||Oronsky Bryan T||Topical Composition for Treating Pain|
|US20080317679||22 Jun 2007||25 Dec 2008||Foamix Ltd.||Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses|
|US20090041680||7 Aug 2008||12 Feb 2009||Foamix Ltd.||Wax Foamable Vehicle and Pharmaceutical Compositions Thereof|
|US20090068118||4 Sep 2008||12 Mar 2009||Foamix Ltd.||Device for delivery of a foamable composition|
|US20090093514||12 Dec 2008||9 Apr 2009||3M Innovative Properties Company||Immune response modifier formulations containing oleic acid and methods|
|US20090130029||21 Nov 2008||21 May 2009||Foamix Ltd.||Glycerol ethers vehicle and pharmaceutical compositions thereof|
|US20090131488||10 May 2006||21 May 2009||Dermipsor Ltd.||Compositions and methods for treating hyperproliferative epidermal diseases|
|US20090175799||8 Jan 2009||9 Jul 2009||Dov Tamarkin||Colored or colorable topical composition foam|
|US20090180970||8 Jan 2009||16 Jul 2009||Foamix Ltd.||Foamable composition combining a polar solvent and a hydrophobic carrier|
|US20090291917||5 Mar 2009||26 Nov 2009||Anacor Pharmaceuticals, Inc.||Boron-Containing Small Molecules as Anti-Inflammatory Agents|
|US20090317338||8 Jul 2009||24 Dec 2009||Foamix Ltd.||Foamable iodine compositions|
|US20100111879||23 Dec 2009||6 May 2010||Foamix Ltd.||Saccharide foamable compositions|
|US20100221194||24 Feb 2010||2 Sep 2010||Loupenok Leon||Topical foam composition|
|US20110002857||14 Sep 2010||6 Jan 2011||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US20110002969||27 Feb 2009||6 Jan 2011||Lipotec, S.A.||Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors|
|US20110212033||7 Jun 2010||1 Sep 2011||Foamix Ltd.||Oil and liquid silicone foamable carriers and formulations|
|US20110268665||6 Oct 2009||3 Nov 2011||Dov Tamarkin||Oil-based foamable carriers and formulations|
|USRE38623||29 Nov 2000||12 Oct 2004||Topix Pharmaceuticals, Inc.||Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use|
|USRE38964||30 Nov 1999||31 Jan 2006||Becton Dickinson And Company||One hand needle release system|
|CA2422244A1||14 Mar 2003||14 Sep 2003||Homax Products, Inc.||Aerosol systems and methods for mixing and dispensing two-part materials|
|CH639913A5||Title not available|
|DE1882100U||2 May 1963||7 Nov 1963||Helene Jeanne Colombe Roger||Vorrichtung mit kanuele oder sonde zur behandlung von insbesondere erkrankungen der scheide mit aerosolen.|
|DE1926796U||12 Oct 1961||11 Nov 1965||Heidolph Elektro K G||Geblaese.|
|DE2608226A1||28 Feb 1976||8 Sep 1977||Haarmann & Reimer Gmbh||Mittel mit physiologischer kuehlwirkung|
|DE4140474C2||9 Dec 1991||13 Jul 1995||Schuelke & Mayr Gmbh||Hautpflegeadditiv|
|DE10009233A1||28 Feb 2000||31 Aug 2000||Wella Ag||Pressurized gas container appliance used for application of foam products for hair treatment includes connecting channels and mixing chamber with small cross sectional area so that products flowing through them remain in fluid phase|
|DE10138495B4||4 Aug 2001||11 Nov 2004||Beiersdorf Ag||Nachschäumende Zubereitungen und deren Verwendung|
|DE102004016710A1||5 Apr 2004||13 Oct 2005||Greppmayr Footcare Gmbh||Foamable foot care formulation, effective e.g. against hot or cold feet and dry skin, comprising propellant and oil-in-water emulsion containing stabilizer, surfactant, fatty alcohol and nonionic emulsifier|
|EP0156507B1||22 Feb 1985||29 Aug 1990||Ortho Pharmaceutical Corporation||Antifungal dermatological solution|
|EP0186453A3||19 Dec 1985||30 Sep 1987||Warner-Lambert Company||A non-irritating cleansing composition|
|EP0211550B1||17 Jul 1986||10 Apr 1991||Deutsche Ici Gmbh||Composition for personal care products comprising alkoxylated fatty alcohol and polysiloxane|
|EP0214865B1||9 Sep 1986||23 Jan 1991||Chesebrough-Pond's Inc.||High oil containing anhydrous foamable compositions|
|EP0216856B1||10 Mar 1986||31 Jul 1991||Product Resources International, Inc.||Aerosol foam|
|EP0270316A3||27 Nov 1987||6 Dec 1989||Pfizer Inc.||Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne|
|EP0297436B1||23 Jun 1988||12 Apr 1995||Carl Richard Thornfeldt||Treatment of hyperhidrosis and ichthyosis|
|EP0326196B1||9 Jan 1989||25 Mar 1992||Akzo N.V.||Aqueous pharmaceutical preparation|
|EP0336812B1||23 Mar 1989||26 Aug 1992||L'oreal||Association of pyrimidine derivatives and urea and/or allantoin derivatives to induce and stimulate hair growth and to reduce hair loss|
|EP0391124B1||20 Mar 1990||21 Jun 1995||Kao Corporation||Cosmetic composition of double emulsion type|
|EP0404376B1||5 Jun 1990||23 Mar 1994||CURATEK PHARMACEUTICALS Limited Partnership||Buffered metronidazole compositions for intravaginal treatment of vaginal infections|
|EP0414920B1||16 Mar 1990||14 May 1997||Taisho Pharmaceutical Co. Ltd||Aerosol preparation for external use|
|EP0484530B1||23 Jul 1990||12 Jul 1995||Hisamitsu Pharmaceutical Co. Inc.||Foamed aerosol preparation|
|EP0485299B1||8 Nov 1991||14 Sep 1994||L'oreal||Aerosol foam anhydrous cosmetic composition|
|EP0488089A1||23 Nov 1991||3 Jun 1992||Kali-Chemie Pharma GmbH||Diclofenac preparations for topical use|
|EP0504301B1||7 Dec 1990||31 Mar 2004||Instead, Inc.||Method of collecting vaginal discharge|
|EP0506197B2||24 Mar 1992||4 Jul 2001||Yamanouchi Europe B.V.||Topical preparation containing a suspension of solid lipid particles|
|EP0528190B1||21 Jul 1992||11 Oct 1995||Bruno Jesswein||Two-component pressurised container especially for two-component foams|
|EP0535327B1||3 Aug 1992||23 Oct 1996||American Cyanamid Company||Pharmaceutical composition containing felbinac|
|EP0552612A3||8 Jan 1993||20 Oct 1993||Hoffmann La Roche||Methods for determining and isolating compounds which bind directly to nucleosolic proteins|
|EP0569773B1||27 Apr 1993||12 Sep 2001||Imaginative Research Associates Inc.||Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters|
|EP0598412A3||19 Nov 1993||19 Apr 1995||Medicon Gmbh||Skinprotection composition.|
|EP0662431B1||28 Dec 1994||28 Jul 1999||Adolf Würth GmbH & Co. KG||Refillable dispensing container, filling device and method of filling the dispensing containers|
|EP0676198B1||24 Mar 1995||7 Oct 1998||Agis Industries (1983) Ltd||Fungicidal compositions containing a combination of bifonazole and fluocinonide|
|EP0738516A4||8 Nov 1995||15 Jan 1997||Mochida Pharm Co Ltd||External preparation for skin protection|
|EP0757959B1||19 Jun 1996||24 Feb 1999||Wella Aktiengesellschaft||Pressurized gas container for dispensing foam|
|EP0824911A3||18 Aug 1997||6 Oct 1999||Bristol-Myers Squibb Company||Non-tacky and quick-drying aqueous-based antiperspirant compositions|
|EP0829259A1||29 Aug 1997||18 Mar 1998||Warner-Lambert Company||Foam/gel with microbeads and/or fine particles|
|EP0928608B1||24 Dec 1998||8 Mar 2006||Ajinomoto Co., Inc.||Cosmetic composition|
|EP0979654B1||3 Mar 1999||24 Aug 2005||Teijin Limited||Activated vitamin d 3 emulsion-type lotions|
|EP0993827A4||11 Jun 1998||5 Jul 2006||Taisho Pharma Co Ltd||Aerosols|
|EP1025836A1||7 Feb 2000||9 Aug 2000||F. Hoffmann-La Roche Ag||Cosmetic light screening composition|
|EP1055425A3||26 May 2000||17 Oct 2001||Bristol-Myers Squibb Company||Ultra-mild, clear, aqueous, foamable skin cleanser|
|EP1189579B1||20 Feb 2001||8 Sep 2004||Color Access, Inc.||Gelled aqueous cosmetic compositions|
|EP1215258B1||12 Dec 2001||17 Feb 2010||Takasago International Corporation||Flavor composition for food and drink or for oral care preparation|
|EP1287813A1||28 Aug 2002||5 Mar 2003||Coty Inc.||Antiperspirant deodorant emulsion|
|EP1308169B9||29 Oct 2002||19 Oct 2005||Merz Pharma GmbH & Co.KGaA||Topically administrable compositions with formation of an external active ingredient depot, the production and use thereof|
|EP1375386B1||22 May 2003||21 Feb 2007||Mitani Valve Co||Dispensing apparatus with metering chamber and aerosol type dispenser therewith|
|EP1428521B1||24 Nov 2003||24 Aug 2011||Unilever PLC||Antiperspirant or deodorant composition|
|EP1438946B1||24 Oct 2002||14 Jan 2009||Taiyo Kagaku Co., Ltd.||Composition for oily foamable aerosol|
|EP1475381A1||14 Feb 2002||10 Nov 2004||Quimversion, S.L.||Aluminium and hexamethylenetetramine complex and the applications thereof|
|EP1483001B1||20 Feb 2003||7 Nov 2007||Abbott Research Group, Inc.||Vaginal douches and vaginal douche applicators|
|EP1500385B1||25 Mar 2003||25 Jun 2008||Hakuto Co., Ltd||Method of foam stabilization for foam cosmetic|
|EP1537916A1||7 May 2004||8 Jun 2005||Rieke Corporation||Multiple liquid foamer|
|EP1584324B1||25 Feb 2005||21 Nov 2007||Kao Corporation||Hair cosmetic composition comprising a dicarboxylic acid and an edetic acid|
|EP1600185A1||24 May 2005||30 Nov 2005||Progine Farmaceutici Srl||Vaginal spray nozzle|
|EP1734927B1||7 Apr 2005||13 Jun 2012||MEDA Pharma S.à.r.l.||Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides|
|EP1758547A1||26 May 2005||7 Mar 2007||L'oreal||Cosmetic mousse formulations|
|EP1889609A2||12 Jul 2007||20 Feb 2008||Meda AB||Immune response modifier foam formulations|
|FR2591331A1||Title not available|
|FR2640942B1||Title not available|
|FR2736824B1||Title not available|
|FR2774595A1||Title not available|
|FR2789371B1||Title not available|
|FR2793479B1||Title not available|
|FR2814959A1||Title not available|
|FR2833246B1||Title not available|
|FR2840903B1||Title not available|
|FR2843373B1||Title not available|
|FR2845672B1||Title not available|
|FR2848998B1||Title not available|
|FR2860976B1||Title not available|
|FR2915891B1||Title not available|
|GB808104A||Title not available|
|GB808105A||Title not available|
|GB922930A||Title not available|
|GB933486A||Title not available|
|GB998490A||Title not available|
|GB1026831A||Title not available|
|GB1033299A||Title not available|
|GB1081949A||Title not available|
|GB1121358A||Title not available|
|GB1162684A||Title not available|
|GB1170152A||Title not available|
|GB1201918A||Title not available|
|GB1347950A||Title not available|
|GB1351761A||Title not available|
|GB1351762A||Title not available|
|GB1353381A||Title not available|
|GB1376649A||Title not available|
|GB1397285A||Title not available|
|GB1408036A||Title not available|
|GB1457671A||Title not available|
|GB1489672A||Title not available|
|GB1561423A||Title not available|
|GB2004746B||Title not available|
|GB2114580B||Title not available|
|GB2153686B||Title not available|
|GB2166651B||Title not available|
|GB2172298B||Title not available|
|GB2206099B||Title not available|
|GB2337461B||Title not available|
|GB2367809A||Title not available|
|GB2406330B||Title not available|
|GB2406791B||Title not available|
|IL49491D0||Title not available|
|IL152486D0||Title not available|
|JP3050289B2||Title not available|
|JP4282311B2||Title not available|
|JP4312521B2||Title not available|
|JP5070340B2||Title not available|
|JP5213734B2||Title not available|
|JP2006525145A||Title not available|
|RU2277501C2||Title not available|
|UA66796C2||Title not available|
|WO2006079632A1||24 Jan 2006||3 Aug 2006||Basf Aktiengesellschaft||Use of a water-in-water emulsion polymers in the form of a thickener for cosmetic preparations|
|WO2007111962A2||22 Mar 2007||4 Oct 2007||The Procter & Gamble Company||Aerosol product comprising a foaming concentrate composition comprising particulate materials|
|1||"Burn patients need vitamin D supplements." Decision News Media, Jan. 23, 2004, http://www.nutraingredients.com/Research/Burn-patients-need-vitamin-D-supplements, Accessed: May 5, 2010.|
|2||"Coal tars and coal-tar pitches," Report on Carcinogens, Twelfth Edition, 2011, 3 pages.|
|3||"HLB Systems", http://pharmcal.tripod.com/ch17.htm, Accessed Sep. 17, 2010, pp. 1-3.|
|4||"Mineral oil USP," Chemical Abstracts Service Registry No. 8012-95-1, 2011, 7 pages.|
|5||"Minocycline" accessed on Oct. 21, 2011 at en.wikipedia.org/wiki/Minocycline, 7 pages.|
|6||"Reaction Rate" Accessed at en.wikipedia.org/wiki/Reaction-rate on Dec. 18, 2011, 6 pages.|
|7||"Reaction Rate" Accessed at en.wikipedia.org/wiki/Reaction—rate on Dec. 18, 2011, 6 pages.|
|8||"Tea tree oil," Chemical Abstract No. 68647-73-4, 2012, 2 pages.|
|9||‘Niram Chemicals’ [online] Niram Chemicals, [retrieved on Jul. 17, 2012]. Retrieved from the Internet: <URL: http://www.indiamart.com/niramchemicals/chemicals.html>, 7 pages.|
|10||‘Surfactant’ [online]. Wikipedia, 2010, [retrieved on Oct. 24, 2010]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Surfactant>, 7 pages.|
|11||Adachi, Shuji. "Storage and Oxidative Stability of O/W/ Nano-emulsions." Foods Food Ingredients. J. Jpn. vol. 209, No. 11. 2004. 1 page.|
|12||Adisen et al. "Topical tetracycline in the treatment of acne vulgaris," J Drugs Dermatol., 2008, 7:953-5.|
|13||Alcohol SDA 40B.http://www.pharmco-prod.com/pages/MSDS/SDA.sub.--40B.sub.--200.pdf Accessed Dec. 9, 2008, 2 pages.|
|14||Ambrose, Ursula et al., "In Vitro Studies of Water Activity and Bacterial Growth Inhibition of Sucrose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400-Hydrogen Peroxide Pastes Used to Treat Infected Wounds,"Antimicrobial Agents and Chemotherapy, vol. 35, No. 9, pp. 1799-1803, 1991.|
|15||Anton, N. et al. "Water-in-Oil Nano-Emulsion Formation by the phase inversion Temperature Method: A Novel and General Concept, a New Template for Nanoencapsulation," Proceedings of the 33rd Annual Meeting and Exposition of the Controlled Release Society, Jul. 2006, Vienna, Austria, 2 pages.|
|16||Arct et al., "Common Cosmetic Hydrophilic Ingredients as Penetration Modifiers of Flavonoids", International Journal of Cosmetic Science, 24(6):357-366 (2002)-Abstract, 1 page.|
|17||Arct et al., "Common Cosmetic Hydrophilic Ingredients as Penetration Modifiers of Flavonoids", International Journal of Cosmetic Science, 24(6):357-366 (2002)—Abstract, 1 page.|
|18||Arisan, http://www.arisankimya.com/kozmetik.htm Accessed Dec. 10, 2008, 8 pages.|
|19||Augsburger, Larry L. et al. "Bubble Size Analysis of High Consistency Aerosol Foams and Its Relationship to Foam Rheology. Effects of Container Emptying, Propellent Type, and Time." Journal of Pharmaceutical Sciences. vol. 57, No. 4. Apr. 1968. pp. 624-631.|
|20||Austria, et al., "Stability of Vitamin C Derivatives in Solution and Topical Formulations", Journal of Pharmaceutical and Biomedical Analysis, 15:795-801 (1997).|
|21||Barry and Badal, "Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays," Current Microbiology, 1978, 1:33-36.|
|22||Barry, B.W. et al, Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments, British Journal of Dermatology, 93, 563-571, 1975.|
|23||Baskaran et al., "Poloxamer-188 improves capillary blood flow and tissue viability in a cutaneous burn wound," J. Surg. Res., 2001, 101(1):56-61.|
|24||Bell-Syer et al. "A systematic review of oral treatments for fungal infections of the skin of the feet," J. Dermatolog. Treat., 2001, 12:69-74.|
|25||Benet, et al., Application of NMR for the Determination of HLB Values of Nonionic Surfactants, Journal of the American Oil Chemists Society, vol. 49, 1972, 499-500.|
|26||Bernstein, et al., Effects of the Immunomodulating Agent R837 on Acute and Latent Herpes Simplex Virus Type 2 Invections, Antimicrobial Agents and Chemotherapy, 33(9):1511-1515 (1989).|
|27||Blute, "Phase behavior of alkyl glycerol ether surfacants", Physical Chemistry Tenside Sur. Det., 35(3):207-212 (1998).|
|28||Boehm et al. 1994, "Synthesis of high specific activity [.sup.3 H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties," J. Med. Chem., 37:408-414.|
|29||Brenes, et al., "Stability of Copigmented Anthocyanins and Asorbics Acid in a Grape Juice Model System", J. Agric Food Chem, 53(1):49-56 (2005)-Abstrace, 1 page.|
|30||Brenes, et al., "Stability of Copigmented Anthocyanins and Asorbics Acid in a Grape Juice Model System", J. Agric Food Chem, 53(1):49-56 (2005)—Abstrace, 1 page.|
|31||Bronopol. Revtrieved online on Jun. 4, 2011. . Jul. 17, 2006. 4 pages.|
|32||Bronopol. Revtrieved online on Jun. 4, 2011. <URL:http://chemicalland21.com/specialtychem/perchem/BRONOPOL.html>. Jul. 17, 2006. 4 pages.|
|33||Brown et al. "Structural dependence of flavonoid interactions with Cu2+ inos: implications for their antioxidant properties," Biochem. J., 1998, 330:1173-1178.|
|34||Buck, et al., "Treatment of Vaginal Intraephithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream", Journal of Lower Genetial Tract Disease, 7(3):290-293 (2003).|
|35||Bucks, Daniel A.W., et al., "Bioavailability of Topically Administered Steroids: A ‘Mass Balance’ Technique," Journal of Investigative Dermatology, vol. 91, No. 1, Jul. 1988, pp. 29-33.|
|36||Bucks, Daniel A.W., et al., "Bioavailability of Topically Administered Steroids: A 'Mass Balance' Technique," Journal of Investigative Dermatology, vol. 91, No. 1, Jul. 1988, pp. 29-33.|
|37||Bunker,et al., "Alterations in Scalp Blood Flow after the Epicutaneous Application of 3% Minoxidil and 0.1% Hexyl Nicotinate in Alopecia", Presented as a poster at the meeting of the British Society for Investigavie Dermatology, York, Sep. 1986 (2 pages).|
|38||Burton, et al., "Hypertrichosis Due to Minoxidil", British Journal of Dermatology, 101:593-595 (1979).|
|39||Campos, et al., "Ascorbic Acid and Its Derivatives in Cosmetic Formulations", Cosmetics and Toiletries, 115(6):59-62 (2000)-Abstract, 1 page.|
|40||Campos, et al., "Ascorbic Acid and Its Derivatives in Cosmetic Formulations", Cosmetics and Toiletries, 115(6):59-62 (2000)—Abstract, 1 page.|
|41||Carapeti et al., "Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects," Dis Colon Rectum, 2000, 43(10):1359-62.|
|42||Carbowax 1000MSDS; http://www.sciencelab.com/xMSDS-Polyethylene.sub.--glycol.sub.--1000-9926- 622. Accessed Dec. 13, 2008, 6 pages.|
|43||Carelli, et al., "Effect of Vehicles on Yohimbine Permeation Across Excised Hairless Mouse Skin", Pharm Acta Helv, 73(3):127-134 (1998)-Abstract, 1 page.|
|44||Carelli, et al., "Effect of Vehicles on Yohimbine Permeation Across Excised Hairless Mouse Skin", Pharm Acta Helv, 73(3):127-134 (1998)—Abstract, 1 page.|
|45||Chebil, et al., "Soulbility of Flavonoids in Organic Solvents", J. Chem. Eng. Data, 52(5):1552-1556 (2007)-Abstract, 1 page.|
|46||Chebil, et al., "Soulbility of Flavonoids in Organic Solvents", J. Chem. Eng. Data, 52(5):1552-1556 (2007)—Abstract, 1 page.|
|47||Cheshire, et al., Disorders of Sweating, www.medscape.com, Semin Neurol 23(4):399-406, 2003.|
|48||Chevrant-Breton, et al., "Etude du Traitement Capillaire <<Bioscalin>> dans les Alopecies Diffuses de la Femme", Gazette Medicale, 93(17):75-79 (1986) [English abstract].|
|49||Chevrant-Breton, et al., "Etude du Traitement Capillaire > dans les Alopecies Diffuses de la Femme", Gazette Medicale, 93(17):75-79 (1986) [English abstract].|
|50||Chiang, et al., "Bioavailability Assessment of Topical Delivery Systems: In Vitro Delivery of Minoxidil from Prototypical Semi-Solid Formulations", Int. J. Pharm, 49(2):109-114 (1989)-Abstract, 1 page.|
|51||Chiang, et al., "Bioavailability Assessment of Topical Delivery Systems: In Vitro Delivery of Minoxidil from Prototypical Semi-Solid Formulations", Int. J. Pharm, 49(2):109-114 (1989)—Abstract, 1 page.|
|52||Chinnian, et al., "Photostability Profiles of Minoxidil Solutions", PDA J. Pharm Sci Technol., 50(2):94-98 (1996)-Abstract, 1 page.|
|53||Chinnian, et al., "Photostability Profiles of Minoxidil Solutions", PDA J. Pharm Sci Technol., 50(2):94-98 (1996)—Abstract, 1 page.|
|54||Chollet, et al., "Development of a Topically Active Imiquimod Formulation", Pharmaceutical Development and Technology, 4(1):35-43 (1999).|
|55||Chollet, et al., "The Effect of Temperatures on the Solubility of Immiquimod in Isostearic Acid", Abstract 3031, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages.|
|56||Cloez-Tayarani. et al., "Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors," Int. Immunol., 2003, 15:233-40.|
|57||Coetzee, "Acceptability and Feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides," Nicol.AIDS 2001, vol. 15, No. 14, pp. 1837-1842.|
|58||Colloidal Silica. Retrieved online on Jun. 4, 2011. . Copyright 2011. 4 pages.|
|59||Colloidal Silica. Retrieved online on Jun. 4, 2011. <URL:http://www.grace.com/engineeredmaterials/materialsciences/colloidalsilica/default.aspx>. Copyright 2011. 4 pages.|
|60||Cook and Mortensen, "Nifedipine for treatment of anal fissures," Dis Colon Rectum, 2000, 43(3):430-1.|
|61||Croda 2. Croda Cetomacrogol 1000 Product Information Sheet. 2011 (no month given). 1 page.|
|62||Croda. Aracel 165 Product Summary. 2011 (no month given). 1 page.|
|63||D.W.A. Sharp Dictionary of Chemistry, Penguin Books, 1983, 3 pages.|
|64||Dalby, "Determination of Drug Solubility in Aerosol Propellants," Pharmaceutical Research, vol. 8, No. 9, 1991, pp. 1206-1209.|
|65||Dawber, et al., "Hypertrichosis in Females Applying Minoxidil Topical Solution and in Normal Controls", JEADV, 17:271-275 (2003).|
|66||Denatonium Benzoate http://www.newdruginfo.com/pharmaceopeia/usp28/v28230/usp28nf23s0.sub.--m- 22790.htm Accessed Dec. 9, 2008, 2 pages.|
|67||Dentinger, et al., "Stability of Nifedipine in an Extemporaneously Compounded Oral Solution", American Journal of Health-System Pharmacy, 60(10):1019-1022 (2003)-Abstract, 1 page.|
|68||Dentinger, et al., "Stability of Nifedipine in an Extemporaneously Compounded Oral Solution", American Journal of Health-System Pharmacy, 60(10):1019-1022 (2003)—Abstract, 1 page.|
|69||Disorder. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/disorder. 1 page.|
|70||Draelos, Z. D. "Antiperspirants and the Hyperhidrosis Patients." Dermatologic Therapy. 2001. vol. 14. pp. 220-224.|
|71||Dumortier et al., "A review of poloxamer 407 pharmaceutical and pharmacological characteristics," Pharmaceutical Res., 2006, 23(12):2709-2728.|
|72||Ebadi et al., "Healing effect of topical nifedipine on skin wounds of diabetic rats," DARU, 2003, 11(1):19-22.|
|73||Edens, et al., "Storage Stability and Safey of Active Vitamin C in a New Dual-Chamber Dispenser", Journal of Applied Cosmetology, 17(4):136-143 (1999)-Abstract, 1 page.|
|74||Edens, et al., "Storage Stability and Safey of Active Vitamin C in a New Dual-Chamber Dispenser", Journal of Applied Cosmetology, 17(4):136-143 (1999)—Abstract, 1 page.|
|75||Edirisinghe, et al., "Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta", Clin Sci (Lond). Aug. 2006; 111(2): 145-51.|
|76||Edwards, "Imiquimod in Clinical Practice", J. Am Acad Dermatol., 43(1, Pt 2):S12-S17 (2000)-Abstract, 1 page.|
|77||Edwards, "Imiquimod in Clinical Practice", J. Am Acad Dermatol., 43(1, Pt 2):S12-S17 (2000)—Abstract, 1 page.|
|78||Effendy and Maibach. "Surfactants and Experimental Irritant Contact Dermatitis." Contact Dermatol., 1995, 33:217-225.|
|79||Elias and Ghadially, "The aged epidermal permeability barrier," Clinical Geriatric Medicine, Feb. 2002, pp. 103-120.|
|80||Emulsifiers with HLB values. http://www.theherbarie.com/files/resources-center/formulating/Emulsifiers- .sub.--HLB.sub.--Values.pdf accessed Aug. 5, 2009 (3 pps).|
|81||Encyclopedia of Pharmaceutical Technology, Second Edition, vol. 3, Copyright 2002, 4 pages.|
|82||Esposito, E. et al. "Nanosystems for Skin Hydration: A Comparative Study." International Journal of Cosmetic Science. 29. 2007. pp. 39-47.|
|83||Ethanol, Accessed http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=E7023SIAL&N5=SEAR- CH.sub.--CONCAT.sub.--PNOBRAND.sub.--KEY&F=SPEC Dec. 9, 2008, 2 pages.|
|84||Ethylene Oxide Derivatives: An Essence of Every Industry. A definition of Emulsifier. Http://www.emulsifiers.in/ethylene-oxide-derivatives2.htm. Accessed Jul. 12, 2011. 3 pages.|
|85||Ethylene Oxide Derivatives: An Essence of Every Industry. A definition of Emulsifier. Http://www.emulsifiers.in/ethylene—oxide—derivatives2.htm. Accessed Jul. 12, 2011. 3 pages.|
|86||Fantin et al., "Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (Quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus," Antimicrob Agents and Chemothery, 1999, 39:400-405.|
|87||Farahmand, et al., "Formulation and Evaluation of a Vitamin C Multiple Emulsion", Pharmaceutical Development and Technology, 11(2):255-261 (2006)-Abstract, 1 page.|
|88||Farahmand, et al., "Formulation and Evaluation of a Vitamin C Multiple Emulsion", Pharmaceutical Development and Technology, 11(2):255-261 (2006)—Abstract, 1 page.|
|89||Final Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., Dec. 16, 2008, 24 pages.|
|90||Flick, Cosmetic and Toiletry Formulations, vol. 5, 2nd Edition, Copyright 1996, 63 pages. Relevant pp. 251-309.|
|91||Fluhr et al., "Glycerol accelerates recovery of barrier function in vivo," Acta Derm. Venereol,. 1999, 79:418-21.|
|92||Fontana, Anthony J., "Water Activity: Why It is Important for Food Safety," International Conference on Food Safety, Nov. 16-18, 1998, pp. 177-185.|
|93||Gallarate, et al., "On the Stability of Ascorbic Acid in Emulsified Systems for Topical and Cosmetic Use", International Journal of Pharmaceutics, 188:233-241 (1999).|
|94||Galligan, John et al., "Adhesive Polyurethane Liners for Anterior Restorations," J. Dent. Res., Jul.-Aug. 1968, pp. 629-632.|
|95||Garti et al. "Sucrose Esters microemulsions," J. Molec. Liquids, 1999, 80:253-296.|
|96||Gelbard et al. "Primary Pediatric Hyperhidrosis: A Review of Current Treatment Options." Pediatric Dermatology. 2008. 25 (6). pp. 591-598.|
|97||Gill, A.M, et al., "Adverse Drug Reactions in a Paediatric Intensive Care Unit," Acta Paediatr 84:438-441, 1995.|
|98||Gladkikh, "Ascorbic Acid and Methods of Increasing its Stability in Drugs", Translated from Khimiko-Farmatsevticheskii Zhurnal, 4(12):37-42 (1970)-1 page.|
|99||Gladkikh, "Ascorbic Acid and Methods of Increasing its Stability in Drugs", Translated from Khimiko-Farmatsevticheskii Zhurnal, 4(12):37-42 (1970)—1 page.|
|100||Glaser, et al., Hyperhidrosis: A Comprehensive and Practical Approach to Patient Management, Expert Rev. Dermatol. 1(6), 773-775 (2006).|
|101||Graves, S. et al. "Structure of Concentrated Nanoemulsions." The Journal of Chemical Physics.. 122 America Institute of Physics. Published Apr. 1, 2005. 6 pages.|
|102||Groveman, et al., "Lack of Efficacy of Polysorbate 60 in the Treatment of Male Pattern Baldness", Arch Intern Med, 145:1454-1458 (1985).|
|103||Gschnait, F., et al., "Topical Indomethacin Protects from UVB and UVA Irriadiation," Arch. Dermatol. Res. 276:131-132, 1984.|
|104||Hakan, et al., "The protective effect of fish oil enema in acetic acid and ethanol induced colitis," The Turkish Journal of Gasroenterology, 2000, vol. 11, No. 2, pp. 155-161.|
|105||Hall, Karla, "Diaper Area Hemangiomas: A Unique Set of Concerns," http://members.tripod.com/.about.Michelle.sub.--G/diaper.html, Dec. 1, 2008, 8 pages.|
|106||Hallstar. Retrieved online on Jun. 4, 2011. . 1 page.|
|107||Hallstar. Retrieved online on Jun. 4, 2011. <URL:http://www.hallstar.com/pis.php?product=1H022>. 1 page.|
|108||Hammer et al. "Anti-Microbial Activity of Essential Oils and other Plant extracts," J. Applied Microbiology, 1999, 86:985-990.|
|109||Hargreaves, "Chemical Formulation, An Overview of Surfactant-Based Preparations Used in Everyday Life", The Royal Society of Chemistry, pp. 114-115 (2003).|
|110||Harrison, et al., "Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs", Antivial Res., 15(4):315-322 (1991).|
|111||Harrison, et al., "Modification of Immunological Responses and Clinical Disease During Topical R-837 Treatment of Genital HSV-2 Infection", Antiviral Research, 10:209-224 (1988).|
|112||Harrison, et al., "Pharmacokinetics and Safety of Iminquimod 5% Cream in the Treatment of Actinic Keratoses of the Face, Scalp, or Hands and Arms", Arch. Dermatol. Res., 296(1):6-11 (2004)-Abstract, 1 page.|
|113||Harrison, et al., "Pharmacokinetics and Safety of Iminquimod 5% Cream in the Treatment of Actinic Keratoses of the Face, Scalp, or Hands and Arms", Arch. Dermatol. Res., 296(1):6-11 (2004)—Abstract, 1 page.|
|114||Harrison, et al., "Posttherapy Suppression of Genital Herpes Simplex Virus (HSV) Recurrences and Enhancement of HSV-Specific T-Cell Memory by Imiquimod in Guinea Pigs", Antimicrobial Agents and Chemotherapy, 38(9):2059-2064 (1994).|
|115||Hashim, et al. "Tinea versicolor and visceral leishmaniasis," Int J Dermatol., Apr. 1994; 33(4), pp. 258-259 (abstract only).|
|116||Heart Failure, The Merck Manual, 2008 <<http://www.merck.com/mmhe/sec03/ch025/ch025a.html>> 12 pages.|
|117||Heart Failure, The Merck Manual, 2008 > 12 pages.|
|118||Hepburn, NC., "Cutaneous leishmaniasis," Clin Exp Dermatol, Jul. 2000; 25(5), pp. 363-370 (abstract only).|
|119||Hill, Randall M. (Ed.) Silicone Surfactants, Table of Contents and Chapter 7, "Silicone Surfactants: Applicants in the Personal Care Industry," by David T. Floyd, 1999 (30 Pages).|
|120||Hormones. Http://www.greenwillowtree.com/Page.bok?file=libido.html. Jan. 2001.|
|121||http://ibabydoc.com/online/diseaseeczema.asp., Atopic Dermatitis, Copyright 2000, 6 pages.|
|122||http://web.archive.org/web/20000106225413/http://pharmacy.wilkes.edu/kibbeweb/lab7.html, Characteristics of Surfactants and Emulsions, Jan. 29, 2010, 5 pages.|
|123||http://www.agworkshop.com/p3.asp, AG&Co. Essential oil workshop. 1 page. Accessed Jan. 31, 2010.|
|124||Hubbe, Martin. Mini-Encyclopedia of Papermaking Wet-End Chemistry: Additives and Ingredients, their Composition, Functions, Strategies for Use. Retrieved online on Jun. 4, 2011. . Feb. 1, 2001. 2 pages.|
|125||Hubbe, Martin. Mini-Encyclopedia of Papermaking Wet-End Chemistry: Additives and Ingredients, their Composition, Functions, Strategies for Use. Retrieved online on Jun. 4, 2011. <URL://http://www4.ncsu.edu/˜hubbe/CSIL.htm>. Feb. 1, 2001. 2 pages.|
|126||Hwang et al. "Isolation and identification of mosquito repellents in Artemisia vulgaris," J. Chem. Ecol., 11: 1297-1306, 1985.|
|127||Hydroxyethylcellulose. Http: //terpconnect.umd.edu/-choi/MSDS/Sigma-Aldrich/HYDROXYETHYL%20CELLULOSE, 5 pages, Jan. 14, 2004.|
|128||ICI Americas Inc. "The HLB System: A Time-Saving Guide to Emulsifier Selection." Mar. 1980. pp. 1-22.|
|129||Ikuta, et al., "Scanning Electron Microscopic Observation of Oil/Wax/Water/Surfacant System", Journal of SCCJ, 34(4):280-291 (2004)-Abstract, 1 page.|
|130||Ikuta, et al., "Scanning Electron Microscopic Observation of Oil/Wax/Water/Surfacant System", Journal of SCCJ, 34(4):280-291 (2004)—Abstract, 1 page.|
|131||Indomethacin. Retrieved online on Jun. 3, 2011. . Aug. 15, 2009. 3 pages.|
|132||Indomethacin. Retrieved online on Jun. 3, 2011. <URL:http://it03.net/com/oxymatrine/down/1249534834.pdf>. Aug. 15, 2009. 3 pages.|
|133||Innocenzi, Daniele et al., "An Open-Label Tolerability and Effacy Study of an Aluminum Sesquichlorhydrate Topical Foam in Axillary and Palmar Primary Hyperhidrosis," Dermatologic Therapy, vol. 21, S27-S30, 2008.|
|134||Izquierdo, P. et al. "Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method." University of Barcelona. Sep. 17, 2001. 1 page.|
|135||Jan. "Troubled Times: Detergent Foam." http://zetatalk.com/health/theall7c.htm. Accessed Feb. 9, 2012. 2 pages.|
|136||Joseph, "Understanding foams & foaming," University of Minnesota (1997), at http://www.aem.umn.edu/people/faculty/joseph/archive/docs/understandingfoams.pdf, pp. 1-8.|
|137||Kalkan, et al., The Measurement of Sweat Intensity Using a New Technique, Tr. J. of Medical Sciences 28, 515-517 (1998).|
|138||Kanamoto, et al., "Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery," J Pharmacobiodyn., Mar. 1988; 11(3):141-5.|
|139||Kang,et al., "Enhancement of the Stability and Skin Penetration of Vitamin C by Polyphenol", Immune Netw., 4(4):250-254 (2004)—Abstract, 1 page.|
|140||Karasu, T.B. et al., "Treatment of Patients with Major Depressive Disorder, Second Edition," pp. 1-78, 2000.|
|141||Kathon.TM. CG (product information sheet by Rohm and Haas, Jun. 2006).|
|142||Kim, "Stability of Minoxidil in Aqueous Solution", Yakhak Hoechi, 30(5):228-231 (1986)—Abstract, 1 page.|
|143||Kinnunen, "Skin reactions to hexylene glycol," Contact Dermatitis Sep. 1989; 21(3): 154-8.|
|144||Kleber, M.D., H.D. et al., "Treatment of Patients with Substance Use Disorders, Second Edition," pp. 1-276, 2006.|
|145||Knight et al., "Topical diltiazem ointment in the treatment of chronic anal fissure," Br. J. Surg., 2001, 88(4):553-6.|
|146||Koerber, S., "Humectants and Water Activity," Water Activity News, 2000, ISSN No. 1083-3943.|
|147||Kreuter, J. "Nanoparticles and microparticles for drug and vaccine delivery," J. Anat. (1996) 189, pp. 503-505.|
|148||Kucharekova et al., "Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction," Contact Dermatitis, Jun. 2002, pp. 331-338.|
|149||Kumar, J. et ak., "Application of Broad Spectrum Antiseptic Povidone Iodine as Powerful Action: A Review," Journal of Pharmaceutical Science and Technology vol. 1(2), 2009, 48-58.|
|150||Kwak et al. "Study of Complete Transparent Nano-Emulsions which Contain Oils." IFSCC Conference 2003, Seoul, Korea, Sep. 22-24, 2003. 3 pages.|
|151||Lautenschlager, Dr. Hans. "A Closer Look on Natural Agents: Facts and Future Aspects." Kosmetic Konzept. Kosmetische Praxis. 2006 (no month given). (5), 8-10. 3 pages.|
|152||Lebwohl et al. "Treatment of Psoriasis. Part 1. Topical Therapy and Phototherapy." J. Am. Acad. Dermatol. 45:487-498. Oct. 2001.|
|153||Lebwohl et al., "A randomized, double-blind, placebo-controlled study of clobestasol propionate 0.05% foam in the treatment of nonscalp psoriasis," International Journal of Dermatology, 2002, 41(5): 269-274.|
|154||Lee, et al., "The Stabilization of L-Ascorbic Acid in Aqueous Solution and Water-in-Oil-in-Water Double Emulsion by Controlling pH and Electrolyte Concentration", J. Cosmet. Sci., 55:1-12 (Jan./Feb. 2004).|
|155||Leive et al, "Tetracyclines of various hydrophobicities as a probe for permeability of Escherichia coli outer membrane," Antimicrobial Agents and Chemotherapy, 1984, 25:539-544.|
|156||Leung, et al., "Bioadhesive Drug Delivery in Water-Soluble Polymers," American Chemical Society, Chapter 23, 1991, pp. 350-366.|
|157||Li, et al., "Solubility Behavior of Imiquimod in Alkanoic Acids", Abstract 3029, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages.|
|158||Licking Vaginal Dryness without a Prescription. Accessed http://www.estronaut.com/a/vag.sub.--dryness.htm on Dec. 14, 2008, 3 pages.|
|159||Lin et al., "Ferulic acid stabilizes a solution of vitamins c and e and doubles its protoprotection of skin," J Invest Dermatol, 2005, 125:826-32.|
|160||Lippacher, A. et al. "Liquid and Semisolid SLN Dispersions for Topical Application" Rheological Characterization. European Journal of Pharmaceutics and Biopharmaceutics. 58. 2004. pp. 561-567.|
|161||Luepke and Kemper, "The HET-CAM Test: An Alternative to the Draize Eye Test," FD Chem. Toxic., 1986, 24:495-196.|
|162||Lupo, "Antioxidants and Vitamins in Cosmetics", Clinics in Dermatology, 19:467-473 (2001).|
|163||Martindale, The extra pharmacopoeia [28th] edition, Eds.: Reynolds, J.E.F. and Prasad, A.B., The Pharmaceutical Press, London, pp. 862-864, 1982.|
|164||Martindale. 33 ed. London, Bath Press, 2002. pp. 1073 and 1473.|
|165||Material Safety Data Sheet, Progesterone, Apr. 26, 2006, 5 pages.|
|166||Material Safety Data Sheet, Science Lab.com, Polyethylene Glycol 1000, MSDS, Nov. 6, 2008, 6 pages.|
|167||Merck index, 10th edition, Merck & Co., Inc.: Rahway, NJ, 1983, pp. 39 (entry 242 for allantoin).|
|168||Merck index, 14th edition, O'Neill, ed., 2006, entry for p-amino benzoic acid.|
|169||Merck index, 14th edition, O'Neill, ed., 2006, entry for zinc oxide.|
|170||Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition. O'Neil et al eds. Entries 1058, 2350, 6143, and 8803. 2001. 7 pages.|
|171||Merck Manual Home Edition. "Excessive Sweating: Sweating Disorders." Accessed Apr. 14, 2011 at www.merckmanuals.com/home/print/sec18/ch206/ch206c.html. 2 pages.|
|172||Merriam Webster Online Dictionary [online] retrieved from http://www.merriam-webster.com/cgi-bin/dictionary?book=dictionary&va=derivative on Jul. 5, 2008; 1 page.|
|173||Merriam-Webster Online Dictionaary, 2008, "Mousse," Merriam-Webster Online, Dec. 8, 2008 http://www.merriam-webster.com/dictionary/mousse, 2 pages.|
|174||Messenger, et al., "Minoxidil: Mechanisms of Action on Hair Growth", British Journal of Dermatology, 150:186-194 (2004).|
|175||Metronidazole. www.usp.org/pdf/EN/veterinary/metronidazole.pdf. accessed Sep. 10, 2009, 4 pages.|
|176||Metz, et al., "A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy", Clinical Cancer Research, 10:6411-6417 (2004).|
|177||Meucci, et al., "Ascorbic Acid Stability in Aqueous Solutions", Acta Vitaminol Enzymol, 7(3-4):147-153 (1985)—Abstract, 1 page.|
|178||MMP Inc. International Development and Manufacturing, "Formulating specialities," http://mmpinc.com, 3 pages. Feb. 2, 2010.|
|179||Molan, Peter Clark, "World Wide Wounds," Dec. 2001, 13 pages.|
|180||Morgan, Timothy M., et al., "Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles," Journal of Pharmaceutical Sciences, vol. 87, No. 10, Oct. 1998, pp. 1213-1218.|
|181||Neutrogena. Http://www.cosmetoscope.com/2010/04/neutrogea-clinical-with-johnson-johnsons-cytomimic-techology/. Published Apr. 28, 2010. Accessed Sep. 11, 2010, 5 pages.|
|182||Nietz, "Molecular orientation at surfaces of solids," J. Phys. Chem., 1928, 32(2): 255-269.|
|183||'Niram Chemicals' [online] Niram Chemicals, [retrieved on Jul. 17, 2012]. Retrieved from the Internet: , 7 pages.|
|184||No Author Listed. "Opitmization of Nano-Emulsions Production by Microfluidization." European Food Research and Technology. vol. 225, No. 5-6. Sep. 2007. Abstract. 1 page.|
|185||Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., May 9, 2008, 27 pages.|
|186||Office Action received from the U.S. Patent Office, U.S. Appl. No. 11/430,599, Jul. 28, 2008 (59 pages).|
|187||Oil. Dictionary of Chemistry. Editor: DWA Sharp. Copyright 1990.|
|188||Olsen, et al., "A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men", J. Am. Acad Dermatol, 57:767-774 (2007).|
|189||OM Cinnamate. http://www.makingcosmetics.com/sunscreens/OM-Cinnamate-p102.html accessed Sep. 26, 2009, 1 page.|
|190||Osborne and Henke, "Skin Penetration Enhancers Cited in the Technical Literature," Pharm. Technology, Nov. 1997, pp. 58-86.|
|191||Padhi et al., "Phospho-olicines as positive-electrode materials for rechargeable lithium batteries," J. Electrochemical Soc., 1997, 144(4): 1188-1194.|
|192||Padi. "Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms," Eur J. Pharmacol, 2008, 601:79-87.|
|193||Pakpayat, et al., "Formulation of Ascorbic Acid Microemulstions with Alkyl Polyglycosides", European Journal of Pharmaceutics and Biopharmaceutics, 72:444-452 (2009).|
|194||Palamaras and Kyriakis, "Calcium antagonists in dermatology: a review of the evidence and research-based studies," Derm. Online Journal, 2005, 11(2):8.|
|195||Paragraph E.3.1 of regulation (EC) No. 2003 (See Directive 67/548/EEC OJ 196, 16.8, 1967, p. 1.|
|196||Partial International Search Report issued for PCT/IB2009/005012 (3 pages).|
|197||Passi et al., Lipophilic antioxidants in human sebum and aging, Free Radical Research, 2002, pp. 471-477.|
|198||Paula. http://ww.cosmeticscop.com/cosmetic-ingredient-dictionary/definition/259/c12-15-alkyl-benzoate.aspx. Printed Oct. 24, 2010. 1 page.|
|199||Pendergrass, "The shape and dimension of the human vagina as seen in three-dimensional vinyl polysiloxane casts," Gynecol Obstet. Invest. 1996:42(3):178-82.|
|200||Perrotti et al., "Topical Nifedipine With Lidocaine Ointment vs. Active Control for Treatment of Chronic Anal Fissure," Dis Colon Rectum, 2002, 45(11):1468-1475.|
|201||Prescription Information for Aldara, Mar. 2007 (29 pages).|
|202||Prevent. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/prevent. 1 page.|
|203||Psoriasis, http://www.quickcare.org/skin/causes-of0psoriasis.html. Accessed Sep. 9, 2010—3 pages.|
|204||Purcell, Hal C. "Natural Jojoba Oil Versus Dryness and Free Radicals." Cosmetics and Toiletries Manufacture Worldwide. 1988. 4 pages.|
|205||Raschke, et al., "Topical Activity of Ascorbic Acid: From In Vitro Optimization to In Vivo Efficacy", Skin Pharmacology and Physiology, 17(4):200-206 (2004)—Abstract, 1 page.|
|206||Ravet et al., "Electroactivity of natural and synthetic triphylite," J. of Power Sources, 2001, 97-98:503-507.|
|207||Raymond, Iodine as an Aerial Disinfectant, Journal of Hygiene, vol. 44, No. 5 (May 1946), pp. 359-361.|
|208||Receptacle. Merriam Webster. Http://www.merriam-webster.com/dictionary/receptacle. Accessed Jul. 12, 2011. 1 page.|
|209||Repa et al. "All-trans-retinol is a ligand for the retinoic acid receptors," Proc. Natl. Acad Sci, USA, 90: 7293-7297, 1993.|
|210||Richwald, "Imiquimod", Drugs Today, 35(7):497 (1999)—Abstract, 1 page.|
|211||Rieger and Rhein. "Emulsifier Selection/HLB." Surfactants in Cosmetics. 1997 (no month given). 1 page.|
|212||Rosacea, http://clinuvel.com/skin-conditions/common-skin-conditions/rosacea#h0-6-prevention. Accessed Sep. 9, 2010, 5 pages.|
|213||Ruledge, "Some corrections to the record on insect repellents and attractants," J. Am. Mosquito Control Assoc, 1988, 4(4): 414-425.|
|214||Sakai et al., "Characterization of the physical properties of the stratum corneum by a new tactile sensor," Skin Research and Technology, Aug. 2000, pp. 128-134.|
|215||Savin, et al., "Tinea versicolor treated with terbinafine 1% solution," Int J. Dermatol, Nov. 1999; 38(11), pp. 863-865.|
|216||Schaefer, "Silicone Surfactants," Tenside, Surfactants, Deterg., 1990, 27(3): 154-158.|
|217||Schmidt A., "Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders," Curtis., Jan. 1997; 59(1), pp. 21-24 (abstract).|
|218||Schulze, M.D., Harry "Iodine and Sodium Hypochlorite as Wound Disinfectants," The British Medical Journal, pp. 921-922, 1915.|
|219||Scientific Discussion for the approval of Aldara, EMEA 2005 (10 pages).|
|220||Scott as Published in Pharmaceutical Dosage Forms; Disperse Systems, vol. 3, Copyright 1998, 120 pages.|
|221||Seborrheic Dermatitis, http://www.cumc.columbia.edu/student/health/pdf/R-S/Seborrhea%20Dermatitis.pdf. Access Sep. 9, 2010, 2 pages.|
|222||Shear, et al., "Pharmacoeconomic analysis of topical treatments for tinea infections," Pharmacoeconomics. Mar. 1995; 7(3); pp. 251-267 (abstract only).|
|223||Sheu, et al., "Effect of Tocopheryl Polyethylene Glycol Succinate on the Percutaneous Penetration of Minoxidil from Water/Ethanol/Polyethylene Glycol 400 Solutions", Drug Dev. Ind. Pharm., 32(5):595-607 (2006)—Abstract, 1 page.|
|224||Shim, et al., "Transdermal Delivery of Mixnoxidil with Block Copolymer Nanoparticles", J. Control Release, 97(3):477-484 (2004)—Abstract, 1 page.|
|225||Shrestha et al., Forming properties of monoglycerol fatty acid esters in nonpolar oil systems, Langmuir, 2006, 22: 8337-8345.|
|226||Sigma Aldrich, "HLB—Numbers in Lithography Nanopatterning," http://www.sigmaaldrich.com/materials-science/micro-and-nanoelectronics/1- ithography-nanopatterning/hlb-numbers.html, accessed: Feb. 2, 2009, pp. 1-3.|
|227||Sigma-Aldrich, Material Safety Data Sheet, Hydroxyethyl Cellulose, Mar. 3, 2004, 5 pages.|
|228||Silicone. Definition. Retrieved Apr. 19, 2011 from http://www.oxforddictionaries.com/definition/silicone?view=uk. 1 page.|
|229||Simoni et al., "Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology," Pure Appl Chem., 2001, 73(9):1437-1444.|
|230||Simovic, S. et al., "The influence of Processing Variables on Performance of O/W Emulsion Gels Based on Polymeric Emulsifier (Pemulen ÒTR-2NF)," International Journal of Cosmetic Science, vol. 2(2): abstract only. Dec. 24, 2001, 1 page.|
|231||Skin Biology, CP Serum—Copper-Peptide Serum for Skin Regeneration and Reducing Wrinkles, Skin Biology, http;//web.archive.org/web/20030810230608/http://www.skinbio.com/cpserum.- html, Dec. 1, 2008, 21 pages.|
|232||Skin Deep Cosmetics. PPG-40-PEG-60 Lanolin Oil http://www.cosmeticsdatabase.com/ingredient/722972/PPG-40-PEG-60—Lanolin—Oil/?ingred06=722972. 3pages.|
|233||Smith, "Hydroxy acids and skin again," Soap Cosmetics Chemical Specialties, 1993, pp. 54-59.|
|234||Smith, Anne. "Sore Nipples." Breastfeeding Mom's Sore Nipples: Breastfeeding Basics. http://breastfeedingbasics.com/articles/sore-nipples. Accessed Feb. 8, 2012. 9 pages.|
|235||Solans et al. "Overview of basic aspects of microemulsions," Industrial Applications of Microemulsions, Solans et al Eds, New York, 1997, 66:1-17.|
|236||Sonneville-Aubrun, O. et al. "Nanoemulsions: A New Vehicle for Skincare Products." Advances in Colloid and Interface Science. 108-109.. 2004. pp. 145-149.|
|237||Squillante et al., "Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin," European J. Pharm. Biopharm., 1998, 46(3):265-71.|
|238||Squire. J, "A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment ofdandruff/seborrhoeic dermatitis," Dermatolog Treat. Jun. 2002;13(2):51-60 (abstract only).|
|239||Sreenivasa, et al., "Preparation and Evaluation of Minoxidil Gels for Topical Application in Alopecia", Indian Journal of Pharmaceutical Sciences, 68(4):432-436 (2006), 11 pages.|
|240||Stehle et al., Uptake of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear hair follicles, J. Invest. Dermatol., 2005, 124(4), A101.|
|241||Sugisaka, et al., "The Physiochemical Properties of Imiquimod, The First Imidazoquinoline Immune Response Modifier", Abstract 3030, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages.|
|242||'Surfactant' [online]. Wikipedia, 2010, [retrieved on Oct. 24, 2010]. Retrieved from the Internet: , 7 pages.|
|243||Surfactant. Chemistry Glossary. Http://chemistry.about.com/od/chemistryglossary/g/surfactant.htm, 2012, 1 page.|
|244||Sweetman, Sean C. Martindale: the Complete Drug Reference. 33rd Edition. London. Pharmaceutical Press. Jun. 21, 2002. pp. 1073 and 1473. 5 pages.|
|245||Tadros, Tharwat F. "Surfactants in Nano-Emulsions." Applied Surfactants: Principles and Applications. Wiley-VCH Verlag GmbH & Co. Weinheim. ISBN: 3-527-30629-3. 2005. pp. 285-308.|
|246||Tan et al., "Effect of Carbopol and Polyvinlpyrrolidone on the Mechanical Rheological and Release Properties of Bioadhesive Polyethylene Glycol Gels," AAPS PharmSciTech, 2000; 1(3) Article 24, 2000, 10 pages.|
|247||Tanhehco, "Potassium Channel Modulators as Anti-Inflammatory Agents", Expert Opinion on Therapeutic Patents, 11(7):1137-1145 (2001)—Abstract, 3 pages.|
|248||Tarumoto, et al., Studies on toxicity of hydrocortisone 17-butyrate 21-propionate-1. Accute toxicity of hydrocortisone 17-butyrate 21-propionate and its analogues in mice, rats and dogs (author's trans), J Toxicol Sci., Jul. 1981; 6 Suppl: 1-16 (Abstract only).|
|249||Tata, et al., "Penetration of Minoxidil from Ethanol Propylene Glycol Solutions: Effect of Application Volume on Occlusion", Journal of Pharmaceutical Sciences, 84(6):688-691 (1995).|
|250||Tata, et al., "Relative Influence of Ethanol and Propylene Glycol Cosolvents on Deposition of Minoxidil into the Skin", Journal of Pharmaceutical Sciences, 83(10):1508-1510 (1994).|
|251||Third Party Submission for U.S. Appl. No. 12/014,088, Feb. 4, 2009, 4 pages.|
|252||Todd et al. "Volatile Silicone Fluids for Cosmetics," 91 Cosmetics and Toiletries, 1976, 27-32.|
|253||Torma et al., "Biologic activities of retinoic acid and 3, 4-dehydroretinoic acid in human keratinoacytes are similar and correlate with receptor affinities and transactivation properties," J. Invest. Dermatology, 1994, 102: 49-54.|
|254||Torres-Rodriguez, JM., "New topical antifungal drugs," Arch Med Res. 1993 Winter; 24(4), pp. 371-375 (abstract).|
|255||Toxicology and Carcinogenesis Studies of t-Butyl Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), http://ntp.niehs.nih.gob/?objectid-=0709F73D-A849-80CA-5FB784E866B576D1. Accessed Dec. 9, 2008, 4 pages.|
|256||Trofatter, "imiquimod in clinical Practice", European Journal of Dermatology, 8(7 Supp.):17-19 (1998)—Abstract, 1 page.|
|257||Tsai, et al., "Drug and Vehicle Deposition from Topical Applications: Use of In Vitro Mass Balance Technique with Minosidil Solutions", J. Pharm. Sci., 81(8):736-743 (1992)—Abstract, 1 page.|
|258||Tsai, et al., "Effect of Minoxidil Concentration on the Deposition of Drug and Vehicle into the Skin", International Journal of Pharmaceutics, 96(1-3):111-117 (1993)—Abstract, 1 page.|
|259||Tsai, et al., "Influence of Application Time and Formulation Reapplication on the Delivery of Minoxidil through Hairless Mouse Skin as Measured in Franz Diffusion Cells", Skin Pharmacol., 7:270-277 (1994).|
|260||Tyring, "Immune-Response Modifiers: A New Paradigm in the Treatment of Human Papillomavirus", Current Therapeutic Research, 61(9):584-596 (2000)—Abstract, 1 page.|
|261||Tzen et al., Lipids, proteins and structure of seed oil bodies from diverse species; Plant Physiol., 1993, 101:267-276.|
|262||Tzen, Jason T.C. et al. "Surface Structure and Properties of Plant Seed Oil Bodies." Department of Botany and Plant Sciences, University of California, Riverside, California 92521. Apr. 15, 1992. 9 pages.|
|263||U.S. Appl. No. 60/789,186, filed Apr. 4, 2006, Tamarkin.|
|264||U.S. Appl. No. 60/815,948, filed Jun. 23, 2006, Tamarkin.|
|265||U.S. Appl. No. 60/818,634, filed Jul. 5, 2006, Friedman.|
|266||U.S. Appl. No. 60/843,140, filed Sep. 8, 2006, Tamarkin.|
|267||U.S. Appl. No. 61/248,144, filed Oct. 2, 2009, Tamarkin.|
|268||U.S. Appl. No. 61/322,148, filed Apr. 8, 2010, Tamarkin.|
|269||U.S. Appl. No. 61/363,577, filed Jul. 12, 2010, Eini.|
|270||Uner, M. et al. "Skin Moisturizing Effect and Skin Penetration of Ascorbyl Palmitate Entrapped in Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Incorporated into Hydrogel." Pharmazie. 60. 2005. 5 pages.|
|271||USP23/NF 18 The United States Pharmacopeia: The National Formulary, US Pharmacopoeia, 1995, p. 10-14.|
|272||Van Cutsem et al., "The antiinflammatory efects of ketoconazole," J. Am. Acad. Dermatol.,1991, 25(2 pt 1):257-261.|
|273||Van Slyke, "On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution," J. Biol. Chem., 1922, 52:525-570.|
|274||Veron, et al., "Stability of Minoxidil Topical Formulations", Ciencia Pharmaceutica, 2(6):411-414 (1992), Abstract, 1 page.|
|275||Wang and Chen, "Preparation and surface active properties of biodegradable dextrin derivative surfactants," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2006, 281(1-3): 190-193.|
|276||Weindl et al., "Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects," Skin Pharmacology and Physiology, 2004, 17: 207-213.|
|277||Wermuth, C.G. "Similarity in drugs: reflections on analogue design," Drug Discovery Today, vol. 11, Nos. 7/8, Apr. 2006, pp. 348-354.|
|278||Williams, "Scale up of an olive/water cream containing 40% diethylene glycol momoethyl ether", Dev. Ind. Pharm., 26(1):71-77 (2000).|
|279||Wormser et al., Protective effect of povidone-iodine ointment against skin lesions induced by sulphur and nitrogen mustards and by non-mustard vesicants, Arch. Toxicol., 1997, 71, 165-170.|
|280||Wormser, Early topical treatment with providone-iodine ointment reduces, and sometimes prevents, skin damage following heat stimulus, Letter to the Editor, Burns 24, pp. 383, 1998.|
|281||Xynos et al., "Effect of nifedipine on rectoanal motility," Dis Colon Rectum, 1996, 39(2):212-216.|
|282||Yamada and Chung, "Crystal Chemistry of the Olivine-Type Li(MnyFe1-y)PO4 and (MnyFe1-y)PO4 as Possible 4 V Cathode Materials for Lithium Batteries," J. Electrochemical Soc., 2001, 148(8): A960-967.|
|283||Yamada et al., "Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats," J. Pharmacol. Exp. Ther., 2003, 307(1)17-23.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8865139||9 Jul 2014||21 Oct 2014||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US8900554||20 Feb 2012||2 Dec 2014||Foamix Pharmaceuticals Ltd.||Foamable composition and uses thereof|
|US8933059||6 Dec 2013||13 Jan 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US8987237||6 Dec 2013||24 Mar 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US8987238||6 Dec 2013||24 Mar 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US8992896||27 Aug 2014||31 Mar 2015||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US8993548||3 Sep 2014||31 Mar 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US8993549||3 Sep 2014||31 Mar 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9006222||6 Dec 2013||14 Apr 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9012434||6 Dec 2013||21 Apr 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9072667||27 Jan 2012||7 Jul 2015||Foamix Pharmaceuticals Ltd.||Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9101662||3 Oct 2013||11 Aug 2015||Foamix Pharmaceuticals Ltd.||Compositions with modulating agents|
|US9114145||3 Sep 2014||25 Aug 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9114146||3 Sep 2014||25 Aug 2015||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9167813||27 Jan 2012||27 Oct 2015||Foamix Pharmaceuticals Ltd.||Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9180091||20 Dec 2013||10 Nov 2015||Therapeuticsmd, Inc.||Soluble estradiol capsule for vaginal insertion|
|US9211259||7 Jun 2006||15 Dec 2015||Foamix Pharmaceuticals Ltd.||Antibiotic kit and composition and uses thereof|
|US9248136||25 Jan 2013||2 Feb 2016||Therapeuticsmd, Inc.||Transdermal hormone replacement therapies|
|US9289382||17 Feb 2015||22 Mar 2016||Therapeuticsmd, Inc.||Vaginal inserted estradiol pharmaceutical compositions and methods|
|US9301920||15 Mar 2013||5 Apr 2016||Therapeuticsmd, Inc.||Natural combination hormone replacement formulations and therapies|
|US9492412||22 Apr 2014||15 Nov 2016||Foamix Pharmaceuticals Ltd.||Penetrating pharmaceutical foam|
|US9539208||4 Feb 2014||10 Jan 2017||Foamix Pharmaceuticals Ltd.||Foam prepared from nanoemulsions and uses|
|US9549898||2 Oct 2014||24 Jan 2017||Foamix Pharmaceuticals Ltd.||Oil and liquid silicone foamable carriers and formulations|
|US9572775||17 Sep 2015||21 Feb 2017||Foamix Pharmaceuticals Ltd.||Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9636405||11 Mar 2013||2 May 2017||Foamix Pharmaceuticals Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US9662298||22 Jan 2014||30 May 2017||Foamix Pharmaceuticals Ltd.||Wax foamable vehicle and pharmaceutical compositions thereof|
|US9668972||11 Mar 2005||6 Jun 2017||Foamix Pharmaceuticals Ltd.||Nonsteroidal immunomodulating kit and composition and uses thereof|
|US9675700||13 Jan 2015||13 Jun 2017||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US9682021||25 Feb 2014||20 Jun 2017||Foamix Pharmaceuticals Ltd.||Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses|
|US9713643||8 May 2014||25 Jul 2017||Foamix Pharmaceuticals Ltd.||Foamable carriers|
|US20050232869 *||11 Mar 2005||20 Oct 2005||Foamix Ltd.||Nonsteroidal immunomodulating kit and composition and uses thereof|
|US20140322153 *||23 Apr 2014||30 Oct 2014||The Gillette Company||Lubricating Skin Engaging Member|
|WO2016007537A1||7 Jul 2015||14 Jan 2016||Mast Therapeutics, Inc.||A poloxamer composition free of long circulating material and methods for production and uses thereof|
|U.S. Classification||424/43, 514/945, 514/871, 514/861, 424/78.05, 514/859, 514/944, 424/45, 424/78.07|
|International Classification||A61P17/00, A61K8/02, A61K31/00, A61K31/60, A61K9/00, A61K8/00, A61P29/00, A61P31/00, A61K9/12|
|Cooperative Classification||A61K31/60, A61K8/90, A61K9/107, A61K31/7056, A61K8/046, A61K9/122, A61K31/506, A61K31/19, A61K9/06, A61K31/196, A61Q19/00, A61K31/522, A61K47/10, A61K47/36|
|3 Aug 2011||AS||Assignment|
Owner name: FOAMIX LTD., ISRAEL
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, DOV;BESNOV, ALEX;BERMAN, TAL;AND OTHERS;SIGNING DATES FROM 20100802 TO 20100920;REEL/FRAME:026697/0357
|30 Jul 2014||AS||Assignment|
Owner name: FOAMIX PHARMACEUTICALS LTD., ISRAEL
Free format text: CHANGE OF NAME;ASSIGNOR:FOAMIX LTD.;REEL/FRAME:033445/0249
Effective date: 20140601
|11 Aug 2015||CC||Certificate of correction|